

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/495, 31/445, 31/535, 31/40, 31/44, C07D 241/04, 265/28, 295/02, 453/02, 211/06, C07C 211/38, 233/05		A1	(11) International Publication Number: WO 95/18617 (43) International Publication Date: 13 July 1995 (13.07.95)
(21) International Application Number: PCT/US95/00245 (22) International Filing Date: 9 January 1995 (09.01.95) (30) Priority Data: 08/179,539 10 January 1994 (10.01.94) US 08/179,607 10 January 1994 (10.01.94) US (60) Parent Application or Grant (63) Related by Continuation US Not furnished (CIP) Filed on Not furnished (71) Applicants (for all designated States except US): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; Science Based Industries Campus, Har Hotzvim, P.O. Box 1142, 91010 Jerusalem (IL). TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. [IL/IL]; Senate House, Technion City, 32000 Haifa (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): COHEN, Sasson [IL/IL]; 10 Meyzan Street, 69018 Tel Aviv (IL). HERZIG, Yaa-cov [IL/IL]; 7 Hashiriyan Street, 43266 Raanana (IL).		LEVY, Ruth [IL/IL]; 7 Alterman Street, 69415 Tel Aviv (IL). SPEISER, Tzipora [IL/IL]; 55 Komemiut Street, 69011 Tel Aviv (IL). SHIRVAN, Mitchell [US/IL]; 7/27 Pinchas Rosen Street, Jerusalem (IL). STERLING, Jeff [IL/IL]; Ramot 156/1, 97275 Jerusalem (IL). VEINBERG, Alex [IL/IL]; 5/16 Aharoni Street, 76281 Rehovot (IL). YODIM, Moussa, B., H. [IL/IL]; 18 Hankin Street, 32763 Haifa (IL). FINBERG, John, P., M. [IL/IL]; 15 Ben Zvi Street, 36000 Tivon (IL). SKLARZ, Benjamin [GB/IL]; 25 Frankfurter Street, 49612 Petah-Tikva (IL). SAYAG, Naim [IL/IL]; P.O. Box 223, 20142 Yuvalim (IL). (74) Agent: WHITE, John, P.; Cooper & Dunham, 1185 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF

(57) Abstract

Novel derivatives of 1-aminoindan and their salts are described. Parkinson's disease, dementia, epilepsy, convulsions, seizures, acute neurological traumatic disorder or neurotrauma are treated by administering a compound of formula (I).





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/495, 31/445, 31/535, 31/40, 31/44, C07D 241/04, 265/28, 295/02, 453/02, 211/06, C07C 211/38, 233/05</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/18617 (43) International Publication Date: 13 July 1995 (13.07.95)</p>
<p>(21) International Application Number: PCT/US95/00245 (22) International Filing Date: 9 January 1995 (09.01.95) (30) Priority Data: 08/179,539 10 January 1994 (10.01.94) US 08/179,607 10 January 1994 (10.01.94) US (60) Parent Application or Grant (63) Related by Continuation US Not furnished (CIP) Filed on Not furnished (71) Applicants (for all designated States except US): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; Science Based Industries Campus, Har Hotzvim, P.O. Box 1142, 91010 Jerusalem (IL). TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. [IL/IL]; Senate House, Technion City, 32000 Haifa (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): COHEN, Sasson [IL/IL]; 10 Meyzan Street, 69018 Tel Aviv (IL). HERZIG, Yaacov [IL/IL]; 7 Hashiryan Street, 43266 Raanana (IL).</p>	<p>LEVY, Ruth [IL/IL]; 7 Alterman Street, 69415 Tel Aviv (IL). SPEISER, Tzipora [IL/IL]; 55 Komemiot Street, 69011 Tel Aviv (IL). SHIRVAN, Mitchell [US/IL]; 7/27 Pinchas Rosen Street, Jerusalem (IL). STERLING, Jeff [IL/IL]; Ramot 156/1, 97275 Jerusalem (IL). VEINBERG, Alex [IL/IL]; 5/16 Aharoni Street, 76281 Rehovot (IL). YAUDIM, Moussa, B., H. [IL/IL]; 18 Hankin Street, 32763 Haifa (IL). FINBERG, John, P., M. [IL/IL]; 15 Ben Zvi Street, 36000 Tivon (IL). SKLARZ, Benjamin [GB/IL]; 25 Frankfurter Street, 49612 Petah-Tikva (IL). SAYAG, Naim [IL/IL]; P.O. Box 223, 20142 Yuvalim (IL). (74) Agent: WHITE, John, P.; Cooper & Dunham, 1185 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF</p> <p>(57) Abstract</p> <p>Novel derivatives of 1-aminoindan and their salts are described. Parkinson's disease, dementia, epilepsy, convulsions, seizures, acute neurological traumatic disorder or neurotrauma are treated by administering a compound of formula (I).</p> <div style="text-align: center;"> <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF

5 This is a continuation-in-part of U.S. application Serial Nos. 08/179,539 and 08/179,607, both filed January 10, 1994, the contents of which are hereby incorporated by reference.

10 Throughout this application, various references are referred to. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

15

Background of the Invention

Various procedures for treating Parkinson's Disease have been established and many of them are currently in widespread use. European Patent No. 436492B provides a
20 detailed discussion of treatments available and summarizes many of their drawbacks. There remains a need for a drug therapy that provides a prolonged and sustained amelioration of the symptoms associated with Parkinson's Disease.

25

A variety of substituted 1-aminoindans have been proposed to have some activity in the central nervous system (CNS). This group of compounds have a wide range of activities, for example, U.S. Patent No. 4,096,173
30 discloses 1-aminoindans with ring chloro substituents as having anti-allergic, anti-spasmodic and local anesthetic activities, whereas U.S. Patent No. 3,886,168 discloses the anti-inflammatory and vasodilatory activity of certain 1-aminomethylindans. It is hypothesized therein
35 that the activity may be based in the CNS though no evidence is provided or suggested to support the hypothesis. British Patent No. 852,735 discloses 1-aminoindans with a lower alkoxy group in the 5 position as being active in dilating coronary blood vessels.

- 2 -

U.S. Patent No. 3,637,740 discloses 4-alkoxy-5-chloro-1-aminoindans as anti-depressants or anti-anxiety agents, although no clear evidence is provided of either activity.

5

Horn et al. (J.Pharm.Exp.Ther. 1972 180(3) 523) have shown that 2-aminoindan is a far superior inhibitor of catecholamine uptake than 1-aminoindan and therefore dismissed the latter as a candidate for use in the treatment of Parkinson's Disease. Martin et al. (J.Med.Chem. 1973 16(2) 147 & J.Med.Chem 1974 17(4) 409) describe experiments wherein N-methyl-5-methoxy derivatives of 1-aminoindan are investigated as having monoamine oxidase (MAO) inhibitory activity.

15

Oshiro et al. (J.Med.Chem. 1991 34 2004-2013) disclose a wide range of 7-hydroxy-1-aminoindan derivatives that they subjected to screening for use as a cerebroprotective agent using an antihypoxic test and as a CNS stimulatory agent using a cerebral trauma test. In the resultant structure-activity-analysis undertaken it was found that replacement of the 7-hydroxy group by a methoxy group resulted in loss of activity in the antihypoxic test but not in the cerebral trauma test. Their conclusion was that the 7-hydroxy group is essential to obtain the desired activity. This is evident from their subsequent paper wherein a broader range of 7-hydroxy derivatives are screened (J.Med.Chem 1991 34 2014-2020). These 7-hydroxy-1-aminoindans are defined in US Patents 4,788,130, 4,792,628, 4,895,847, 5,055,474 and 5,242,919 all assigned to Otsuka Pharmaceutical Co. Japan.

20

25

30

35

It has surprisingly been found that a range of substituted and unsubstituted 1-aminoindans have activity in suppressing the symptoms emanating from the dopaminergic hypofunction that is associated with Parkinson's Disease; in improving cognition in dementias

- 3 -


such as senile dementia, Parkinson-type dementia and dementia of the Alzheimer's type; in providing protection against epilepsy, convulsions, seizures; and in improving post-head trauma motor function, and reducing trauma-induced cerebral oedema.

5

- 4 -

Summary of the Invention

This invention provides a method for treating Parkinson's disease, dementia, epilepsy, convulsions, or seizures in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:




(Formula 1)

or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R_1 and R_2 are each independently hydrogen, hydroxy, substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted C_1 - C_4 alkoxy, halogen, nitro, $NH-R_3$, $C(O)-R_3$, or $C(O)-NR_3R_{10}$; R_3 is hydrogen, substituted or unsubstituted C_1 - C_4 alkyl, hydroxy, substituted or unsubstituted C_1 - C_4 alkoxy, or substituted or unsubstituted C_6 - C_{12} aryl; and R_4 and R_5 are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, $-C(O)-R_6$, $-Y-C(O)-R_7$, or $Y-(SO_2)NR_3R_{10}$; wherein R_6 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or $A-NR_3R_{10}$, wherein A is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, and R_3 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl; Y is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl or substituted or unsubstituted C_7 - C_{12} aralkyl, and R_7 is hydrogen, hydroxy,

- 5 -

substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl or NR_9R_{10} , wherein R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl.

This invention provides a method for treating epilepsy, convulsions, or seizures in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:



(Formula 1)

or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R_1 and R_2 are each independently hydrogen, hydroxy, substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted C_1 - C_4 alkoxy, halogen, nitro, $NH-R_3$ or $C(O)-R_3$, or $C(O)-NR_9R_{10}$; R_3 is hydrogen, substituted or unsubstituted C_1 - C_4 alkyl, hydroxy, substituted or unsubstituted C_{1-4} alkoxy, or substituted or unsubstituted C_6 - C_{12} aryl; and R_4 and R_5 are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, alkynyl, $-C(O)-R_6$, $-Y-C(O)-R_7$, or $Y-(SO_2)NR_9R_{10}$; wherein R_6 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or $A-NR_9R_{10}$, wherein A is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, and R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12}

- 6 -


alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl; Y is substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl or substituted or unsubstituted C₇-C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl or NR₉R₁₀, wherein R₉ and R₁₀ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

This invention provides a compound selected from the group consisting of 7-methyl-1-aminoindan, 5-methyl-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 3,5,7-trimethyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan, (S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan, N-(2-acetamido)-1-aminotetralin, N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-Propylpentanoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan, (S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile

- 7 -

6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis(R)-(1-indanyl)succinamide, trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, and salts thereof.

The compounds of general formula 1 possess neuroprotective activity. Accordingly, this invention provides a method for treating acute neurological traumatic disorder or neurotrauma in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:



(Formula 1)

25 or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R₁ and R₂ are each independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁-C₄ alkoxy, halogen, nitro, NH-R₃, C(O)-R₃, or C(O)-NR₃R₁₀; R₃ is hydrogen, substituted or unsubstituted C₁-C₄ alkyl, hydroxy, substituted or unsubstituted C₁-C₄ alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, -C(O)-R₆, -Y-C(O)-R₇, or Y-(SO₂)NR₃R₁₀; wherein R₆ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl,

- 8 -

substituted or unsubstituted C₇-C₁₂ aralkyl, or A-NR₉R₁₀,
wherein A is substituted or unsubstituted C₁-C₁₂ alkyl,
substituted or unsubstituted C₆-C₁₂ aryl, substituted or
unsubstituted C₇-C₁₂ aralkyl, and R₉ and R₁₀ are each
5 independently hydrogen, substituted or unsubstituted C₁-C₁₂
alkyl, substituted or unsubstituted C₆-C₁₂ aryl,
substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl;
Y is substituted or unsubstituted C₁-C₁₂ alkyl, substituted
or unsubstituted C₆-C₁₂ aryl or substituted or
10 unsubstituted C₇-C₁₂ aralkyl, and R₇ is hydrogen, hydroxy,
substituted or unsubstituted C₁-C₁₂ alkyl, substituted or
unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-
C₁₂ aralkyl or NR₉R₁₀, wherein R₉ and R₁₀ are each
independently hydrogen, substituted or unsubstituted C₁-C₁₂
15 alkyl, substituted or unsubstituted C₆-C₁₂ aryl,
substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

- 9 -

Description of the Figures

Figure 1: Experiment 1A: α -MpT-induced hypokinesia in hypoxic rat. Effect of the hypoxic episode as compared to control animals. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as total movements.

Figure 2: Experiment 1A: α -MpT-induced hypokinesia in hypoxic rat. Effect of the drug treated group as compared to the untreated hypoxic group. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as total movements.

Figure 3: Experiment 1A: α -MpT-induced hypokinesia in hypoxic rat. Effect of the hypoxic episode as compared to control animals. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as big movements.

Figure 4: Experiment 1A: α -MpT-induced hypokinesia in hypoxic rat. Effect of the drug treated group as compared to the untreated hypoxic group. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as big movements.

Figure 5: Experiment 1B: α -MpT-induced hypokinesia in hypoxic rat. Effect of the drug treated group as compared to the untreated hypoxic group. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as total movements.

Figure 6: Experiment 1B: α -MpT-induced hypokinesia in hypoxic rat. Effect of the drug treated group as compared to the untreated hypoxic group. X-axis: hours after α -MpT injection. Y-axis: percent of respective control recorded as big movements.

- 10 -

Figure 7: Experiment 3B: Water Maze Working Memory Test. X-axis: water maze - working memory performance. Y-axis: ratio of averages of latencies of run2/run1 in four sessions. Bars are, from left to right: control;
5 hypoxia; hypoxia + AI; hypoxia + deprenyl


Figure 8: Experiment 1C: α -MpT-induced hypokinesia in hypoxic rat. Effect of the drug treated group as compared to the untreated hypoxic group. Y-axis: total
10 movements over 10 hours. The drugs tested are identified in the figure legend using codes, identified as follows:
(R)-1-aminoindan, (RAI), 0.8mg/kg, n=5; 4,5-dimethoxy-1-aminoindan, (31), 0.8mg/kg, n=6; 6-fluoro-(R)-1-aminoindan, (FAI), 1.2mg/kg, n=3; (R)-N-acetyl-1-
15 aminoindan, (18), 0.8mg/kg, n=2; (R)-6-hydroxy-1-aminoindan, (35), 1.2mg/kg, n=3.

Figure 9: Experiment 2C: Effect of 1-Aminoindans on Amphetamine-Induced Stereotype Behavior in Rats. Y-axis:
20 number of head movements per minute, measured 45 minutes after amphetamine injection. The drugs tested are identified in the figure legend using codes, identified as follows: (R)-N-acetyl-1-aminoindan (18), (R)-4,5-dimethoxy-1-aminoindan (29), (R)-1-aminoindan (R-AI),
25 (R)-6-hydroxy-1-aminoindan (35), (R)-6-fluoro-1-aminoindan (R-FAI), (S)-4,5-dimethoxy-1-aminoindan (30).

- 11 -

Detailed Description of the Invention

This invention provides a method for treating Parkinson's disease, dementia, epilepsy, convulsions, or seizures in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:



(Formula 1)

or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R_1 and R_2 are each independently hydrogen, hydroxy, substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted C_1 - C_4 alkoxy, halogen, nitro, $NH-R_3$, $C(O)-R_3$, or $C(O)-NR_3R_{10}$; R_3 is hydrogen, substituted or unsubstituted C_1 - C_4 alkyl, hydroxy, substituted or unsubstituted C_1 - C_4 alkoxy, or substituted or unsubstituted C_6 - C_{12} aryl; and R_4 and R_5 are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, $-C(O)-R_6$, $-Y-C(O)-R_7$, or $Y-(SO_2)NR_9R_{10}$; wherein R_6 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or $A-NR_9R_{10}$, wherein A is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, and R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl; Y is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl or substituted or unsubstituted C_7 - C_{12} aralkyl, and R_7 is hydrogen, hydroxy,

- 12 -

substituted or unsubstituted C₁-C₁₂ alkyl, substituted or
unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-
C₁₂ aralkyl or NR₉R₁₀, wherein R₉ and R₁₀ are each
independently hydrogen, substituted or unsubstituted C₁-C₁₂
5 alkyl, substituted or unsubstituted C₆-C₁₂ aryl,
substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

One of skill in the art will appreciate that substituted
or unsubstituted alkyl refers to both straight-chain and
10 branched-chain alkyl groups. Halogen is used herein to
refer to fluoro, chloro, bromo, and iodo groups.

The subject is any animal, preferably a mammal. In an
embodiment, the subject is a human subject. In another
15 embodiment, the subject is a mouse or a rat.

The administering can be performed according to
techniques well known to those of skill in the art. In
embodiments of this invention the administering comprises
20 administering orally, rectally, transdermally, or
parenterally.

In an embodiment the therapeutically effective amount is
from about 1 mg to about 1000 mg, preferably from about
25 10 mg to about 100 mg.

Pharmaceutically acceptable salts and their preparation
are well known to those of skill in the art. Examples of
pharmaceutically acceptable salts are a hydrochloride
30 salt, a mesylate salt, an ethylsulphonate salt, or a
sulfate salt.

In an embodiment of this invention n is 1. In another
embodiment n is 2.

35

This invention provides the above method wherein R₁ and R₂
are each independently hydrogen, fluoro, hydroxy, methyl

- 13 -

or methoxy.

In an embodiment of this invention R_3 is hydrogen or methyl.

5

In an embodiment of this invention R_4 and R_5 are each independently hydrogen, or substituted or unsubstituted C_1 - C_{12} alkyl.

10

In an embodiment of this invention R_4 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group. In preferred embodiments the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidinyl, and substituted derivatives thereof.

15

In another embodiment of this invention R_5 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group. In preferred embodiments the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidinyl, and substituted derivatives thereof.

20

25

This invention provides the above method wherein A is substituted or unsubstituted C_1 - C_{12} alkyl.

30

This invention provides the above method wherein Y is substituted or unsubstituted C_1 - C_{12} alkyl.

This invention provides the above method wherein R_7 is substituted or unsubstituted C_1 - C_{12} alkyl.

35

In an embodiment R_4 is $-C(0)-R_6$, wherein R_6 is alkyl or

- 14 -

ANR₉R₁₀, wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, or substituted or unsubstituted C₁-C₁₂ alkyl. In another embodiment R₅ is -C(0)-R₆, wherein R₆ is alkyl or ANR₉R₁₀, wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, or substituted or unsubstituted C₁-C₁₂ alkyl.

In an embodiment R₄ is -Y-C(0)-R₇, wherein Y is substituted or unsubstituted C₁-C₁₂ alkyl and R₇ is NR₉R₁₀. In another embodiment R₅ is -Y-C(0)-R₇, wherein Y is substituted or unsubstituted C₁-C₁₂ alkyl and R₇ is NR₉R₁₀.

In a specific embodiment of this invention R₃ and NR₄R₅ are in a cis spatial configuration. In another specific embodiment R₃ and NR₄R₅ are in a trans spatial configuration. The compound may also be a mixture of the cis and trans isomers.

In the method of this invention the compound may be a racemate of the R and S enantiomers. In a specific preferred embodiment the compound is an R enantiomer.

In a specific embodiment of this invention the compound is selected from the group consisting of 1-aminoindan, (R)-1-aminoindan, 1-aminotetralin, 1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 7-hydroxy-1-aminoindan, 6-fluoro-1-aminoindan, (R)-6-fluoro-1-aminoindan, 5-methoxy-1-aminoindan, 7-methyl-1-aminoindan, 5-methyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, trans-2-methyl-1-aminoindan, cis-2-methyl-1-aminoindan, 3,5,7-trimethyl-1-aminoindan, N-methyl-1-aminoindan, (R)-N-methyl-1-aminoindan, N,N-dimethyl-1-aminoindan, N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan, N-acetyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, N-acetyl-7-

- 15 -

methy1-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan, (R)-
N-acetyl-6-fluoro-1-aminoindan, 6-Methoxy-1-aminoindan,
N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-
dimethoxy-1-aminoindan, N-butyryl-1-aminoindan, N-benzyl-
5 1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, N-(2-
acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-
aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-
cyanopropyl)-1-aminoindan, N-(4-butanamido)-1-aminoindan,
N-(2-acetamido)-1-aminotetralin, N,N-Di-(1-indanyl)amine,
10 N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-
1-aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-
Propylpentanoyl)-1-aminoindan, N-acetyl-6-nitro-1-
aminoindan, 6-amino-N-acetyl-1-aminoindan, 6-acetamido-N-
acetyl-1-aminoindan, cis-3-(methoxycarbonyl)-1-
15 aminoindan, cis-1-aminoindan-3-carboxylic acid, trans-2-
methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-
aminoindan, (R)-N-trifluoroacetyl-1-aminoindan, N-(4-(di-
n-propylsulfamoyl)benzoyl)-1-aminoindan, N-methyl-N-
acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan,
20 N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-
aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-
fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-
aminoindan, N,N-di-(2-acetamido)-1-aminoindan, N-(1-
indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-
25 aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-
ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-
isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-
indanyl)ethanesulfonamide, (R,R)-2-(1-indanamino)-N-(1-
indanyl)ethanesulfonamide, N,N'-bis-(1-indanyl)adipamide,
30 N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis-(R)-(1-
indanyl)succinamide, and pharmaceutically acceptable acid
addition salts thereof.

This invention provides the above method for treating
35 Parkinson's disease in a subject. For treating
Parkinson's disease in a subject the compound is
preferably an R enantiomer.

- 16 -

The method of the present invention may involve the administration of any one of the compounds of formula 1 alone or in combination with conventional L-DOPA treatments. In combination treatments the compound of formula 1 may be administered before, after, or together with the conventional L-DOPA treatments.

This invention also provides the above method which further comprises administering to the subject a therapeutically effective amount of Levodopa. In a preferred embodiment the therapeutically effective amount of Levodopa is from about 50 mg to about 250 mg.

Another embodiment further comprises administering to the subject a therapeutically effective amount of decarboxylase inhibitor. The definition of a decarboxylase inhibitor, as well as the identity of specific decarboxylase inhibitors, is well known in the art to which this application pertains.

In a specific embodiment the decarboxylase inhibitor is L-Carbidopa. In an embodiment the therapeutically effective amount of L-Carbidopa is from about 10 mg to about 25 mg.

In a specific embodiment the decarboxylase inhibitor is benserazide. In an embodiment the therapeutically effective amount of benserazide is from about 12.5 mg to about 50 mg.

This invention provides the above method for treating dementia, epilepsy, convulsions, or seizures in a subject. In an embodiment the compound is an R enantiomer. In another embodiment the compound is an S enantiomer.


In a specific embodiment the compound is selected from

- 17 -

the group consisting of (S)-1-aminoindan, (S)-6-fluoro-1-aminoindan, (S)-6-methoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, (S)-N-methyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, (S)-N-acetyl-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan, N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan, (S)-(1-indanyl)-glycine, and pharmaceutically acceptable acid addition salts thereof.

This invention provides the above method for treating Parkinson's-type dementia. This invention also provides the above method for treating senile dementia in a subject. This invention also provides the above method for treating Alzheimer's-type dementia in a subject.

This invention provides a method for treating epilepsy, convulsions, or seizures in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:



(Formula 1)

or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R₁ and R₂ are each independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁-C₄ alkoxy, halogen, nitro, NH-R₃, C(O)-R₃, or C(O)-NR₉R₁₀; R₃ is hydrogen, substituted or unsubstituted C₁-C₄ alkyl, hydroxy, substituted or unsubstituted C₁₋₄ alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, alkynyl, -C(O)-R₆, -Y-C(O)-R₇, or Y-(SO₂)NR₉R₁₀;

- 18 -

- wherein R_6 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or $A-NR_9R_{10}$, wherein A is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, and R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl; Y is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl or substituted or unsubstituted C_7 - C_{12} aralkyl, and R_7 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl or NR_9R_{10} , wherein R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl.
- 20 In a specific embodiment the subject is a human subject.
- In an embodiment n is 1. In another embodiment wherein n is 2.
- 25 In an embodiment R_1 and R_2 are each independently hydrogen, fluoro, hydroxy, methyl or methoxy. In another embodiment R_3 is hydrogen or methyl.
- 30 This invention provides the above method wherein R_4 is propargyl. This invention also provides the above method wherein R_5 is propargyl.
- 35 In an embodiment R_3 and NR_4R_5 are in a cis spatial configuration. In another embodiment R_3 and NR_4R_5 are in a trans spatial configuration.
- In a specific embodiment the compound is an R enantiomer.

- 19 -

In another embodiment the compound is an S enantiomer.

This invention provides the above method for treating epilepsy in a subject.

5

This invention also provides the above method for treating convulsions or seizures in a subject.

10 This invention provides a compound selected from the group consisting of 7-methyl-1-aminoindan, 5-methyl-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 3,5,7-trimethyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan, (S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan, N-(2-acetamido)-1-aminotetralin, N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-Propylpentanoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan, (S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-

15

20

25

30

35

- 20 -

indanamino)-N-(1-indanyl)ethanesulfonamide, N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis(R)-(1-indanyl)succinamide, trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, and salts thereof.

For those above-listed compounds where no indication as to the nature of the isomerism is given, this invention provides for the racemic mixture, the R enantiomer, and the S enantiomer.

In an embodiment the salt is a hydrochloride salt, a mesylate salt, an ethylsulfonate salt, or a sulfate salt.

This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the above-listed compounds and a pharmaceutically acceptable carrier.

This invention provides for the pharmaceutical composition the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet. In an embodiment the therapeutically effective amount is from about 1 mg to about 1000 mg. In a more specific embodiment the therapeutically effective amount is from about 10 mg to about 100 mg.

In another embodiment of the pharmaceutical composition the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution. In a specific embodiment the therapeutically effective amount is from about 1 mg/ml to about 1000 mg/ml. In a more specific embodiment the therapeutically effective amount is from about 10 mg/ml to about 100 mg/ml.

In an embodiment of the pharmaceutical composition the

- 21 -

carrier is a gel and the pharmaceutical composition is a suppository.

5 This invention further provides for the above pharmaceutical composition, further comprising a therapeutically effective amount of Levodopa.


10 This invention also provides for an embodiment of the pharmaceutical composition further comprising a therapeutically effective amount of a decarboxylase inhibitor.

15 In a specific embodiment the decarboxylase inhibitor is L-Carbidopa. In a specific embodiment of the pharmaceutical composition the effective amount of the compound is from about 1 mg to about 1000 mg, the therapeutically effective amount of Levodopa is from about 50 mg to about 250 mg, and the therapeutically effective amount of L-Carbidopa is from about 10 mg to
20 about 25 mg.

25 In an embodiment of the pharmaceutical composition the decarboxylase inhibitor is benserazide. In a specific embodiment the therapeutically effective amount of the compound is from about 1 mg to about 1000 mg, the therapeutically effective amount of Levodopa is from about 50 mg to about 200 mg, and the therapeutically effective amount of benserazide is from about 12.5 mg to about 50 mg.

30 The compounds of general formula 1 possess neuroprotective activity. Accordingly, this invention provides a method for treating acute neurological traumatic disorder or neurotrauma in a subject comprising
35 administering to the subject a therapeutically effective amount of a compound of the formula:

- 22 -



(Formula 1)

or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2; R_1 and R_2 are each independently hydrogen, hydroxy, substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted C_1 - C_4 alkoxy, halogen, nitro, $NH-R_3$, $C(O)-R_3$, or $C(O)-NR_9R_{10}$; R_3 is hydrogen, substituted or unsubstituted C_1 - C_4 alkyl, hydroxy, substituted or unsubstituted C_1 - C_4 alkoxy, or substituted or unsubstituted C_6 - C_{12} aryl; and R_4 and R_5 are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, $-C(O)-R_6$, $-Y-C(O)-R_7$, or $Y-(SO_2)NR_9R_{10}$; wherein R_6 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or $A-NR_9R_{10}$, wherein A is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, and R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl; Y is substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl or substituted or unsubstituted C_7 - C_{12} aralkyl, and R_7 is hydrogen, hydroxy, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl or NR_9R_{10} , wherein R_9 and R_{10} are each independently hydrogen, substituted or unsubstituted C_1 - C_{12} alkyl, substituted or unsubstituted C_6 - C_{12} aryl, substituted or unsubstituted C_7 - C_{12} aralkyl, or indanyl.

- 23 -

The subject is any animal, preferably a mammal. In an embodiment, the subject is a human subject. In another embodiment, the subject is a mouse or a rat.

5 The administering can be performed according to techniques well known to those of skill in the art. In embodiments of this invention the administering comprises administering orally, rectally, transdermally, or parenterally.

10 In an embodiment the therapeutically effective amount is from about 1 mg to about 1000 mg, preferably from about 10 mg to about 100 mg.

15 Pharmaceutically acceptable salts and their preparation are well known to those of skill in the art. Examples of pharmaceutically acceptable salts are a hydrochloride salt, a mesylate salt, an esylate salt, or a sulfate salt.

20 In an embodiment of this invention n is 1. In another embodiment n is 2.

25 This invention provides the above method wherein R_1 and R_2 are each independently hydrogen, fluoro, hydroxy, methyl or methoxy. In a specific embodiment R_1 is 4-fluoro, 6-fluoro, 4-hydroxy, 6-hydroxy, 4-methyl, 6-methyl, 4-methoxy, or 6-methoxy. In another embodiment R_2 is 4-fluoro, 6-fluoro, 4-hydroxy, 6-hydroxy, 4-methyl, 6-methyl, 4-methoxy, or 6-methoxy.

30 In an embodiment of this invention R_3 is hydrogen or methyl.

35 In an embodiment of this invention R_4 and R_5 are each independently hydrogen, or substituted or unsubstituted C_1 - C_{12} alkyl.

- 24 -

In an embodiment of this invention R_4 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group. In preferred
5 embodiments the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidyl, and substituted derivatives thereof.

10 In another embodiment of this invention R_5 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group. In a preferred
15 embodiments the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidyl, and substituted derivatives thereof.

20 This invention provides the above method wherein A is substituted or unsubstituted C_1 - C_{12} alkyl.

This invention provides the above method wherein Y is substituted or unsubstituted C_1 - C_{12} alkyl.

25 This invention provides the above method wherein R_7 is substituted or unsubstituted C_1 - C_{12} alkyl.

30 In an embodiment R_4 is $-C(O)-R_6$, wherein R_6 is alkyl or ANR_9R_{10} , wherein A is alkyl, and R_9 and R_{10} are each independently hydrogen, or substituted or unsubstituted C_1 - C_{12} alkyl. In another embodiment R_5 is $-C(O)-R_6$, wherein R_6 is alkyl or ANR_9R_{10} , wherein A is alkyl, and R_9 and R_{10} are each independently hydrogen, or substituted or unsubstituted C_1 - C_{12} alkyl.

35 In an embodiment R_4 is $-Y-C(O)-R_7$, wherein Y is substituted or unsubstituted C_1 - C_{12} alkyl and R_7 is NR_9R_{10} .

- 25 -

In another embodiment R_5 is $-Y-C(=O)-R_7$, wherein Y is substituted or unsubstituted C_1-C_{12} alkyl and R_7 is NR_9R_{10} .

5 In a specific embodiment of this invention R_3 and NR_4R_5 are in a cis spatial configuration. In another specific embodiment R_3 and NR_4R_5 are in a trans spatial configuration. The compound may also be a mixture of the cis and trans isomers.

10 In a specific embodiment the compound is an R enantiomer. In another embodiment the compound is an S enantiomer.

In an embodiment of the above method the compound is selected from the group consisting of 1-aminoindan, (R)-
15 1-aminoindan, (S)-1-aminoindan, 1-aminotetralin, 1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 6-fluoro-1-aminoindan, (R)-6-fluoro-1-aminoindan, (S)-6-fluoro-1-aminoindan, 5-methoxy-1-aminoindan, (S)-6-methoxy-1-aminoindan, 7-
20 methyl-1-aminoindan, 5-methyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, trans-2-methyl-1-aminoindan, cis-2-methyl-1-aminoindan, 3,5,7-
25 trimethyl-1-aminoindan, N-methyl-1-aminoindan, (R)-N-methyl-1-aminoindan, (S)-N-methyl-1-aminoindan, N,N-dimethyl-1-aminoindan, N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan, N-acetyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, (S)-N-acetyl-1-
30 aminoindan, N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan, 6-Methoxy-1-aminoindan, (S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-butyryl-1-aminoindan, N-benzyl-
35 1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-

- 26 -

cyanopropyl)-1-aminoindan, N-(4-butanamido)-1-aminoindan,
 (S)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-1-
 aminotetralin, N,N-Di-(1-indanyl)amine, N-(2-N-Boc-
 aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-
 5 aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-
 Propylpentanoyl)-1-aminoindan, N-acetyl-6-nitro-1-
 aminoindan, 6-amino-N-acetyl-1-aminoindan, 6-acetamido-N-
 acetyl-1-aminoindan, cis-3-(methoxycarbonyl)-1-
 aminoindan, cis-1-aminoindan-3-carboxylic acid, trans-2-
 10 methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-
 aminoindan, (R)-N-trifluoroacetyl-1-aminoindan, N-(4-(di-
 n-propylsulfamoyl)benzoyl)-1-aminoindan, N-methyl-N-
 acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan,
 N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-
 15 aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-
 fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-
 aminoindan, (S)-(1-indanyl)-glycine, N,N-di-(2-
 acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile,
 6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-
 20 aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-
 indanamino)-N-isopropylethanesulfonamide, 2-(1-
 indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-
 indanamino)-N-(1-indanyl)ethanesulfonamide, N,N'-bis-(1-
 indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide,
 25 N,N'-bis-(R)-(1-indanyl)succinamide, and pharmaceutically
 acceptable acid addition salts thereof.

Accordingly, this invention provides the above method for
 treating acute neurological traumatic disorder in a
 30 subject.

This invention provides the above method for treating
 neurotrauma in a subject. In a still more specific
 embodiment the neurotrauma is caused by a closed head
 35 injury.

The subject invention further provides a method of

- 27 -

treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the memory disorder in the subject.

The subject invention further provides a method of treating a subject afflicted with dementia which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat dementia in the subject. In one embodiment, the dementia is of the Alzheimer type (DAT).

The subject invention further provides a method of treating a subject afflicted with depression which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat depression in the subject.

The subject invention further provides a method of treating a subject afflicted with hyperactive syndrome which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat hyperactive syndrome in the subject.

The administering may comprise orally administering, rectally administering, or parenterally administering.

The subject invention further provides a method of treating a subject afflicted with an affective illness which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the affective illness in the subject.

- 28 -

The subject invention further provides a method of treating a subject afflicted with a neurodegenerative disease which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurodegenerative disease in the subject.

The subject invention further provides a method of treating a subject afflicted with a neurotoxic injury which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurotoxic injury in the subject.

The subject invention further provides a method of treating a subject afflicted with brain ischemia which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat brain ischemia in the subject.

The subject invention further provides a method of treating a subject afflicted with a head trauma injury which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the head trauma injury in the subject.

The subject invention further provides a method of treating a subject afflicted with a spinal trauma injury which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the spinal trauma injury in the subject.

- 29 -

5 The subject invention further provides a method of treating a subject afflicted with schizophrenia which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat schizophrenia in the subject.

10 The subject invention further provides a method of treating a subject afflicted with an attention deficit disorder which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the attention deficit disorder in the subject.

15 The subject invention further provides a method of treating a subject afflicted with multiple sclerosis which comprises administering to the subject an amount of a compound of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat multiple sclerosis in the subject.

25 The subject invention further provides a method of preventing nerve damage in a subject which comprises administering to the subject an amount of general formula 1 or the pharmaceutically acceptable salt thereof of the subject invention effective to prevent nerve damage in the subject.

30 In one embodiment, the nerve damage is structural nerve damage. In another embodiment, the structural nerve damage is optic nerve damage.

35 The subject invention further provides a method of treating a subject suffering from symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of a compound of general formula

- 30 -

1 or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the symptoms of withdrawal in the subject.

5 As used herein, the term "symptoms of withdrawal" refers to physical and/or psychological symptoms, including drug craving, depression, irritability, anergia, amotivation, appetite change, nausea, shaking and sleep irregularity.

10 As used herein, the term "addictive substance" includes, by way of example, (a) addictive opiates such as opium, heroin and morphine, (b) psychostimulants such as cocaine, amphetamines and methamphetamines, (c) alcohol, (d) nicotine, (e) barbiturates and (f) narcotics such as
15 fentanyl, codeine, diphenoxylate and thebaine.

In one embodiment, the addictive substance is cocaine. In another embodiment, the addictive substance is alcohol.

20

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of
5 the invention as described more fully in the claims which follow thereafter.

- 31 -

Experimental DetailsA. SYNTHESIS OF COMPOUNDS5 Preparation of 1-Aminoindans:

The R-1-aminoindan starting material can be prepared by methods known in the art which include, by way of example, the method of Lawson and Rao, Biochemistry, 19, 2133 (1980), methods in references cited therein, and the
10 method of European Patent No. 235,590.

R-1-aminoindan can also be prepared by resolution of a racemic mixture of the R and S enantiomers, which involves, for example, the formation of diastereomeric
15 salts with chiral acids, or any other known method such as those reported in J. Jacques, et al., ibid. Alternatively, R-1-aminoindan may be prepared by reacting 1-indanone with an optically active amine, followed by reduction of the carbon nitrogen double bond of the
20 resulting imine by hydrogenation over a suitable catalyst, such as palladium on carbon, platinum oxide or Raney nickel. Suitable optically active amines include, for example, one of the antipodes of phenethylamine or an ester of an amino acid, such as valine or phenylalanine.
25 The benzylic N-C bond may be cleaved subsequently by hydrogenation under non-vigorous conditions.

An additional method for preparing R-1-aminoindan is the hydrogenation of indan-1-one oxime ethers as described
30 above, wherein the alkyl portion of the ether contains an optically pure chiral center. Alternatively, a non-chiral derivative of indan-1-one containing a carbon-nitrogen double bond, such as an imine or oxime, can be reduced with a chiral reducing agent, e.g., a complex of
35 lithium aluminum-hydride and ephedrine.

- 32 -

Resolution of Enantiomers:

The R- and S- enantiomers of each compound may be obtained by optical resolution of the corresponding racemic mixtures. Such a resolution can be accomplished by any conventional resolution method well known to a person skilled in the art, such as those described in U.S. Patent No. 4,833,273, issued May 23, 1989 (Goel) and in J. Jacques, A. Collet and S. Wilen, "Enantiomers, Racemates and Resolutions," Wiley, New York (1981). For example, the resolution may be carried out by preparative chromatography on a chiral column. Another example of a suitable resolution method is the formation of diastereomeric salts with a chiral acid such as tartaric, malic, mandelic acid or N-acetyl derivatives of amino acids, such as N-acetyl leucine, followed by recrystallization to isolate the diastereomeric salt of the desired R enantiomer.

The racemic mixture of R and S enantiomers of N-propargyl-1-aminoindan (PAI) may be prepared, for example, as described in GB 1,003,676 and GB 1,037,014. The racemic mixture of PAI can also be prepared by reacting 1-chloroindan with propargylamine. Alternatively, this racemate may be prepared by reacting propargylamine with 1-indanone to form the corresponding imine, followed by reduction of the carbon-nitrogen double bond of the imine with a suitable agent, such as sodium borohydride.

The 1-aminoindans of general formula 1 where R₁ and R₂ are as indicated and R₄ and R₅ are hydrogen may be prepared by the chemical reduction of the relevant oximes, by means of zinc/acetic acid or by catalytic hydrogenation. The oximes may be prepared by reaction of the corresponding indan-1-ones with hydroxylamine hydrochloride. The indan-1-ones may be prepared by Friedel-Crafts cyclization of substituted dihydrocinnamic acids or the corresponding

- 33 -

chlorides using aluminum trichloride or other Lewis acids, such as polyphosphoric acid or methanesulphonic acid as condensing agents, for example according to procedures described in J. Org. Chem. 46, 2974 (1981) and
5 in J. Chem. Soc. Perkin Trans, 1, 151 (1972).

N-methyl-1-aminoindan may be prepared from 1-aminoindan according to the procedure described in J.Med.Chem.9, 830 (1966).

10

N,N-dimethyl-1-aminoindan may be prepared from 1-aminoindan according to the procedure described in Yakugaku Zasshi, 82 1597 (1962) - Chem. Abs. 59 611f.

15

N-formyl and N-acyl derivatives of 1-aminoindan and 1-aminotetralin may be prepared from the corresponding 1-aminoindan or 1-aminotetralin using the methods described in J.Med.Chem. 9, 830 (1966), J.Chromatog. 502, 154 (1990) or Boll.Chim.Farm. 115, 489 (1976).

20

The compounds of general formula 1, where R_4 is hydrogen or lower alkyl and R_5 is $C(O)-R_6$, and R_6 is $A-NR_7R_{10}$ are indanylamides of amino acids, and may be prepared by procedures known to those skilled in the art, for example, by reacting the aminoindan with an activated
25 form of the amino acid in the presence or absence (as necessary) of acylation catalysts such as 4-N,N-dimethylaminopyridine.

30

Thus the aminoindan is reacted with an amino acid anhydride having the amino terminus protected by a suitable radical such as t-butoxycarbonyl (Boc), in the presence of for example DMAP, in an aprotic organic solvent such as THF, at a temperature within the range of 0-50 C, preferably from 25-40 C, for a period of from 1-
35 24 hours, preferably from 5-10 hours.

Alternatively, the 1-aminoindan may be reacted with an N-

- 34 -

hydroxy succinimide ester of an amino acid having the terminal amino group protected as above, in an aprotic solvent such as 1,2-dimethoxyethane (DME), at a temperature within the range of 0-70 C, preferably from 25-50 C, for a period of from 12-48 hours, preferably from 24-36 hours.

The product may be purified by column chromatography and/or by crystallization. Removal of the protecting group may be accomplished by subjecting said group to acidic conditions for example to hydrochloric acid or trifluoroacetic acid in a suitable organic solvent such as isopropanol or dioxane. The desired products are then obtained as their acid addition salts.

The compounds of general formula 1 wherein R_1 or R_2 are hydrogen or lower alkyl, R_4 is hydrogen and R_5 is $Y-C(O)-R$, and R_7 is NR_8R_{10} , are N-indanyl derivatives of amino acid amides, and may be prepared by reacting the relevant amino acid amide with a 1-halogeno-indan or with a 1-indanone. In the latter case, the resulting Schiff base is further reduced, by a suitable reducing agent such as sodium borohydride, to afford the desired amine.

Alternatively these compounds may be prepared by reacting the 1-aminoindan with an omega-halogeno derivative of the relevant amino acid amide, in an alcoholic solvent such as ethanol in the presence of a base such as potassium carbonate, at a temperature within the range of 50-100 C, preferably at the reflux temperature of the solvent, for a period of from 12-36 hours, preferably 24 hours. The product may then be converted into its acid addition salt. The R and S enantiomers of each of these compounds may be resolved using procedures known to those skilled in the art.

The following list provides an Example number, a European Patent Application number or a Chemical Abstracts

- 35 -

Registry Number for some of the compounds of general formula 1 that are of interest in the present invention. A Chem. Abs. number with an asterisk indicates the number of a closely related compound.

5	1-aminoindan,	EP 436492	34698-41-4*
	(R)-1-aminoindan,	10305-73-4	
	(S)-1-aminoindan,	32457-23-1	
	1-aminotetralin,	49800-23-9	
10	1-aminobenzocyclobutene,	EXAMPLE 27	
	6-hydroxy-1-aminoindan,	EXAMPLE 34	
	(R)-6-hydroxy-1-aminoindan,	EXAMPLE 35	
	7-hydroxy-1-aminoindan,	EXAMPLE 42	EP 173 331
	6-fluoro-1-aminoindan,	EP 538	134
15	(R)-6-fluoro-1-aminoindan,	EP 538	134
	(S)-6-fluoro-1-aminoindan,	EP 538	134
	5-methyl-1-aminoindan,	EXAMPLE 38	
	5-methoxy-1-aminoindan,	EXAMPLE 36	41566-77-6
	6-methoxy-1-aminoindan,	EXAMPLE 25	103028-80-4
20	(S)-6-methoxy-1-aminoindan,	EXAMPLE 24	
	7-methyl-1-aminoindan,	EXAMPLE 28	
	3,5,7-trimethyl-1-aminoindan,	EXAMPLE 41	
	4,5-dimethoxy-1-aminoindan,	EXAMPLE 31	
	(R)-4,5-dimethoxy-1-aminoindan,	EXAMPLE 29	
25	(S)-4,5-dimethoxy-1-aminoindan,	EXAMPLE 30	
	4-hydroxy-5-methoxy-1-aminoindan,	EXAMPLE 33	
	6-hydroxy-5-methoxy-1-aminoindan,	EXAMPLE 32	
	trans-2-methyl-1-aminoindan	EXAMPLE 39	13943-76-6 *
	cis-2-methyl-1-aminoindan,	EXAMPLE 40	13943-41-4 *
30	N-methyl-1-aminoindan,	EXAMPLE 12	90874-50-3
	(R)-N-methyl-1-aminoindan,	EXAMPLE 13	10277-78-7 *
	(S)-N-methyl-1-aminoindan,	EXAMPLE 14	68533-22-2
	N,N-dimethyl-1-aminoindan,	EXAMPLE 15	10277-80-2 *
	N-formyl-1-aminoindan,	EXAMPLE 8	10277-75-5
35	(R)-N-formyl-1-aminoindan,	EXAMPLE 9	
	(S)-N-formyl-1-aminoindan,	EXAMPLE 10	
	N-acetyl-1-aminoindan,	EXAMPLE 17	127761-17-5

- 36 -

- (R)-N-acetyl-1-aminoindan, EXAMPLE 18 71744-38-2 *
- (S)-N-acetyl-1-aminoindan, EXAMPLE 19 61899-41-0
- N-acetyl-7-methyl-1-aminoindan, EXAMPLE 20
- N-acetyl-6-methoxy-1-aminoindan, EXAMPLE 26
- 5 N-acetyl-6-fluoro-1-aminoindan, EXAMPLE 22
- (R)-N-acetyl-6-fluoro-1-aminoindan, EXAMPLE 23
- (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, EXAMPLE 21
- N-butyryl-1-aminoindan, EXAMPLE 11 144602-65-3
- N-benzyl-1-aminoindan, EXAMPLE 16 66399-68-6 *
- 10 N-benzoyl-1-aminoindan, EXAMPLE 46
- N-(4-aminobutyryl)-1-aminoindan, EXAMPLE 7
- N-(2-acetamido)-1-aminoindan, EXAMPLE 3
- (R)-N-(2-acetamido)-1-aminoindan, EXAMPLE 1
- (S)-N-(2-acetamido)-1-aminoindan, EXAMPLE 2
- 15 N-(2-acetamido)-6-fluoro-1-aminoindan, EXAMPLE 5
- N-(2-acetamido)-1-aminotetralin, EXAMPLE 4
- N-(2-aminoacetyl)-1-aminoindan, EXAMPLE 45
- N-(3-cyanopropyl)-1-aminoindan, EXAMPLE 37
- N,N-di-(1-indanyl)amine EXAMPLE 43 113535-01-6 *
- 20 N-(2-n-Propylpentanoyl)-1-aminoindan EXAMPLE 47
- N-methyl-N-acetyl-1-aminoindan, EXAMPLE 48
- (R)-N-methyl-N-acetyl-1-aminoindan, EXAMPLE 49
- N-(2-propionamido)-1-aminoindan, EXAMPLE 50
- N-(2-phenylacetyl)-1-aminoindan, EXAMPLE 51 EP488, 616
- 25 N-(m-anisoyl)-1-aminoindan, EXAMPLE 52
- N-(4'-fluorobenzoyl)-1-aminoindan, EXAMPLE 53
- N-(p-4-toluoyl)-1-aminoindan, EXAMPLE 54
- (S)-(1-indanyl)-glycine, EXAMPLE 55
- N,N-di-(2-acetamido)-1-aminoindan, EXAMPLE 56
- 30 N-(1-indanyl)-aminoacetonitrile EXAMPLE 57
- N-acetyl-6-nitro-1-aminoindan, EXAMPLE 58
- 6-amino-N-acetyl-1-aminoindan, EXAMPLE 59
- 6-acetamido-N-acetyl-1-aminoindan, EXAMPLE 60
- 6-cyano-N-acetyl-1-aminoindan, EXAMPLE 61
- 35 6-carboxamido-N-acetyl-1-aminoindan, EXAMPLE 62
- 6-ethoxycarbonyl-N-acetyl-1-aminoindan, EXAMPLE 63
- cis-3-(methoxycarbonyl)-1-aminoindan, EXAMPLE 64

- 37 -

- cis-1-aminoindan-3-carboxylic acid, EXAMPLE 65
 trans-2-methyl-N-acetyl-1-aminoindan, EXAMPLE 66
 cis-2-methyl-N-acetyl-1-aminoindan, EXAMPLE 67
 (R)-N-trifluoroacetyl-1-aminoindan, EXAMPLE 68
 5 N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, EXAMPLE 69
 2-(1-indanamino)-N-isopropylethanesulfonamide, EXAMPLE 70
 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, EXAMPLE 71
 10 (R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, EXAMPLE 72
 N,N'-bis-(1-indanyl)adipamide, EXAMPLE 73
 N,N'-bis-(R)-(1-indanyl)adipamide, EXAMPLE 74
 N,N'-bis-(R)-(1-indanyl)succinamide, EXAMPLE 75

15

The following examples provide additional data relating to specific compounds of this invention.

EXAMPLE 120 (R)-N-(2-Acetamido)-1-aminoindan.HCl

A mixture of (R)-1-aminoindan (5.5 g, 40.7 mmole), 2-chloro-acetamide (3.7 g, 39.6 mmole), sodium bicarbonate (3.7 g, 44 mmole) and absolute ethanol (80 ml) was stirred under reflux for 24 hr. The reaction mixture was
 25 then filtered hot, the filtrate ice-cooled for 1 hr, and filtered. The solid was collected and washed with ether. The crude product was dissolved in isopropanol (135 ml), and 25% w/v isopropanolic HCl (6.5 ml, 44 mmole) was added; the mixture was stirred for 3 hr under ice cooling
 30 and filtered. The solid was washed with ether/hexane (5:1, 50 ml) and dried to afford 3.4 g (37%), m.p.: 224°-5°C.

35 ¹H NMR δ (DMSO): 9.60 (br s, 2H, NH₂'), 8.04, 7.58 (s, 2H, CONH₂), 7.70 (d, 1H, Ph), 7.34 (m, 3H, Ph), 4.80 (br s, 1H, C1-H), 3.62 (m, 1H, CH₂), 3.14 (m, 1H, C3-H), 2.84 (m, 1H, C3-H'), 2.38 (m, 1H, C2-H), 2.23 (m, 1H, C2-H') ppm.

- 38 -

MS: 191 (MH⁺, 58), 117 (100).

IR (KBr): 3391, 3252, 3193, 2947, 2807, 1692, 1616, 1559, 1443, 1381, 1339 cm⁻¹.

5 EXAMPLE 2

(S)-N-(2-Acetamido)-1-aminoindan.HCl

 The title compound was obtained from (S)-1-aminoindan in a manner analogous to that described in Ex. 1, m.p.: 222-3°. The NMR, MS and IR spectral data are identical to those given in Example 1.

Anal. calc. for C₁₁H₁₅ClN₂O: C, 58.29; H, 6.66; N, 12.35.

Found: C, 58.51; H, 6.71; N, 12.31.

15 EXAMPLE 3

(rac)-N-(2-Acetamido)-1-aminoindan.HCl

 The title compound was prepared from (rac)-1-aminoindan in a manner analogous to that described in Example 1, m.p.: 201-2°C. The free base melted at 131-3°C.

Found: C, 58.58; H, 6.77; N, 12.35.

The NMR, MS and IR spectral data are identical to those given in Example 1.

25 EXAMPLE 4

(rac)-N-(2-Acetamido)-1-aminotetralin

 The title compound was prepared in 25% yield from 1-aminotetralin and 2-chloroacetamide according to the procedure described in Example 1. The base was purified by filtration through silica with acetone as eluent, to give a white solid, m.p.: 139°-41°C.

Anal. calcd. for C₁₂H₁₆N₂O: C, 70.59; H, 7.84; N, 13.72.

Found: C, 70.58; H, 7.83; N, 13.80.

35 ¹H NMR δ (CDCl₃): 7.36 (m, 1H, Ph), 7.20 (m, 3H, Ph, CONH₂), 7.10 (m, 1H, Ph), 5.52 (br s, 1H, CONH₂), 3.78 (br t, 1H, Cl-H), 3.39 (s, 2H, CH₂), 2.78 (m, 2H, C4-H), 1.96-

- 39 -

1.70 (m, 4H, C2-H, C3-H) ppm.

MS: 205 (MH⁺, 100), 146 (10), 131 (13), 93 (47).

IR (KBr): 3382, 3183, 2936, 1632, 1487, 1445, 1395, 1333 cm⁻¹.

5

EXAMPLE 5

(rac)-6-Fluoro-N-(2-acetamido)-1-aminoindan.HCl

A mixture of 6-fluoro-1-aminoindan (10.6 g, 70.2 mmole),
2-chloroacetamide (6.4 g, 68 mmole), sodium bicarbonate
10 (6.4 g, 76 mmole) and absolute ethanol (130 ml) was
refluxed for 22 hr. The reaction mixture was then
filtered, ice-cooled and gaseous HCl was bubbled through
for 40 min. The solid was collected, washed with
ether/hexane and dried. Crystallization from 2:1
15 MeOH:EtOH afforded the title compound (3.4 g, 21%). M.p.
of the free base: 100-102°C.

Anal. calcd. for C₁₁H₁₄ClFN₂O: C, 53.99; H, 5.77; N, 11.45;
F, 7.77.

20 Found: C, 53.91; H, 5.63; N, 11.24; F, 8.12.

¹H NMR δ (D₂O): 7.38 (m, 1H, Ph), 7.28 (m, 1H, Ph), 7.15
(m, 1H, Ph), 4.91 (m, 1H, C1-H), 3.92 (m, 2H, CH₂), 3.08
(m, 1H, C3-H), 2.96 (m, 1H, C3-H'), 2.63 (m, 1H, C2-H),
2.28 (m, 1H, C2-H') ppm.

25 MS: 209 (MH⁺, 100), 150 (10), 135 (6).

IR (KBr): 3360, 3190, 3020, 2910, 2410, 1690, 1600, 1500,
1405 cm⁻¹.

30

EXAMPLE 6

(rac)-N-(N-Boc-4-aminobutyryl)-1-aminoindan

A solution of Boc-GABA anhydride (4.46 g, 11.5 mmole,
prepared from Boc GABA and DCC in CH₂Cl₂) in dry THF (15
ml) was added to a solution of 1-aminoindan (1.5 g, 11.2
35 mmole) in dry THF (15 ml), and DMAP (1.5 g, 12.3 mmole)
was then added in one portion. The reaction mixture was
stirred at RT for 6 hr, filtered and the filtrate was

- 40 -

evaporated to dryness. The residue was dissolved in CH_2Cl_2 (25 ml), the solution was then washed with 10% NaHCO_3 (25 ml) and H_2O (15 ml), dried over MgSO_4 and evaporated to dryness. The residue was treated with
5 hexane/ether (1:1, 100 ml), and the resultant crude product was filtered, dried and purified by filtering-column chromatography (Silica, 1:1 hexane/EtOAc as eluent), and crystallized from hexane:EtOAc, to give 2.5 g (7.84 mmole, 71%) of a white crystalline solid, m.p.:
10 $118^\circ\text{-}20^\circ\text{C}$.

^1H NMR δ (DMSO): 8.15 (d, 1H, NHCO), 7.20 (m, 4H, Ph), 6.80 (br t, 1H, NHCOO), 5.26 (q, 1H, C1-H), 2.92 (m, 3H, CH_2NHBoc , C3-H), 2.78 (m, 1H, C3-H'), 2.36 (m, 1H, C2-H),
15 2.11 (m, 2H, CH_2CONH), 1.76 (m, 1H, C2-H'), 1.64 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{NHBoc}$), 1.38 (s, 9H, Boc) ppm.
MS: 319 (MH^+ , 100), 263 ($\text{MH}^+ - \text{CH}_2 = \text{CMe}_2$, 68), 219 (263- CO_2 , 30).

20 EXAMPLE 7

(rac)-N-(4-Aminobutyryl)-1-aminoindan.HCl

Also called N-(4-aminobutanoyl)-1-aminoindan.HCl.

N-(N-Boc-4-aminobutyryl)-1-aminoindan (2.50 g, 7.8 mmole) was dissolved in dry dioxane (20 ml), and 1.7N HCl in
25 dioxane (20 ml) was added. The solution was stirred at ambient temperature for 4 hr, evaporated to dryness, and the residue taken up in $\text{CH}_2\text{Cl}_2\text{:H}_2\text{O}$ mixture (1:1, 160 ml). The aqueous phase was separated, filtered through millipore and evaporated to dryness in vacuo. The crude
30 product was crystallized from 40:60 EtOAc:ethanol to give 1.55 g (78%) white crystalline solid, m.p.: 168°C .

Anal. calcd. for $\text{C}_{13}\text{H}_{19}\text{ClN}_2\text{O}$: C, 61.28; H, 7.51; N, 10.99;

Found: C, 61.37; H, 7.66; N, 11.11.

35 ^1H NMR δ (DMSO): 8.37 (d, 1H, NHCO), 8.00 (br s, 3H, NH_3^+), 7.20 (m, 4H, Ph), 5.28 (q, 1H, C1-H), 2.92 (m, 1H, C3-H), 2.80 (m, 3H, C3-H', CH_2NH_3^+), 2.37 (m, 1H, C2-H), 2.26

- 41 -

(t, 2H, CH_2CONH), 1.85 (m, 2H, $\text{CH}_2\text{CH}_2\text{CONH}$), 1.77 (m, 1H, C2-H') ppm.

MS: 219 (MH⁺, 100), 202 (14), 117 (31).

IR (KBr): 3272, 3235, 3032, 1644, 1628, 1553, 1462, 1454 cm⁻¹.

EXAMPLE 8

(rac)-N-Formyl-1-aminoindan

The title compound was prepared from 1-aminoindan according to the procedure described in J.Med.Chem., 9,830 (1966), and crystallized from EtOAc (40% overall yield), m.p.: 105°C.

Anal. calcd. for C₁₀H₁₁NO: C, 74.50; H, 6.88; N, 8.69.

Found: C, 74.59; H, 6.88; N, 8.67.

¹H NMR δ (CDCl₃): 8.26 (m, 1H, HCO), 7.25 (m, 4H, Ph), 5.80 (br s, 1H, NH), 5.56, 5.00 (q, 1H, C1-H, 2 rotamers), 3.01 (m, 1H, C3-H), 2.88 (m, 1H, C3-H'), 2.62 (m, 1H, C2-H), 1.85 (m, 1H, C2-H') ppm.

MS: 162 (MH⁺, 30), 117 (MH⁺-HCONH₂, 100).

IR (KBr): 3270, 3040, 2960, 1635, 1545, 1400, 1245 cm⁻¹.

EXAMPLE 9

(R)-N-Formyl-1-aminoindan

The title compound was obtained from (R)-1-aminoindan in a manner analogous to that described in Ex. 8, m.p.: 123-5°C.

Anal. found: C, 74.61; H, 6.97; N, 8.76.

The NMR, MS and IR spectral data are identical to those given in Ex. 8.

EXAMPLE 10

(S)-N-Formyl-1-aminoindan

The title compound was obtained from (S)-1-aminoindan in a manner analogous to that described in Ex. 8, m.p.: 124-

- 42 -

125°C.

Anal. found: C, 74.70; H, 7.13; N, 8.94.

The NMR, MS and IR spectral data are identical to those given in Ex. 8.

EXAMPLE 11

(rac)-N-Butyryl-1-aminoindan

A solution of butyryl chloride (5.33 g, 50 mmole) in anh. DME (60 ml) was added slowly to a stirred and ice-cooled solution of 1-aminoindan (6.66 g, 50 mmole) and Et₃N (10.0 g, 100 mmole) in anh. DME (75 ml), and the mixture stirred at ambient temperature for 24 hr. After removal of volatiles under reduced pressure, the residue was taken up in 1:1 water/EtOAc mixture (300 ml). The organic layer was separated, dried on Na₂SO₄ and evaporated to dryness. The crude product was crystallized from EtOAc, to give 5.9 g (58%) of the title compound as a white solid, m.p.: 84°-5°C.

Anal. calcd. for C₁₃H₁₇NO: C, 76.81; H, 8.43; N, 6.89.

Found: C, 77.18; H, 8.48; N, 7.08.

¹H NMR δ(CDCl₃): 7.24 (m, 4H, Ph), 5.73 (br d, 1H, NH), 5.48 (q, 1H, C1-H), 2.97 (m, 1H, C3-H), 2.85 (m, 1H, C3-H'), 2.59 (m, 1H, C2-H), 2.19 (t, 2H, CH₂CO), 1.78 (m, 1H, C2-H'), 1.70 (m, 2H, CH₂CH₂), 0.97 (t, 3H, CH₃) ppm.

MS: 204 (MH⁺, 100), 179 (12), 160 (18).

IR (KBr): 3279, 2961, 1640, 1545, 1481, 1458 cm⁻¹.

EXAMPLE 12

(rac)-N-Methyl-1-aminoindan.HCl

The title compound was prepared from (rac)-1-aminoindan, according to J. Med. Chem., 9, 830 (1963), and crystallized from iPrOH/Et₂O (overall yield 25%), m.p.: 147-9°C.

¹H NMR δ (CDCl₃): 9.81 (br s, 2H, NH₂⁺), 7.80 (d, 1H, Ph), 7.28 (m, 3H, Ph), 4.65 (m, 1H, C1-H), 3.28 (m, 1H, C3-H),

- 43 -

2.93 (m, 1H, C3-H'), 2.47 (t, 4H, CH₃, C2-H), 2.36 (m, 1H, C2-H') ppm.

MS: 148 (MH⁺, 100), 117 (18).

IR (KBr): 2934, 2751, 2694, 1462, 1431, 1414, 1339 cm⁻¹.

5

EXAMPLE 13

(R)-N-Methyl-1-aminoindan.HCl

The title compound was prepared from (R)-1-aminoindan in a manner analogous to that described in Example 12, m.p.: 153°C.

10

Anal. calcd. for C₁₀H₁₄ClN: C, 65.39; H, 7.68; N, 7.63; Cl, 19.30.

Found: C, 65.66; H, 7.89; N, 7.57; Cl, 19.80.

15

The NMR, MS and IR spectral data are identical to those given in Example 12.

EXAMPLE 14

(S)-N-Methyl-1-aminoindan.HCl

20

The title compound was prepared from (S)-1-aminoindan in a manner analogous to that described in Example 12, m.p.: 154°C.

Found: C, 65.30; H, 7.83; N, 7.77; Cl, 19.48.

25

The NMR, MS and IR spectral data are identical to those given in Example 12.

EXAMPLE 15

(rac)-N,N-Dimethyl-1-aminoindan.HCl

30

The title compound was prepared from 1-aminoindan, according to Yakugaku Zasshi, 82, 1597 (1962), Chem. Abs., 59, 611f (1963) and crystallized from iPrOH/Et₂O (40% overall yield), m.p.: 195°-7°C.

Anal. calcd. for C₁₂H₁₆ClN: C, 66.82; H, 8.16; N, 7.09; Cl, 17.93.

35

Found: C, 66.86; H, 8.33; N, 6.85; Cl, 18.30.

¹H NMR δ (CDCl₃): 7.93 (d, 1H, Ph), 7.35 (m, 3H, Ph), 4.95

- 44 -

(dd, 1H, C1-H), 3.15 (m, 1H, C3-H), 3.02 (m, 1H, C3-H'), 2.71 (s, 6H, CH₃), 2.55 (m, 1H, C2-H), 2.46 (m, 1H, C2-H') ppm.

MS: 162 (MH⁺, 100), 117 (MH⁺-Me₂NH, 19).

5 IR (KBr): 2932, 2561, 2525, 2467, 1478, 1422, 1362, 1192 cm⁻¹.

EXAMPLE 16

(rac)-N-Benzyl-1-aminoindan.HCl

10 A solution of 1-chloroindan (7.6 g, 49.7 mmole) and benzylamine (21.3 g, 199 mmole) in toluene (55 ml) was refluxed for 10 hr. The reaction mixture was filtered, water (50 ml) was added to the filtrate and acidified to
15 pH=2.5 by means of 33% H₂SO₄. The aqueous phase was separated, its pH was adjusted to 6-6.5 by means of 25% NH₄OH, and extracted with toluene. The organic phase was dried and evaporated to dryness (8.2 g, 74%). 1.7 g of the crude free base was converted to the HCl salt by means of isopropanolic HCl, affording 1.3 g (66%) of a
20 white crystalline solid, m.p.: 180°C.
Anal. calcd. for C₁₆H₁₈ClN: C, 73.96; H, 6.98; N, 5.39; Cl, 13.65.

Found: C, 73.93; H, 7.04; N, 5.63; Cl, 13.62.

¹H NMR δ (DMSO): 10.0 (br d, 2H, NH₂⁺), 7.90-7.25 (m, 9H, Ph), 4.74 (br s, 1H, C1-H), 4.15 (br s, 2H, PhCH₂), 3.16
25 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.40 (m, 2H, C2-H) ppm.

MS: 224 (MH⁺, 100), 117 (MH⁺-PhCH₂NH₂, 68).

30 IR (KBr): 2886, 2776, 2759, 2730, 2629, 2552, 1582, 1484, 1458, 1433, 1424, 1383, 1210 cm⁻¹.

EXAMPLE 17

(rac)-N-Acetyl-1-aminoindan

35 The title compound was obtained in 52% yield by acetylation of 1-aminoindan, according to J. Med. Chem., 9, 830 (1966), m.p.: 124-5°C.

¹H NMR δ (CDCl₃): 7.25 (m, 4H, Ph), 5.78 (br s, 1H, NH),

- 45 -

5.46 (q, 1H, C1-H), 2.98 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 2.01 (s, 3H, CH₃), 1.80 (m, 1H, C2-H') ppm.

MS: 176 (MH⁺, 100), 117 (MH⁺ - CH₃CONH₂, 100).

5 IR (KBr): 1632, 1551, 1481, 1458, 1437, 1372, 1290 cm⁻¹.

EXAMPLE 18

(R)-N-Acetyl-1-aminoindan

10 The title compound was obtained from (R)-1-aminoindan in a manner analogous to that described in Example 17, m.p.: 152-3°C.

Anal. calcd. for C₁₁H₁₃NO: C, 75.40; H, 7.48; N, 8.00.

15 Found: C, 75.42; H, 7.43; N, 7.80.

The NMR, MS and IR spectral data are identical to those given in Example 17.

EXAMPLE 19

(S)-N-Acetyl-1-aminoindan

20 The title compound was obtained from (S)-1-aminoindan in a manner analogous to that described in Example 17, m.p.: 154°C.

25 Anal. calcd. for C₁₁H₁₃NO: C, 75.40; H, 7.48; N, 8.00.

Found: C, 75.68; H, 7.66; N, 7.99.

The NMR, MS and IR data are identical to those given in Example 17.

EXAMPLE 20

(rac)-7-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 55% yield according to the procedure described in Example 17, m.p.: 166-7°C.

35 Anal. calcd. for C₁₂H₁₅NO: C, 75.87; H, 7.77; N, 7.54.

Found: C, 76.16; H, 7.98; N, 7.40.

¹H NMR δ (CDCl₃): 7.10 (m, 3H, Ph), 5.60 (br d, 1H, NH),

- 46 -

5.48 (m, 1H, C1-H), 3.03 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.43 (m, 1H, C2-H), 2.29 (s, 3H, PhMe), 2.01 (m, 1H, C2-H'), 1.96 (s, 3H, CH₃) ppm.

MS: 190 (MH⁺, 100), 182 (35), 165 (11).

5 IR: 3281, 2919, 1636, 1547, 1375, 1291 cm⁻¹.

EXAMPLE 21

(R)-4,5-Dimethoxy-N-acetyl-1-aminoindan

10 The title compound was prepared in 66% yield according to the procedure described in Example 17, m.p.: 175°C.

Anal. calcd. for C₁₃H₁₇NO₃: C, 66.6; H, 7.43; N, 6.06.

Found: C, 66.37; H, 7.43; N, 5.95.

15 ¹H NMR δ (CDCl₃): 6.95 (d, 1H, Ph), 6.77 (d, 1H, Ph), 5.82 (br d, 1H, NH), 5.38 (m, 1H, C1-H), 3.84 (s, 6H, OMe), 3.0 (m, 1H, C3-H), 2.84 (m, 1H, C3-H'), 2.56 (m, 1H, C2-H), 2.01 (s, 3H, Me), 1.80 (m, 1H, C2-H') ppm.

MS: 236 (MH⁺, 11), 177 (MH⁺ - CH₃CONH₂, 100).

20 IR: 3281, 2959, 2835, 1638, 1551, 1495, 1296, 1260, 1217 cm⁻¹.

EXAMPLE 22

(rac)-6-Fluoro-N-acetyl-1-aminoindan

25 The title compound was prepared in 51% yield according to the procedure described in Example 17, m.p.: 139-141°C.

Anal. calcd. for C₁₁H₁₂FNO: C, 68.37; H, 6.26; F, 9.84; N, 7.25.

Found: C, 68.50; H, 6.48; F, 10.25; N, 7.44.

30 ¹H NMR δ (CDCl₃): 7.15 (dd, 1H, Ph), 6.93 (m, 2H, Ph), 5.78 (br s, 1H, NH), 2.92 (m, 1H, C3-H), 2.82 (m, 1H, C3-H'), 2.03 (s, 3H, Me), 2.60 (m, 1H, C2-H), 1.82 (m, 1H, C2-H') ppm.

MS: 194 (MH⁺, 100), 135 (MH⁺-AcNH₂, 31).

35 IR (KBr): 3279, 2963, 1634, 1551, 1489, 1373, 1296 cm⁻¹.

- 47 -

EXAMPLE 23(R)-6-Fluoro-N-acetyl-1-aminoindan

The title compound was obtained in 47% yield from (R)-6-fluoro-1-aminoindan in a manner analogous to that described in Example 17, m.p.: 181-3°C.

The NMR, MS and IR spectral data are identical to those given in Example 22.

Anal. found for $C_{11}H_{12}FNO$: C, 68.31; H, 6.22; N, 7.31, F, 10.23.

EXAMPLE 24(S)-6-Methoxy-1-aminoindan.HCl

The title compound was prepared in 53% yield from 6-methoxy-1-indanone (prepared via the methods described in J.Org.Chem., 46, 2974 (1981) and in J.Chem.Soc. Peskin Trans I, 151 (1972)) in a manner analogous to that described in Eur.Pat.Appl. 436492, m.p.: 239-242°C (dec.).

Anal. calcd. for $C_{10}H_{14}ClNO$: C, 60.15; H, 7.02; N, 7.02; Cl, 17.79.

Found: C, 60.46; H, 7.15; N, 7.11; Cl, 17.53.

1H NMR δ (D_2O): 7.35 (1H, Ph), 7.12 (1H, Ph), 7.06 (1H, Ph), 4.85 (m, 1H, Cl-H), 3.85 (s, 3H, OMe), 3.08 (m, 1H, C3-H), 2.95 (m, 1H, C3-H'), 2.62 (m, 1H, C2-H), 2.17 (m, 1H, C2-H') ppm.

MS: 162 (M-H, 63), 147 (100).

IR (KBr): 2940, 1609, 1500, 1250 cm^{-1} .

EXAMPLE 25(rac)-6-Methoxy-1-aminoindan.HCl

The title compound was prepared in 72% from 6-methoxy-1-indanone in a manner analogous to that described in Ex. 24, except that 6-methoxy-1-oximinindan was reduced by hydrogen over Pd on charcoal; m.p.: 244-5°C.

- 48 -

The NMR, MS and IR data are identical to those described in Ex. 24.

Found for $C_{10}H_{14}ClNO$: C, 60.22; H, 6.97; N, 6.83; Cl, 17.59.

EXAMPLE 26

(rac) 6-methoxy-N-acetyl-1-aminoindan

The title compound was prepared in 27% yield from (rac)-6-methoxy aminoindan according to the procedure described in Example 17, m.p.: 131-2°C.

Anal. calcd. for $C_{12}H_{15}NO_2$: C, 70.22; H, 7.37; N, 6.82.

Found: C, 70.22; H, 7.41; N, 6.84.

1H NMR δ ($CDCl_3$): 7.12 (d, 1H, Ph), 6.80 (m, 2H, Ph), 5.77 (br d, 1H, NH), 5.43 (m, 1H, Cl-H), 3.78 (s, 3H, OMe), 2.90 (m, 1H, C3-H), 2.78 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 2.02 (s, 3H, Me), 1.80 (m, 1H, C2-H') ppm.

IR: 3283, 3075, 3002, 2963, 2940, 2836, 1638, 1551, 1489, 1372, 1327, 1294, 1240, 1146 cm^{-1} .

EXAMPLE 27

1-Aminobenzocyclobutene.HCl

The title compound was prepared from benzocyclobutene-1-carboxylic acid in 44% yield, according to the procedure described in J.Med.Chem., 8,255 (1965); m.p.: 184°C.

Anal. calcd. for C_8H_9ClN : C, 61.74; H, 6.48; N, 9.0.

Found: C, 61.04; H, 6.59; N, 9.30.

1H NMR δ (DMSO): 8.96 (br s, 3H, NH_3^+), 7.40-7.20 (m, 4H, Ph), 4.71 (m, 1H, Cl-H), 3.55 (dd, 1H, C2-H), 3.24 (dd, 1H, C2-H') ppm.

MS: 120 (MH^+ , 79), 103 ($M-NH_3$, 100).

IR (KBr): 2963, 2942, 1601, 1584, 1495, 1458, 1368 cm^{-1} .

EXAMPLE 28

(rac)-7-Methyl-1-aminoindan.HCl

3-Methyl benzaldehyde was converted to a mixture of 5-

- 49 -

5 methyl-1-indanone and 7-methyl-1-indanone according to the procedure described in Ex. 24. The two isomers were separated by column chromatography (hexane:CH₂Cl₂) and the latter was converted to the title compound as in Ex. 24. Overall yield 18%, m.p.: >280°C (dec.).

Anal. calcd. for C₁₀H₁₄ClN: C, 65.4; H, 7.63; N, 7.63; Cl, 19.35.

Found: C, 65.62; H, 7.66; N, 7.66; Cl, 18.99.

10 EXAMPLE 29

(R)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in 24% yield from (rac)-4,5-dimethoxy-1-aminoindan (Ex. 31), m.p.: 213-4°C (dec.).

Anal. calcd. for C₁₁H₁₆ClNO₂: C, 57.52; H, 7.02; N, 6.10.

Found: C, 57.18; H, 7.08; N, 6.38.

¹H NMR δ (D₂O): 7.29 (d, 1H, Ph), 7.10 (d, 1H, Ph), 4.85 (m, 1H, C1-H), 3.95 (s, 3H, OMe), 3.88 (s, 3H, OMe), 3.20 (m, 1H, C3-H), 3.07 (m, 1H, C3-H'), 2.65 (m, 1H, C2-H), 2.20 (m, 1H, C2-H') ppm.

MS: 192 (M-H⁺, 100), 177 (61).

IR (KBr): 3262, 2928, 1620, 1605, 1532, 1489, 1443, 1432, 1375 cm⁻¹.

25 EXAMPLE 30

(S)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in a manner analogous to that described in Example 29, m.p.: 209-10°C (dec.).

The NMR, MS and IR spectral data are identical to those described in Example 29.

35 Found for C₁₁H₁₆ClNO₂: C, 56.36; H, 7.00; N, 6.22.

- 50 -

EXAMPLE 31(rac)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in 70% yield from 2,3-dimethoxy benzaldehyde in a manner analogous to that described in Ex. 24, m.p.: 202-4°C (dec.).

Anal. calcd. for $C_{11}H_{16}ClNO_2$: C, 57.51; H, 7.02; N, 6.10.

Found: C, 57.58; H, 6.99; N, 5.69.

The NMR, MS and IR spectral data are identical to those described in Ex. 29.

EXAMPLE 32(rac)-6-Hydroxy-5-methoxy-1-aminoindan.HCl

The title compound was prepared in 5% yield from 3-methoxy-4-hydroxy-benzaldehyde in a manner analogous to that described in Ex. 24.

Anal. calcd. for: $C_{10}H_{13}NO_2$ (free base): C, 67.02; H, 7.31; N, 7.81.

Found: C, 66.97; H, 7.39; N, 7.88.

1H NMR δ (D_2O): 7.08, 7.01 (s, 2H, Ph), 4.80 (m, 1H, C1-H) 3.91 (s, 3H, OMe), 3.12 (m, 1H, C3-H), 2.95 (m, 1H, C3-H'), 2.60 (m, 1H, C2-H), 2.15 (m, 1H, C2-H') ppm.

IR (KBr): 3485, 3413, 3009, 2943, 1611, 1509, 1456, 1442, 1379, 1325, 1269, 1233 cm^{-1} .

EXAMPLE 33(rac)-4-Hydroxy-5-methoxy-1-aminoindan.HCl

The title compound was prepared in 45% yield from 4-benzyloxy-5-methoxy-1-indanone oxime, m.p.: 188-90°C (dec.).

1H NMR δ (D_2O): 7.05 (m, 2H, Ph), 4.80 (m, 1H, C1-H), 3.88 (s, 3H, OMe), 3.05 (m, 1H, C3-H), 2.92 (m, 1H, C3-H'), 2.63 (m, 1H, C2-H), 2.18 (m, 1H, C2-H') ppm.

MS: 178 (M-H⁺, 100), 148 (12).

IR (KBr): 3401, 2932, 1615, 1526, 1487, 1425, 1279 cm^{-1} .

- 51 -

EXAMPLE 34(rac)-6-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 45% yield from (rac)-6-methoxy-1-aminoindan, m.p.: 202-3°C (dec.).

5

Anal. calcd. for $C_9H_{12}ClNO$: C, 58.22; H, 6.52; N, 7.55.

Found: C, 58.08; H, 6.41; N, 7.39.

1H NMR δ (D_2O): 7.15 (d, 1H, Ph), 6.90 (s, 1H, Ph), 6.80 (d, 1H, Ph), 4.67 (m, 1H, Cl-H), 3.05 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.55 (m, 1H, C2-H), 2.06 (m, 1H, C2-H') ppm.

10

MS: 148 ($M-H^+$, 65), 132 (100).

IR (KBr): 3297, 3044, 1615, 1499, 1460, 1451, 1375, 1281, 1213 cm^{-1} .

15

EXAMPLE 35(R)-6-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 43% yield from (R)-6-methoxy-1-aminoindan, m.p.: 199-200°C.

20

Found for: $C_9H_{12}ClNO$: C, 57.98; H, 6.30; Cl, 18.88; N, 7.55.

The NMR and MS spectral data are identical to those described in Ex. 34.

25

EXAMPLE 36(rac)-5-Methoxy-1-aminoindan.HCl

The title compound was prepared in 25% yield from 5-methoxy-1-indanone in a manner analogous to that described in Ex. 24, m.p.: 225-7°C (dec.).

30

Anal. calcd. for $C_{10}H_{14}ClNO$: C, 60.15; H, 7.02; N, 7.02, Cl, 17.79.

Found: C, 59.77; H, 6.94; N, 7.08; Cl, 17.53

35

1H NMR δ (D_2O): 7.43 (d, 1H, Ph), 7.00 (d, 1H, Ph), 6.93 (m, 1H, Ph), 4.85 (m, 1H, Cl-H), 3.85 (s, 3H, OMe), 3.15

- 52 -

(m, 1H, C3-H), 2.98 (m, 1H, C3-H'), 2.63 (m, 1H, C2-H),
2.17 (m, 1H, C2-H') ppm.

MS: 162 (M-H⁺, 100), 147 (100).

IR (KBr): 2900, 1602, 1509, 1500, 1300, 1252 cm⁻¹.

5

EXAMPLE 37

(rac)-N-(3-Cyanopropyl)-1-aminoindan

Potassium carbonate (15.5 g, 112 mmole) and 4-chlorobutyronitrile (11.58 g, 112 mmole) was added to a
10 solution of 1-aminoindan (5.0 g, 37.6 mmole) in acetonitrile (50 ml), and the mixture refluxed for 2 hr. A second portion of 4-chlorobutyronitrile (5.0 g) was then added, the mixture further heated for 24 hr, filtered and the filtrate evaporated to dryness.
15 Unreacted 4-chlorobutyronitrile was removed by treating the residue (20 g) with isopropanolic HCl (16.7 ml, 24%) followed by successive extractions with ether (3x150 ml). The crude product thus obtained was further purified by column chromatography (Silica, CH₂Cl₂:MeOH 98:2) to afford
20 3.7 g (49%) of tan-colored crystalline mass.

¹H NMR δ (CDCl₃): 7.32 (m, 1H, Ph), 7.20 (m, 3H, Ph), 4.22 (t, 1H, C1-H), 2.98 (m, 1H, C3-H), 2.85 (m, 2H, CH₂NH),
2.81 (m, 1H, C3-H'), 2.49 (t, 2H, CH₂CN), 2.42 (m, 1H, C2-H),
25 H), 1.83 (m, 2H, CH₂CH₂CH₂), 1.77 (m, 1H, C2-H') ppm.
MS: 201 (MH⁺, 63), 117 (63), 85 (100).

EXAMPLE 38

(rac)-5-Methyl-1-aminoindan.HCl

30 5-Methyl-1-indanone, obtained from 3-methyl benzaldehyde as described in Ex. 28, was converted to the title compound according to the procedure described in Ex. 24 (overall yield 6%), m.p.: 247-9°C (dec.).

35 Anal. calcd. for C₁₀H₁₄ClN: C, 65.40; H, 7.63; N, 7.63; Cl, 19.35

Found: C, 65.12; H, 7.36; N, 7.58; Cl 19.18.

- 53 -

^1H NMR δ (D_2O): 7.45 (d, 1H, Ph), 7.25 (s, 1H, Ph), 7.20 (d, 1H, Ph), 4.81 (m, 1H, Cl-H), 3.22 (m, 1H, C3-H), 2.90 (m, 1H, C3-H'), 2.56 (m, 1H, C2-H), 2.35 (s, 3H, CH_3), 2.12 (m, 1H, C2-H') ppm.

5

EXAMPLE 39**(rac)-trans-2-Methyl-1-aminoindan.HCl**

2-Methyl-1-indanone was prepared from benzene and α -bromoisobutyryl bromide, as in Polish J. Chem. 52, 2059 (1978), and converted to the oximino derivative, from which the title compound was obtained by reduction with Zn/HOAc. The overall yield was 14%, m.p.: $>275^\circ\text{C}$ (dec.).

10

Anal. calcd. for $\text{C}_{10}\text{H}_{14}\text{NCl}$: C, 65.40; H, 7.63; N, 7.63; Cl, 19.35.

15

Found: C, 65.49; H, 7.90; N, 7.68; Cl, 19.14.

^1H NMR δ (D_2O): 7.60-7.25 (m, 4H, Ph); 4.70 (d, 1H, Cl-H), 3.17 (dd, 1H, C3-H), 2.87 (m, 1H, C2-H), 2.79 (dd, 1H, C3-H'), 1.19 (d, 3H, CH_3) ppm.

20

EXAMPLE 40**(rac)-cis-2-Methyl-1-aminoindan.HCl**

The title compound was prepared according to procedure described in Ex. 39, except that 2-methyl-1-oximinoindan was reduced by hydrogenation over Pd on charcoal, m.p.: $235-7^\circ\text{C}$ (dec.).

25

Found for $\text{C}_{10}\text{H}_{14}\text{Cl,N}$: C, 65.78; H, 7.93; N, 7.72; Cl, 19.39.

30

^1H NMR δ (D_2O): 7.60-7.25 (m, 4H, Ph), 4.45 (d, 1H, Cl-H), 3.33 (dd, 1H, C3-H), 2.68 (dd, 1H, C3-H'), 2.58 (m, 1H, C2-H), 1.25 (d, 3H, CH_3) ppm.

35

- 54 -

EXAMPLE 41(rac)-3,5,7-Trimethyl-1-aminoindan.HCl

The title compound was prepared in 9% yield from m-xylene and crotonic acid, according to the procedures described in Ex. 24, m.p.: >275°C (dec.).

Anal. calcd. for $C_{12}H_{18}NCl$: C, 68.08; H, 8.51; N, 6.62; Cl, 16.78.

Found: C, 68.11; H, 8.46; N, 6.73; Cl, 17.08.

1H NMR δ (D_2O): 7.10 (s, H, Ph), 7.05 (s, H, Ph), 4.89 (m, 1H, Cl-H), 3.25 (m, 1H, C3-H), 2.90 (m, 1H, C2-H), 2.37 (s, 3H, CH_3), 2.33 (s, 3H, CH_3), 1.70 (m, 1H, C2-H'), 1.34 (d, 3H, CH_3) ppm.

EXAMPLE 42(rac)-7-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 6% yield from phenol and 3-chloro-propionylchloride according to the procedures described in Ex. 24, m.p.: 179-81°C.

Anal. calcd. for $C_9H_{11}ClNO$: C, 58.22; H, 6.52; N, 7.55; Cl, 19.10.

Found: C, 58.15; H, 6.47; N, 7.42; Cl, 19.39.

1H NMR δ (D_2O): 7.29 (t, 1H, Ph), 6.93 (d, 1H, Ph), 6.78 (d, 1H, Ph), 4.94 (m, 1H, Cl-H), 3.12 (m, 1H, C3-H), 2.97 (m, 1H, C3-H'), 2.61 (m, 1H, C2-H), 2.12 (m, 1H, C2-H') ppm.

EXAMPLE 43(rac)-N,N-Di-(1-indanyl)amine.HCl

A solution of (rac)-1-chloroindan (9.2 g, 60 mmole) in acetonitrile (25 ml) was added dropwise (10 min.) to a stirred and heated (65°C) suspension of (rac)-1-aminoindan (8.0 g, 60 mmole), K_2CO_3 (8.3 g, 60 mmole) in acetonitrile (100 ml), under N_2 atmosphere. The mixture

- 55 -

was further stirred at 65°C for 24 hrs; the solvent was removed under reduced pressure and the residue was partitioned between 10% NaOH (100 ml) and CH₂Cl₂ (100 ml). The aqueous layer was separated, extracted with CH₂Cl₂ (50 ml), and the combined organic layer was dried (Na₂SO₄) and evaporated to dryness. The crude product was purified by flash column chromatography (silica, hexane:ETOAc 80:20), to give 5.4 g (36%) of the free base, which was converted to its HCl salt by dissolving it in Et₂O (60 ml) and adding to it an Et₂O solution saturated with HCl gas (75 ml). The resulting suspension was filtered, and the collected solid was crystallized from EtOH/iPrOH, to give 4.90 g (79%) of the title compound as a mixture of two diastereomers, white crystalline solid, m.p.: 226-8°C.

15

Anal. calcd. for C₁₈H₂₀NCl: C, 75.64; H, 7.05; N, 4.90; Cl, 12.41.

Found: C, 75.90; H, 6.85; N, 4.96; Cl, 12.34.

20

¹H NMR δ (DMSO): 9.80, 9.60 (brs, 2H, NH₂⁺), 7.80, 7.78 (d,d, 2H, Ph), 7.36, 7.28 (m, m, 6H, Ph), 4.93, 4.87 (m, m, 2H, C1-H), 3.24, 2.91 (m, 2H, C3-H), 2.91 (m, 2H, C3-H'), 2.52 (m, 2H, C2-H), 2.38 (m, 2H, C2-H') ppm.

MS: 250 (MH⁺, 100)

25

IR: 3455, 2938, 2786, 2692, 2625, 1578, 1482, 1460, 1435, 1425, 1358, 1028 cm⁻¹.

EXAMPLE 44

(rac)-N-(2-N-Boc-aminoacetyl)-1-aminoindan

30

A mixture of (rac)-1-aminoindan (2.5 g, 18.8 mmole), N-Boc-glycin-N-hydroxysuccinimide ester (5.0 g, 17.7 mmole), DMAP (2.5 g, 20.5 mmole) in 1,2-dimethoxyethane (30 ml) was stirred at ambient temperature for 20 hrs and evaporated to dryness under reduced pressure. The residue was taken up in Et₂O (30 ml) and water (15 ml); the organic phase was separated, washed with 0.1N HCl (15 ml), 10% NaHCO₃ (15 ml) and water (20 ml), dried (MgSO₄)

35

- 56 -

and evaporated to dryness under reduced pressure. The residue was treated (30 min. stirring, RT) with hexane (30 ml) to give 4.55 g (15.7 mmole, 88%) of a white solid, m.p.: 82-4°C.

5

^1H NMR δ (CDCl_3): 7.22 (m, 4H, Ph), 6.45 (br d, 1H, CONH), 5.47 (m, 1H, C1-H), 5.25 (br s, 1H, Boc NH), 3.82 (d, 2H, CH_2), 2.95 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 1.79 (m, 1H, C2-H') ppm.

10 MS: 291 (MH^+ , 32), 235 ($\text{MH}^+ - \text{Me}_2\text{CCH}_2$, 100), 119 (48), 117 (59).

EXAMPLE 45

(rac)-N-(2-Aminoacetyl)-1-aminoindan.HCl

15 To a solution of (rac)-N-(2-N-Boc-aminoacetyl)-1-aminoindan (5.9 g, 20.34 mmole) in iPrOH (60 ml) was added 24% isorpopanolic HCl (12.5 ml). The mixture was stirred at ambient temperature for 20 hrs and evaporated to dryness under reduced pressure. The residue was taken
20 up in a 1:1 water/ CH_2Cl_2 (400 ml) mixture. The aqueous layer was separated, filtered through millipore and evaporated to dryness under reduced conditions. The crude product was crystallized from EtOH to give 2.7 g (59%), white crystalline solid, m.p.: 201-5°C.

25

Anal. calcd. for $\text{C}_{10}\text{H}_{13}\text{ClN}_2\text{O}$: C, 58.54; H, 6.25; N, 12.41; Cl, 15.71.

Found: C, 58.24; H, 6.50; N, 12.44; Cl, 15.47.

30

^1H NMR δ (DMSO): 8.93 (d, 1H, CONH), 8.35 (brs, 3H, NH_3^+), 5.31 (m, 1H, C1-H), 3.58 (m, 2H, CH_2), 2.95 (m, 1H, C3-H), 2.83 (m, 1H, C3-H'), 2.40 (m, 1H, C2-H), 1.84 (m, 1H, C2-H') ppm.

MS: 191 (MH^+ , 100).

35

IR: 3241, 3000, 2978, 1659, 1613, 1562, 1478 cm^{-1} .

- 57 -

EXAMPLE 46(rac)-N-Benzoyl-1-aminoindan

The title compound was prepared in 77% from (rac)-1-aminoindan (1.0 g, 7.5 mmole) and benzoyl chloride (2.1 g, 15 mmole), under the Schotten-Bauman conditions, according to J.Chem.Soc. 71, 251 (1897) and J.Org.Chem. 27, 4465 (1962), m.p.: 140-2°C.

Anal. calcd. for $C_{16}H_{15}NO$: C, 80.98; H, 6.37; N, 5.90.
Found: C, 80.11; H, 6.42; N, 5.89.

1H NMR δ ($CDCl_3$): 7.90-7.20 (m, 9H, Ph), 6.40 (br d, 1H, NH), 5.70 (m, 1H, C1-H), 3.05 (m, 1H, C3-H), 2.92 (m, 1H, C3-H'), 2.72 (m, 1H, C2-H), 1.97 (m, 1H, C2-H') ppm.
MS: 238 (MH^+ , 100) 122 (48).

EXAMPLE 47N-(2-n-Propylpentanoyl)-1-aminoindan

A solution of valproyl chloride (1.55g, 9.6 mmole) in toluene (25 ml) was added dropwise to a stirred and ice-cooled solution of 1-aminoindan (1.47g, 10.0 mmole) and Et_3N (1.11g, 11 mmole). The mixture was stirred at ambient temperature for 17 hours, $EtOAc$ (60 ml) and water (50 ml) were added and the phases were separated. The organic phase was washed successively with 0.1N HCl (40 ml), 0.1N $NaHCO_3$ (40 ml) and saturated $NaCl$ (40 ml), dried over magnesium sulphate and evaporated to dryness under reduced pressure. The residue was treated with hexane (15 ml, 30 min stirring, RT) and filtered. The crude product was crystallized from hexane: $EtOAc$ (70:30 mixture), to give 1.72g (6.65 mmole, 69%) of a white crystalline solid, mpt: 133-40C.

Anal. Calcd. for $C_{17}H_{25}NO$: C, 78.71; H, 9.72; N, 5.40.
Found: C, 78.83; H, 9.69; N, 5.55.

1H -NMR δ ($CDCl_3$): 7.23 (m, 4H, Ph), 5.65 (br d, 1H, C2-H),

- 58 -

5.53 (m, 1H, C1-H), 2.97, 2.86 (m, 2H, C3-H, H'), 2.61 (m, 1H, C2-H), 2.03 (m, 1H, Pr_2CH), 1.77 (m, 1H, C2-H'), 1.66, 1.63 (m, 8H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 0.93 (t, 3H, CH_3), 0.90 (t, 3H, CH_3) ppm.

5

MS: 260 (MH^+ , 100), 172 (9), 144 (48), 117 (14).

IR: 3270, 2955, 2932, 1640, 1545, 1481, 1458, 1257 cm^{-1}

EXAMPLE 48

10

(rac)-N-Methyl-N-acetyl-1-aminoindan

(rac)-N-Methyl-1-aminoindan.HCl ((1.0 g, 5.4 mmole), prepared from (rac)-1-aminoindan, as described in Ex. 12) was acetylated by Ac_2O in a manner analogous to that described in Ex. 17, to give 0.7 g (3.7 mmole, 69%) of a white solid, melting at ambient temperature.

15

^1H NMR δ (CDCl_3), a mixture of 2 rotamers: 7.30-7.07 (m, 4H, Ph), 6.30, 5.42 (t, 1H, C1-H), 3.02 (m, 1H, C3-H), 2.88 (m, 1H, C3-H'), 2.69, 2.64 (s, 3H, Me), 2.42 (m, 1H, C2-H), 2.29, 2.18 (s, 3H, Ac), 2.05, 1.86 (m, 1H, C2-H') ppm.

20

MS: 190 (MH^+ , 34), 174 (M^+-CH_3 , 15), 132 (16), 116 (27).

25

EXAMPLE 49

(R)-N-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 73% from (R)-N-methyl-1-aminoindan.HCl (2.8 g, 15.2 mmole) as described in Ex. 48, to give 2.1 g (11.1 mmole) of an off-white crystalline solid, mp: 34-6°C.

30

NMR and MS identical to those given in Ex. 48.

IR: 3472, 2944, 1650, 1480, 1402, 1330, 1291, 1155, 1122, 1020, 766 cm^{-1} .

35

- 59 -

EXAMPLE 50(rac)-N-(2-Propionamido)-1-aminoindan.HCl.H₂O

A mixture of 2-bromopropionamide (3.19 g, 21.3 mmole),
(rac)-1-aminoindan (3.0 g, 22.2 mmole), sodium
bicarbonate (2.0 g, 23.8 mmole) and absolute ethanol (45
ml) was stirred under reflux for 24 hrs. The reaction
mixture was then filtered hot, and the filtrate
concentrated in vacuo to about 1/3 of its initial volume,
and filtered. The collected solid was dissolved in CH₂Cl₂,
and washed successively with 0.1 N HCl and water. The
aqueous phase was basified to pH 12-13, and filtered.
The solid was dried, dissolved in CH₂Cl₂ (30 ml) and
converted to the HCl salt by isopropanolic HCl. The
latter was collected by filtration, washed with CH₂Cl₂ (3
ml) and dried, to give 2.4 g (9.3 mmole, 44%) of a white
solid, mp: 245°C.

Anal. calc. for C₁₂H₁₃ClN₂O₂: C, 55.7; H, 7.4; N, 10.8.
Found: C, 55.3; H, 6.5; N, 10.8.

¹H NMR δ(DMSO), two diastereomers: 9.86, 9.54, 9.30, 9.18
(br m, 2H, NH₂⁺), 8.34, 8.28, 7.72, 7.68 (br s, 2H, CONH₂),
7.70, 7.40-7.22 (m, 4H, Ph), 4.65 (br s, 1H, C1-H), 3.98
(br m, 1H, Cα-H), 3.20 (m, 1H, C₃-H), 2.84 (m, 1H, C₃-H'),
2.40 (m, 1H, C2-H), 2.26 (m, 1H, C2-H'), 1.52, 1.48 (d,
3H, Me) ppm.

MS: 205 (MH⁺, 72), 160 (MH⁺-HCONH₂, 8), 132 (6), 117 (24).

IR (KBr): 3409, 3253, 3133, 2757, 1687, 1553, 1533, 1458,
1400, 1378, 1332, 1256, 1143, 1091, 1035, 762, 641 cm⁻¹.

EXAMPLE 51(rac)-N-(2-Phenylacetyl)-1-aminoindan.HCl

Phenylacetyl chloride (4.76 g, 30.8 mmole) was added
dropwise to an ice-cooled solution of (rac)-1-aminoindan
(4.0 g, 30 mmole) and Et₃N (6.0 g) in 1,2-dimethoxyethane

- 60 -

(40 ml). After completion of addition, the reaction mixture was stirred for 5 hrs at 70°C and filtered. The solid was dissolved in CH₂Cl₂ (100 ml), washed successively with 0.3 N HCl, 10% NaHCO₃, water (50 ml each) and dried. The crude product was crystallized from 1:1 hexane:EtOAc (90 ml) to give 2.9 g (11.6 mmole, 39%) white solid, mp: 145-7°C.

Anal. calc. for C₁₇H₁₇NO: C, 81.24; H, 6.82; N, 5.57.
Found: C, 81.31; H, 6.97; N, 5.69.

¹H NMR δ (CDCl₃): 7.40-7.10 (m, 9H, Ph), 5.62 (br d, 1H, CONH), 5.48 (q, 1H, Cl-H), 3.62 (AB q, 2H, CH₂), 2.86 (m, 2H, C3-H, H'), 2.58 (m, 1H, C2-H), 1.65 (m, 1H, C2-H') ppm.

IR (KBr): 3275, 1638, 1545, 1456, 1364, 748, 710 cm⁻¹.

EXAMPLE 52

(rac)-N-(m-Anisoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (1.6 g, 12.3 mmole) and m-anisoyl chloride (1.9 g, 13.54 mmole) as in Ex. 46; crystallization from EtOAc:hexane gave 2.0 g (7.2 mmole, 59%) white solid, mp: 140°C.

Anal. calc. for C₁₇H₁₇NO₂: C, 76.38; H, 6.4; N, 5.2.
Found: C, 76.55; H, 5.75; N, 5.63.

¹H NMR δ (CDCl₃): 7.45-7.18 (m, 7H, Ph), 7.04 (m, 1H, Ph), 6.35 (br d, 1H, CONH), 5.68 (q, 1H, Cl-H), 3.84 (s, 3H, OMe), 2.98 (m, 2H, C3-H, H'), 2.70 (m, 1H, C2-H), 1.92 (m, 1H, C2-H') ppm.

MS: 268 (MH⁺, 100), 152 (7).

IR (KBr), 3268, 1632, 1586, 1543, 1481, 1350, 1246, 1038, 758, 743, 725 cm⁻¹.

- 61 -

EXAMPLE 53(rac)-N-(4'-Fluorobenzoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (1.7 g, 12.85 mmole) and 4-fluorobenzoyl chloride (2.24 g, 14.1 mmole) as in Ex. 52; 1.71 g (6.7 mmole, 52%), mp: 109-10°C.

¹H NMR δ (CDCl₃): 8.15 (td, 1H, Ph), 7.55-7.05 (m, 7H, Ph), 6.95 (m, 1H, CONH), 5.74 (m, 1H, Cl-H), 2.98 (m, 2H, C3-H, H'), 2.75 (m, 1H, C2-H), 1.94 (m, 1H, C2-H') ppm.

MS: 256 (MH⁺, 100), 140 (9).

IR (KBr): 3233, 1638, 1541, 1229, 756, 745 cm⁻¹.

EXAMPLE 54(rac)-N-(p-Toluoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (5.0 g, 37.6 mmole) and p-toluoyl chloride (5.2 g, 33.8 mmole) as in Ex. 52; 4.8 g (19.1 mmole, 57%), mp: 140°C.

Anal. calc. for C₁₇H₁₇NO: C, 81.24; H, 6.82; N, 5.57.

Found: C, 80.98; H, 6.80; N, 5.48.

¹H NMR δ (CDCl₃): 7.68, 7.34, 7.30-7.16 (m, 8H, Ph), 6.34 (br d, 1H, CONH), 5.69 (q, 1H, Cl-H), 2.96 (m, 2H, C3-H, H'), 2.70 (m, 1H, C2-H), 2.40 (s, 3H, Me), 1.92 (m, 1H, C2-H') ppm.

MS: 504 (MMH⁺, 38), 252 (MH⁺, 100).

IR (KBr): 3273, 3025, 2964, 1630, 1532, 1294, 830, 742 cm⁻¹.

EXAMPLE 55(S)-(1-Indanyl)-glycine.HCl

A mixture of N-(2-acetamido)-1-aminoindan (4.95 g, 26

- 62 -

mmole, prepared as described in Ex. 2) in conc. HCl (25 ml) was stirred under reflux for 3 hrs, and evaporated to dryness under reduced pressure. The residue was dissolved in water (30 ml) and the solution was basified to pH 9 by 10% NaOH. Volatiles were stripped under reduced pressure and the residue was dissolved in water, brought to pH 2 by 2.5N HCl and the solution evaporated to dryness. The crude product was slurried in ethanol (60 ml), collected by filtration and dried, to give 2.75 g (12.1 mmole, 46%) white solid.

¹H NMR δ (DMSO): 7.70 (d, 1H, Ph), 7.60-7.20 (m, 6H, Ph, NH₂⁺), 4.77 (m, 1H, C1-H), 3.66 (AB q, 2H, CH₂), 3.14 (m, 1H, C3-H), 2.85 (m, 1H, C3-H'), 2.40 (m, 1H, C2-H), 2.22 (m, 1H, C2-H') ppm.

EXAMPLE 56

(rac)-N,N-di-(2-Acetamido)-1-aminoindan.HCl.H₂O.

A mixture of (rac)-1-aminoindan (10.0 g, 75.1 mmole), 2-chloroacetamide (14.8 g, 159.1 mmole), NaHCO₃ (15.8 g) in water (200 ml) was stirred under reflux for 3 hrs, cooled to RT and filtered. The solid was dried, slurried in methanol, filtered and dried. The free base was converted to the HCl salt by isopropanolic HCl (5 ml) in ethanol (120 ml); further treatment with water afforded the title product as a hydrate, 5.2 g (18.3 mmole, 24%), mp: 148-150°C.

Anal. calc. for C₁₃H₁₈ClN₃O₂.H₂O: C, 51.74; H, 6.68; N, 13.92.

Found: C, 50.96; H, 6.45; N, 14.16.

¹H NMR δ (DMSO): 7.92 (br s, 2, CONH₂), 7.62 (br s, 2H, CONH₂), 3.58 (d, 1H, Ph), 7.48-7.25 (m, 3H, Ph), 5.04 (m, 1H, C1-H), 3.95 (d, 2H, CH₂), 3.75 (d, 2H, CH₂), 3.10 (m, 1H, C3-H), 2.95 (m, 1H, C3-H'), 2.46 (m, 1H, C2-H), 2.36 (m, 1H, C2-H') ppm.

- 63 -

MS: 248 (MH⁺, 67), 231 (MH⁺-NH₃, 15), 203 (MH⁺-HCONH₂, 8),
132 (100), 117 (47).

IR (KBr): 3390, 3220, 3088, 1713, 1688, 1400, 1377, 1215,
5 723, 691 cm⁻¹.

EXAMPLE 57

(rac)-N-(1-Indanyl)-aminoacetonitrile.HCl

A mixture of (rac)-1-aminoindan (5.0 g, 37.6 mmole), 2-
10 chloroacetonitrile (2.84 g, 37.6 mmole), NaHCO₃ (3.5 g) in
ethanol (20 ml) was stirred under reflux for 3 hrs,
filtered hot, and the filtrate was evaporated to dryness.
The residue was treated with Et₂O (20 ml, 1/2 hr, RT) and
filtered; the filtrate was evaporated to dryness and the
15 oily residue was taken up in 60 ml 1:1 toluene: H₂O
mixture, and the pH of the aqueous phase was adjusted to
7.5. The organic layer was separated and evaporated to
dryness. The free base thus obtained was dissolved in
CH₂Cl₂ (15 ml) and converted to the hydrochloride with
20 isopropanolic HCl. The solid product was collected by
filtration and dried, to give 4.5 g (17.9 mmole, 48%),
mp: >250°C.

Anal. calc. for C₁₁H₁₃ClN₂: C, 63.31; H, 6.28; N, 13.42.
25 Found: C, 63.01; H, 6.22; N, 13.34.

¹H NMR δ (DMSO): 7.77 (d, 1H, Ph), 7.42-7.25 (m, 3H, Ph),
4.80 (m, 1H, Cl-H), 4.35 (s, 2H, CH₂), 3.16 (m, 1H, C3-H),
2.88 (m, 1H, C3-H'), 2.40 (m, 1H, C2-H), 2.28 (m, 1H, C2-
30 H') ppm.

MS: 173 (MH⁺, 8), 146 (MH⁺-CN, 100), 117 (35).

IR (KBr): 2972, 2936, 2910, 2721, 2631, 2569, 2432, 1582,
35 1445, 1372, 1022, 758 cm⁻¹.

- 64 -

EXAMPLE 58N-Acetyl-6-nitro-1-aminoindan

To an ice-cooled suspension of (rac)-N-acetyl-1-aminoindan (Ex. 17, 17.5 g, 0.1 mole) in nitromethane (165 ml), was added dropwise a nitrating mixture (H_2SO_4 , HNO_3 , H_2O) while the temperature was kept between 8°C and 2°C . Stirring was continued for 1.5 hours in the ice-bath and the mixture was then poured on to a mechanically stirred mixture of ice (500 g) and water (1300 ml), stirring being continued for 1 hour. The suspension was filtered, the white solid washed with water and dried (14.05 g, 63.9%). It is sufficiently pure for hydrogenation (Ex. 59).

Crystallization from EtOAc/EtOH/Toluene afforded analytically pure compound, mp: 179°C .

Anal. calc. for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_3$: C, 59.99; H, 5.59; N, 12.72.
Found: C, 60.10; H, 5.38; N, 12.70.

^1H NMR δ (CDCl_3): 8.09 (br, 2H, C5-H, C7-H), 7.35 (d, 1H, C4-H), 5.88 (br d, 1H, CONH), 5.55 (q, 1H, C1-H), 3.07, 2.94 (m, 2H, C3-H, H'), 2.71 (m, 1H, C2-H), 2.09 (s, 3H, Me), 1.90 (m, 1H, C2-H') ppm.

MS: 221 (MH^+ , 100).

IR (KBr): 3267, 1643, 1556, 1516 cm^{-1} .

EXAMPLE 59(rac)-6-Amino-N-acetyl-1-aminoindan.HCl.1/2 H₂O.

(rac)-6-Nitro-N-acetyl-1-aminoindan (Ex. 58, 14.0 g, 64 mmole) was hydrogenated in EtOH (1.3 g, 5% Pd/C) for 3.5 hrs. The mixture was filtered through filter aid and the ethanol thoroughly evaporated in vacuo. The solid residue was crystallized from boiling water (100 ml) and the crystallizing mixture refrigerated (for 2 days). The

- 65 -

solid was filtered off, washed with cold water and dried (10.65 g, 84.1%), mp: 161°C.

5 The free base was dissolved in CH_2Cl_2 (250 ml) and converted to the hydrochloride by isopropanolic HCl (9.4 g, 61.8 mmole). The crude HCl salt was crystallized from EtOH/EtOAc: 9.9 g (42.1 mmole, 66%), mp: 224-5°C.

10 Anal. calc. for $\text{C}_{11}\text{H}_{15}\text{ClN}_2\text{O} \cdot 1/2 \text{H}_2\text{O}$: C, 56.05; H, 6.84; N, 11.88; Cl, 15.04.

Found: C, 56.48; H, 6.55; N, 11.82; Cl, 15.38.

15 ^1H NMR δ (D_2O): 7.45 (d, 1H, C4-H), 7.31, 7.29 (s, dd, 2H, C5-H, C7-H), 5.36 (t, 1H, C1-H), 3.07 (m, 1H, C3-H), 2.93 (m, 1H, C3-H'), 2.53 (m, 1H, C2-H), 2.09 (s, 3H, Me), 1.97 (m, 1H, C2-H') ppm.

MS: 191 (MH^+).

20 IR (KBr): 1621, 1548 cm^{-1} .

EXAMPLE 60

(rac)-1.6-Bis (acetylamino) indan

25 1-Acetylamino-6-aminoindan (Ex. 59, 1.90 g, 0.01 mole) was stirred with a solution of sodium hydroxide (0.8 g, 0.02 mole) in water (5 ml); ethyl acetate (5 ml) was then added and the mixture ice-cooled, and acetic anhydride (1.3 ml, 0.014 mole) was added slowly, and the mixture stirred for 0.5 hr. The flask was washed down
30 with water, ethyl acetate removed in vacuo and the solid filtered off, washed with water and oven-dried (2.0 g) in vacuo.

35 The crude solid was crystallized from ethanol (28 ml). Filtration, washing with ice-cold ethanol and vacuum oven-drying gave the title compound (1.54 g, 65.8%), mp: 225-6°C.

- 66 -

Anal. calc. for $C_{13}H_{16}N_2O_2$: C, 67.22; H, 6.94; N, 12.06.
Found: C, 67.20; H, 6.99; N, 11.76.

1H NMR δ ($CDCl_3$): 7.41 (br s, 1H, C7-H), 7.35 (dd, 1H, C5-H), 7.18 (d, 1H, C4-H), 5.74 (br d, 1H, NHCO), 5.44 (q, 1H, C1-H), 3.49 (br d, 1H, ArNHCO), 2.93 (m, 2H, C3-H, H'), 2.80 (m, 1H, C2-H), 2.61 (m, 1H, C2-H'), 2.15 (s, 3H, ArNHCOMe), 2.03 (s, 3H, Me) ppm.

MS: 233 (MH^+ , 45).

IR (KBr): 1676, 1649, 1602, 1551 cm^{-1} .

EXAMPLE 61

(rac)-6-Cyano-N-acetyl-1-aminoindan

1-Acetyl-amino-6-aminoindan (Ex. 59, 11.42 g, 0.060 mole) was mechanically stirred with water (15.5 ml) in an ice-salt bath and treated with conc. hydrochloric acid (15.5 ml, 0.16 mole) to give a uniform thick suspension which was allowed to cool to ca 0°C. It was then treated dropwise with a solution of sodium nitrite (4.46 g, 0.063 mole) in water (9 ml) so that the temperature stayed below 5°C. After complete addition, the mixture was neutralized by the portionwise addition of sodium carbonate (3.1 g). The resulting solution was added in portions to a previously warmed (65°C) solution prepared from KCN (9.45 g, 0.145 mole) and CuCN (6.94 g, 0.078 mole) in water (23 ml). The suspension was heated for 15 min, then cooled to 40°C, and the solid was collected by filtration, washed with water, dried and extracted with acetone (100 ml). The latter was evaporated to dryness and the residue purified by flash column chromatography (silica, EtOAc:CH₂Cl₂, 2:1). The crude product was crystallized from iPrOH to give 7.50 g (37.5 mmole, 62.5%) of a yellow crystalline solid, mp: 175-6°C.

Anal. calc. for $C_{12}H_{12}N_2O$: C, 71.98; H, 6.04; N, 13.99.

- 67 -

Found: C, 71.97; H, 6.03; N, 13.85.

¹H NMR δ (CDCl₃): 7.55 (br s, 1H, C7-H), 7.49 (dd, 1H, C5-H), 7.32 (d, 1H, C4-H), 5.97 (br d, 1H, CONH), 5.49 (q, 1H, C1-H), 3.04 (m, 1H, C3-H), 2.92 (m, 1H, C3-H'), 2.64 (m, 1H, C2-H), 2.06 (s, 3H, Me), 1.85 (m, 1H, C2-H') ppm.

IR (KBr): 2227, 1645, 1557 cm⁻¹.

10 EXAMPLE 62

(rac)-6-Carboxamido-N-acetyl-1-aminoindan

(rac)-6-Cyano-N-acetyl-1-aminoindan (Ex. 61, 2.50 g, 0.0125 mole) was suspended in ethanol (15 ml) and treated with 25% sodium hydroxide (0.63 ml, 0.005 mole). The mixture was warmed to 40°C and 30% hydrogen peroxide solution (6.5 ml) added in small portions while the temperature was kept at 40-50°C. The mixture was stirred for 3 hrs, neutralized with 5% sulphuric acid (4.5 ml, pH 6), cooled to 20°C, filtered, and the white solid washed with water. It was dissolved in acetic acid (10 ml) at 40°C, filtered through "hiflo", and washed with acetic acid (2 x 2 ml). The filtrate was warmed to 70°C, treated with water (35 ml) and cooled; the solid was filtered off, washed with acetic acid/water 5:30 v/v and finally water, and dried to give 2.0 g (9.2 mmole, 73%), mp: 250-2°C.

Anal. calc. for C₁₂H₁₄N₂O₂: C, 66.04; H, 6.47; N, 12.83.

Found: C, 66.14; H, 6.51; N, 12.78.

30

¹H NMR δ (DMSO): 8.24 (d, 1H, MeCONH), 7.92 (br s, 1H, ArCONH), 7.74 (d, 1H, C5-H), 7.72 (s, 1H, C7-H), 7.29 (d, 1H, C4-H), 7.25 (br s, 1H, ArCONH), 5.29 (br q, 1H, C1-H), 2.94 (m, 1H, C3-H), 2.81 (m, 1H, C3-H'), 2.41 (m, 1H, C2-H), 1.89 (s, 3H, Me), 1.77 (m, 1H, C2-H') ppm.

35

MS: 437 (MMH⁺, 10), 236 (MNH⁺, 100), 219 (MH⁺, 10).

- 68 -

IR (KBr): 1654, 1554, 1409 cm^{-1} .

EXAMPLE 63

(rac)-6-Ethoxycarbonyl-N-acetyl-1-aminoindan

5 (rac)-6-Cyano-N-acetyl-1-aminoindan (Ex. 61, 2.575 g, 0.013 mole) was suspended in ethanol (10 ml) and a mixture of 98% sulphuric acid (4 ml) and ethanol (4 ml) was added. The mixture was stirred (internal temp. 80°C) overnight and poured into ice water (120 ml) with
10 stirring. The thick grey slurry was filtered and the grey solid filtered off, washed thoroughly with water and dried in vacuo at 50°C. The crude product was crystallized from EtOAc, then from HOAc/water and dried, to give 1.5 g (6.1 mmole, 47%), mp: 146-7°C.

15

Anal. calc. for $\text{C}_{14}\text{H}_{17}\text{NO}_3$: C, 67.99; H, 6.93; N, 5.67
Found: C, 67.78; H, 6.97; N, 5.78.

^1H NMR δ (CDCl_3): 7.94 (m, 2, C5-H, C7-H), 7.29 (d, 1H, C4-H), 5.69 (br d, 1H, NHCO), 5.51 (q, 1H, C1-H), 4.37 (dq, 2H, Et), 3.01 (m, 1H, C3-H), 2.89 (m, 1H, C3-H'), 2.66 (m, 1H, C2-H), 2.05 (s, 3H, Me), 1.83 (m, 1H, C2-H'), 1.40 (t, 3H, Et) ppm.

25 MS: 248 (MH^+ , 100), 247 (M^+ , 25), 189 ($\text{MH}^+ - \text{MeCONH}_2$, 50), 188 ($\text{M}^+ - \text{MeCONH}_2$, 70), 202 ($\text{MH}^+ - \text{EtOH}$, 25), 201 ($\text{M}^+ - \text{EtOH}$, 10).

30 IR (KBr): 1711 (ester), 1634, 1558 (amide) cm^{-1} .

EXAMPLE 64

(cis)-3-(Methoxycarbonyl)-1-aminoindan.HCl

The title compound was prepared in 70% from phenylsuccinic anhydride, according to the procedure
35 described in J.Med.Chem., 31, 433 (1988), mp: 216-7°C.

Anal. calc. for $\text{C}_{11}\text{H}_{14}\text{ClNO}_2$: C, 58.02; H, 6.15; N, 6.15;

- 69 -

Cl, 15.60

Found: C, 57.82; H, 6.20; N, 6.27; Cl, 15.68

5 ^1H NMR δ (DMSO): 8.80 (br s, 3H, NH_3^+), 7.75, 7.40 (m, 4H, Ph), 4.70 (t, 1H, C1-H), 4.18 (t, 1H, C3-H), 3.74 (s, 3H, Me), 2.78 (m, 1H, C2-H), 2.26 (m, 1H, C2-H') ppm.

MS: 192 (MH^+ , 63), 175 (100), 160 (82), 143 (27), 131 (74), 115 (59).

10

IR (KBr): 3000-2700, 2024, 1744, 1616, 1381, 1289, 1179, 772 cm^{-1} .

EXAMPLE 6515 (cis)-1-Aminoindan-3-carboxylic acid.HCl

The title compound was prepared in 86% from (cis)-3-(methoxycarbonyl)-1-aminoindan.HCl, according to the procedure described in J.Med.Chem., 31, 433 (1988), mp: 217-8°C.

20

Anal. calc. for $\text{C}_{10}\text{H}_{12}\text{ClNO}_2$: C, 56.21; H, 5.62; N, 6.56; Cl, 16.53

Found: C, 56.05; H, 5.79; N, 6.80; Cl, 16.71.

25 ^1H NMR δ (DMSO): 8.76 (br s, 3H, NH_3^+), 7.73, 7.54-7.30 (m, 4H, Ph), 4.67 (br t, 1H, C1-H), 4.06 (t, 1H, C3-H), 2.73 (m, 1H, C2-H), 2.25 (m, 1H, C2-H') ppm.

MS: 178 (MH^+ , 100), 160 ($\text{MH}^+ - \text{H}_2\text{O}$, 80), 130 (61), 115 (42).

30

IR (KBr): 3150-2700, 1963, 1732, 1711, 1481, 1397, 1366, 1188, 875, 773, 752 cm^{-1} .

EXAMPLE 6635 (rac), (trans)-2-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 59% yield from (rac), (trans)-2-methyl-1-aminoindan (Ex. 40, 3.0 g)

- 70 -

according to the procedure described in Ex. 17, mp: 137°C.

Anal. calc. for $C_{12}H_{15}NO$: C, 76.16; H, 7.99; N, 7.40.

5 Found: C, 76.14; H, 8.14; N, 7.49.

1H NMR δ ($CDCl_3$): 7.24 (m, 4H, Ph), 5.64 (br d, 1H, CONH), 5.45 (m, 1H, C1-H), 3.04 (dd, 1H, C3-H), 2.79 (m, 1H, C2-H), 2.59 (dd, 1H, C3-H'), 0.97 (d, 3H, Me) ppm.

10

MS: 190 (MH^+ , 45), 146 (MH^+-CH_3COH , 11), 130 ($M^+-CH_3CONH_2$, 100).

IR (KBr): 3300, 2939, 1646, 1547, 1370, 745 cm^{-1} .

15

EXAMPLE 67

(rac), (cis)-2-Methyl-N-acetyl-1-aminoindan

To a solution of Ac_2O (1.45 g, 14.2 mmole) in toluene (12 ml), was added dropwise a solution of (rac), (cis)-2-methyl-1-aminoindan (Ex. 39, 1.85 g, 12.6 mmole). The mixture was heated at 90°C for 15 min, cooled to 70°C, and a solution of 1.1 g KOH in 8.3 ml water was added. The reaction mixture was stirred at ambient temperature for 2 hrs; the solid was collected by filtration, washed with toluene (10 ml), dried and crystallized from hexane:EtOAc, to give 1.85 g (9.8 mmole, 78%), mp: 146-7°C.

20

25

Anal. calc. for $C_{12}H_{15}NO$: C, 76.16; H, 7.99; N, 7.40

30

Found: C, 76.16; H, 7.80; N, 7.45.

1H NMR δ ($CDCl_3$): 7.24 (m, 4H, Ph), 5.70 (br d, 1H, CONH), 5.15 (t, 1H, C1-H), 3.10 (dd, 1H, C3-H), 2.57 (dd, 1H, C3-H'), 2.22 (m, 1H, C2-H), 2.10 (s, 3H, Ac), 1.30 (d, 3H, Me) ppm.

35

MS: 190 (MH^+ , 7), 131 (48), 130 (100).

- 71 -

EXAMPLE 68(R)-N-Trifluoroacetyl-1-aminoindan

The title compound was prepared in 67% yield from (R)-1-aminoindan (3.35 g, 25.2 mmole) and trifluoroacetic anhydride (5.75 g, 27.4 mmole), as described in Ex. 67; mp: 152-3°C.

Anal. calc. for $C_{11}H_{10}NO$: C,

Found:

10

1H NMR δ ($CDCl_3$): 7.28 (m, 4H, Ph), 6.50 (br s, 1H, CONH), 5.49 (q, 1H, C1-H), 3.05, 2.94 (m, 2H, C3-H, H'), 2.65 (m, 1H, C2-H), 1.92 (m, 1H, C2-H') ppm.

15

MS: 230 (MH^+ , 0.3), 229 (M^+ , 0.4), 228 (6), 117 (72), 116 (100).

EXAMPLE 69(rac)-N-(4-(di-n-Propylsulfamoyl)benzoyl)-1-aminoindan

The title compound was prepared in 63% yield from (rac)-1-aminoindan (10.0 g, 75.2 mmole) and 4-(di-n-propylsulfamoyl) benzoyl chloride (16.3 g, 53.6 mmole, prepared from probenecid and $SOCl_2$) via a procedure analogous to that described in Ex. 46, followed by crystallization from hexane:EtOAc, mp: 124-5°C.

25

Anal. calc. for $C_{22}H_{28}N_2O_3S$: C, 65.97; H, 7.05; N, 7.0; S, 8.0

Found: C, 65.70; H, 6.91; N, 7.03; S, 7.70.

30

1H NMR δ ($CDCl_3$): 7.94-7.80 (m, 4H, Ph), 7.35 (m, 1H, Ph), 7.32-7.20 (m, 3H, Ph), 6.44 (br d, 1H, CONH), 5.69 (q, 1H, C1-H), 3.08 (m, 4H, CH_2CH_2N), 3.06 (m, 1H, C3-H), 2.95 (m, 1H, C3-H'), 2.71 (m, 1H, C2-H), 1.96 (m, 1H, C2-H'), 1.54 (m, 4H, $CH_2CH_2CH_3$), 0.86 (t, 6H, Me) ppm.

35

MS: 401 (MH^+ , 100), 371 (39), 285 (56), 236 (9).

- 72 -

EXAMPLE 702-(1-Indanamino)-N-isopropylethanesulphonamide.HCl

5 2-Chloroethanesulphonyl chloride (8.15g, 50mmoles) in ether (60ml) was cooled to -2°C, stirred mechanically and treated dropwise with isopropylamine (12.75ml, 150mmoles) in ether (40ml). After complete addition (15 min) the mixture was allowed to stir at -2°C for 30min. and allowed to warm to 20°C. 1-Indanamine (6.71g 50 mmoles) in ether
10 (20ml) was added dropwise followed by stirring for one hour. The mixture was filtered and the solid isopropylamine hydrochloride washed thoroughly with ether. The combined filtrates were evaporated to dryness and the residue (11.3g) was chromatographed on silica gel (257g) using ethyl acetate/hexane 4:1 v/v. The fractions
15 immediately following the yellow band were evaporated to give the base (2.85g). The base was dissolved in isopropanol (20ml) and converted to the HCl salt with 24% isopropanolic HCl (16ml). The combined solution was then treated slowly with ether (ca 40ml) and the solid was
20 filtered, washed with cold ethanol/ether and finally ether. It was dried in vacuo at 50°C and left in vacuo for several days (3.0g, 9.4mmole, 19%). Melting point 177.2-177.8°C.

25

Anal. calc. for $C_{14}H_{23}ClN_2O_2S$: C, 52.73; H, 7.27; N, 8.78, Cl, 11.12; S, 10.06.

Found: C, 52.52; H, 7.35; N, 8.84; S, 10.88: Cl, 10.88.

30

1H NMR δ (DMSO): 9.70 (br, 2H), 7.75 (d, 1H), 7.45 (d, 1H), 7.28-7.41 (m, 3H), 4.83 (brt 1H), 3.31-3.62 (m, 3H), 3.10-3.30 (m, 3H), 2.89 (m, 1H), 2.43 (m, 1H), 2.22 (m, 1H), 1.13 (d, 6H) ppm

35

MS: 566 (2MH, 40), 283 (MH, 100), 132 (20), 117 (15).

IR (KBr): 3128, 2976, 2824, 1322, 1121 cm^{-1} .

- 73 -

EXAMPLE 712-(1-Indanamino)-N-(1-indanyl)ethanesulphonamide.HCl

2-Chloroethanesulphonyl chloride (2.1g, 20mmoles) in ether (10ml) was cooled to 10°C and while stirred mechanically, treated dropwise with 1-indanamine (10.2ml, 80mmoles) in ether (40ml). After the addition, the mixture was stirred at RT for 2.5 hours. It was then filtered, the white solid (indanamine hydrochloride) washed thoroughly with ether and the combined filtrates evaporated to a thick yellow oil. Purification by chromatography (EtOAc:hexane 2:1) afforded the free base which was taken up in ether (20ml) and treated carefully with a 24% solution of HCl in isopropanol (ca 3ml). The sticky mass gradually broke up on trituration in ether, filtered to give a white solid (3.06g) crystallized from EtOH/Et2O and dried, (1.31g, 3.3mmole, 17%).

Melting point 186-187°C.

Anal. calc. for $C_{20}H_{25}ClN_2O_2S$: C, 61.13; H, 6.41; N, 7.13; S, 8.16; Cl, 9.02::

Found: C, 60.83; H, 6.51; N, 7.28.

1H NMR δ (DMSO): 9.82 (br s, 2H), 8.01 (d, 1H), 7.78 (d, 1H), 7.2-7.4 (m, 8H), 4.79 (q, 1H), 4.84 (br s, 1H), 3.68 (m, 2H), 3.32 (m, 2H), 3.17 (m, 1H), 2.77, 2.92 (m, 3H), 2.56, 2.46 (m), 2.25 (m, 1H), 1.88 (m, 1H) ppm.

MS: 357 (MH, 100), 132 (98), 117 (18).

IR (KBr): 3074, 2940, 1446, 1327, 1148 cm^{-1} .

EXAMPLE 72(R,R)-2-(1-Indanamino)-N-(1-indanyl)ethanesulphonamide.HCl

The free base (2.8g) was obtained by the same procedure as in Example 71 using (R)-1-aminoindan (10.66g, 80mmole). It was triturated with hexane and the resultant solid recrystallized from ethanol (15ml), to give a white

- 74 -

crystalline solid (1.185g). The free base was then dissolve in warm abs. ethanol (32ml) and 0.1N HCl(33.5ml, 3.31mmole) was added. The solution was evaporated in vacuo at 55°C(bath). It was evaporated again with ethanol, the residual white foam dissolved in warm ethanol (10ml) and diluted with ether (20ml). The solid was collected by filtration, washed with alcohol/ether and ether, and dried to give 1.15g (2.9mmole, 8%) of title compound. Melting point 172-173°C.

Anal. calc. for $C_{20}H_{25}ClN_2O_2S$: C, 61.13; H, 6.41; N, 7.13; S, 8.16; Cl, 9.02:

Found: C, 60.14; H, 6.40; N, 7.13, S, 8.16; Cl, 8.39..

1H NMR δ (DMSO): 9.76 (br s, 2H), 8.01 (1H), 7.7 (1H), 7.19-7.41 (m, 6H), 4.80 (q, 1H), 4.86 (br m, 1H), 3.68 (m, 2H), 3.3, 3.17 (m, 1H), 2.76 (quint) and 2.92 (m, 3H), 2.55 (m, 1H), 2.44 (m 1H), 2.22 (m, 1H), 1.88 (m, 1H)ppm.

MS: 357 (100), 241 (40), 159 (10), 132 (20).

IR (KBr): 3167, 2940, 2719, 1458, 1336, 1144 cm^{-1} .

EXAMPLE 73

N,N'-Bis-(1-indanyl)adipamide

Racemic 1-aminoindan (5.7g, 43mmole) in ether (20ml) stirred in ice, was treated dropwise with adipoyl chloride (1.83g, 10mmole) in ether (10ml). After 30min. the solid was filtered and slurried with water for 45min. The insoluble solid was collected, air dried (2.82g) and crystallized from HOAc/H₂O, washed with acetic acid/water (1:1), ethanol and ether and then dried to give 2.26g (60% title compound. Melting point: 227°C.

Anal. calc. for $C_{24}H_{28}N_2O_2$: C, 76.56; H, 7.50; N, 7.44.

Found: C, 76.35; H, 7.69; N, 7.61.

- 75 -

¹H NMR δ (DMSO): 8.17 (d, 1H, NH), 7.14-7.26 (m, 4H, Ar), 5.28 (q, 1H, C1-H), 2.91, 2.78 (m, m, 2H, C3-H₂), 2.37 (m, 1H, C2-H), 2.14 (br, 2H, α -CH₂), 1.76 (m, 1H, C2-H), 1.56 (br, 2H, β -CH₂) ppm.

5

IR (KBr): 3288, 2936, 1638, 1539, 1256, 749 cm⁻¹.

EXAMPLE 74

N,N'-Bis-((R)-1-indanyl)adipamide

10 This was prepared by the same procedure as in Example 73 starting from (R)-1-aminoindan (5.32g, 40mmole), with an additional recrystallization from ethanol (20ml) and acetic acid (15ml) to give the white product (2.37g, 62.9%). Melting point: 244-7°C.

15

Anal. calc. for C₂₄H₂₈N₂O₂: C, 76.56; H, 7.50; N, 7.44.
Found: C, 76.28; H, 7.59; N, 7.74.

20 ¹H NMR δ (DMSO): 8.16 (d, 1H, NH), 7.10-7.30 (m, 4H, Ar), 5.28 (q, 1H, C1-H), 2.92, 2.78 (m, m, 2H, C3-H₂), 2.36 (m, 1H, C2-H), 2.14 (br, 2H, α -CH₂), 1.76 (m, 1H, C2-H), 1.56 (br, 2H, β -CH₂) ppm.

MS: 377 (MH⁺, 25), 253 (45), 132 (100).

25

IR (KBr): 3289, 2959, 1642, 1541, 1254, 745 cm⁻¹.

EXAMPLE 75

N,N'-Bis-((R)-1-indanyl)succinamide

30 This was prepared by the same procedure as in Example 73 starting from (R)-1-aminoindan (8.02g, 60mmole) and succinoyl chloride (2.32g, 14mmole), to give the white product, (1.30g, 26.7%). Melting point: 266-9°C.

Anal. calc. for C₂₂H₂₄N₂O₂: C, 75.83; H, 6.94; N, 8.09.

35

Found: C, 74.50; H, 7.03; N, 8.16.

¹H NMR δ (DMSO): 8.22 (d, 1H, NH), 7.10-7.26 (m, 4H, Ar),

- 76 -

5.29 (q, 1H, C1-H), 2.92 (ddd, 2H, C3-H), 2.78 (m, 1H, C3-H), 2.30-2.46 (m, 1H, C2-H and α -CH₂), 1.77 (m, 1H, C2-H) ppm.

5 MS: 349 (MH⁺, 78), 233 (25), 216 (5), 132 (100).

- 77 -

B. EXPERIMENTAL EXAMPLES

EXAMPLE 1: EFFECT OF 1-AMINOINDANS IN AN EXPERIMENTAL
MODEL OF DOPAMINERGIC HYPOFUNCTION

5 Experiments 1A and 1B. Alpha-MpT- induced hypokinesia in
hypoxic rat

Procedure

10 Experiment 1A. Wistar male rats, 15-19 month-old, were
exposed to a single hypoxic episode which is assumed to
decrease the level of dopamine in the brain. Four to five
rats were kept for six hours in a glass chamber equipped
with an inlet and outlet tubes for the admission of an
atmosphere of premixed nitrogen (92%) and oxygen (8%) at
15 a flow rate of 3L/min. Control rats received room air
from a compressed tank under similar conditions.

20 1-R-aminoindan HCl (hereinafter R-AI) or deprenyl (an MAO
B inhibitor) were administered to the rats immediately
following the conclusion of the hypoxic episode at the
standard dose of 0.5mg/kg/Day for 70-80 days. Given the
different ratios of amine to salt in these compounds, the
dose of free amine (the active species) corresponding to
0.5 mg/kg salt is actually 0.39mg/kg for R-AI and 0.42
mg/kg for deprenyl. The drugs were administered by
25 gavage, using a special syringe equipped with rounded tip
that could be directed into the stomach. The dose was
contained in 0.3-0.5 mL of distilled water.

30 The rats were pretreated for 70-80 days with daily doses
of the test drugs and received intra-peritoneal (i.p.)
 α -MpT (α -methyl-p-tyrosine) at a dose of 100mg/kg in
0.3-0.5 mL saline. Controls received saline. α -MpT is
assumed to inhibit the formation of L-Dopa from tyrosine
and, consequently the formation of dopamine itself. Lack
of central dopamine is expressed as hypokinesia.

35 Following the injection of α -MpT, motor activity was
recorded for the duration of 10 hours.

Locomotion scores were taken in seven fully-computerized

- 78 -

cages (26x25cm) having a grid of infra-red beams at 4 cm-intervals.

Crossing of a beam initiated an electric signal which was fed into a computer. The number of crossings over a given period provided a measure of locomotion.

The records gave two data categories: (a) "small movements" originating in stationary activities such as grooming and

scratching and (b) "big movements" originating in ambulation and recorded as the simultaneous crossing of more than two beams. "Total movements" include both categories.

Counts of motor activity in the presence of α -MpT were related as percent with respect to counts in its absence in the corresponding control group (unlesioned or hypoxia-lesioned). Motor activity counts of drug-treated rats were related to the hypoxia saline-treated as 100%. All behavioral tests were performed 90-120 min. after administration of the last dose of the test compound.

Results

Experiment 1A.

"Total movements" after α -MpT are given in Table 1 and Figures 1 and 2. In Figures 1 and 2, hours after alpha-methyl-p-tyrosine injection are given on the x-axis and percent response as compared to the relevant control is given on the y-axis. Figure 1 shows the effect the hypoxic episode had as compared to the control animals, whereas Figure 2 shows the effect the drug treated group compared to the untreated hypoxic group.

- 79 -

TABLE 1: Locomotor activity after α -MpT treatment, recorded as total movements.

Hour	Control	Hypoxia	Hypoxia +R-AI	Hypoxia + deprenyl
1	77 \pm 11	39 \pm 12	67 \pm 8	88 \pm 23
2	92 \pm 20	36 \pm 8	79 \pm 12	131 \pm 30
3	115 \pm 44	61 \pm 15	198 \pm 60	141 \pm 26
4	186 \pm 44	105 \pm 42	196 \pm 17	191 \pm 45
5	168 \pm 46	60 \pm 28	138 \pm 19	229 \pm 40
6	61 \pm 23	32 \pm 15	77 \pm 17	82 \pm 14
7	84 \pm 22	32 \pm 19	173 \pm 30	204 \pm 7
8	114 \pm 23	29 \pm 15	104 \pm 18	131 \pm 23
9	114 \pm 40	43 \pm 17	95 \pm 16	137 \pm 21
10	103 \pm 31	29 \pm 15	114 \pm 41	116 \pm 22

Control rats underwent two phases of hypokinesia. The first at hour 1-2 after α -MpT followed by full recovery and rebound at hour 3. Then, another phase of hypokinesia at hours 6-7 followed by full recovery to control level at hours 7-8.

In the hypoxic group, the decrease in motor activity was more pronounced during the first phase at hours 1-2, with some recovery at hour 4, followed by a second phase of hypokinesia which lasted till hour 10 with no signs of recovery.

Hypoxic rats that had been pretreated with R-AI or deprenyl behaved similarly (Figure 2). In either case the two-phase cyclic pattern of depression-rebound-depression found for α -MpT-treated hypoxic controls could be observed. However, the level of activity of the R-AI and deprenyl-treated groups was much higher than the corresponding control group controls. In fact, in either case the levels and fluctuations of motor activity were not different from hypoxia-unlesioned control rats that

- 80 -

had received α -MpT alone.

The score of "big movements" is given in Table 2 and Figures 3 and 4, the Figures having the same axes as Figures 1 and 2.

5

TABLE 2: Locomotor activity after α -MpT treatment, recorded as big movements.

10

Hour	Control	Hypoxia	Hypoxia +R-AI	Hypoxia + deprenyl
1	85 \pm 25	43 \pm 11	109 \pm 27	61 \pm 15
2	187 \pm 56	48 \pm 18	125 \pm 29	103 \pm 22
3	195 \pm 94	69 \pm 34	151 \pm 36	184 \pm 39
4	119 \pm 71	67 \pm 40	165 \pm 40	85 \pm 34
5	224 \pm 93	71 \pm 43	254 \pm 55	171 \pm 61
6	107 \pm 64	50 \pm 24	201 \pm 50	65 \pm 17
7	123 \pm 37	39 \pm 20	201 \pm 50	96 \pm 29
8	113 \pm 46	26 \pm 15	89 \pm 23	91 \pm 40
9	220 \pm 72	45 \pm 18	121 \pm 52	84 \pm 23
10	269 \pm 106	25 \pm 10	190 \pm 34	29 \pm 10

15

20

N = 7 - 10 in a group.
Results are given as Mean \pm SEM.

25

α -MpT produced a paradoxical effect in control rats, with outbursts of hyperkinesia which lasted for as long as ten hours after an initial small decrease in activity which may not be significant.

30

In contradistinction, hypoxia-lesioned rats were hypokinetic for as long as ten hours with no signs of recovery. R-AI corrected the hypokinetic syndrome in the hypoxia group, bringing the level of activity almost to

35

- 81 -

that seen in the control hypoxia-unlesioned group. There were at least three outbursts of hyperactivity during the ten hour-observation period. Deprenyl was less effective in this respect, with outbursts of hyperactivity alternating with periods of depression.

Experiment 1B. The procedure of Experiment 1A was repeated with the following changes:

- (1) Animal: 11-14 month-old rats.
- (2) Drug treatment: R-AI and deprenyl at a daily dose of 0.3 mg/Kg in 0.2 mL. The drugs were given i.p.
- (3) Duration of the treatment: 21 days.
- (4) Dose of α -MpT: 70 mg/Kg.

Results

Experiment 1B

Total movements after α -MpT are given in Table 3 and Figure 5. The score of big movements is given in Table 4 and Figure 6. In Figures 5 and 6 hours after alpha-methyl-p-tyrosine injection are given on the x-axis and percent response as compared to the relevant control is given on the y-axis. Figure 5 shows the fate of the groups treated with R-AI or deprenyl as compared to the hypoxic group over the first four hours, with respect to total movements. Figure 6 shows the same data with respect to big movements. Antagonism to α -MpT by R-AI and deprenyl is best perceived within the 2-4 hours after the α -MpT injection as shown in Figures 5 and 6. Note that in the first hour the level of motor activity (total movements) of R-AI treated rats was almost normal (80%), but not in the hypoxic group (50%). None of the drugs was active at the second phase of hypokinesia, except deprenyl which showed some activity.

- 82 -

TABLE 3: Locomotor activity after α -MPT treatment, recorded as total movements.

Hour	Control	Hypoxia	Hypoxia +R-AI	Hypoxia + deprenyl
1	69 \pm 7	52 \pm 10	80 \pm 15	68 \pm 9
2	90 \pm 13	119 \pm 12	87 \pm 13	95 \pm 11
3	117 \pm 35	93 \pm 24	132 \pm 25	126 \pm 22
4	93 \pm 24	104 \pm 8	115 \pm 24	118 \pm 20
5	92 \pm 12	80 \pm 14	65 \pm 28	83 \pm 24
6	65 \pm 14	72 \pm 6	76 \pm 11	78 \pm 9
7	71 \pm 15	84 \pm 7	65 \pm 7	56 \pm 7
8	75 \pm 16	69 \pm 8	40 \pm 6	85 \pm 13
9	79 \pm 0	66 \pm 11	72 \pm 12	111 \pm 12
10	86 \pm 4	69 \pm 6	69 \pm 18	61 \pm 12

- 83 -

TABLE 4: Locomotor activity after α -MPT treatment, recorded as big movements.

Hour	Control	Hypoxia	Hypoxia +R-AI	Hypoxia ± deprenyl
1	75 ± 6	51 ± 10	96 ± 18	70 ± 10
2	55 ± 14	124 ± 20	97 ± 16	91 ± 19
3	114 ± 42	83 ± 28	117 ± 45	85 ± 19
4	51 ± 16	95 ± 16	91 ± 11	88 ± 23
5	60 ± 18	52 ± 7	67 ± 11	87 ± 11
6	49 ± 21	60 ± 8	58 ± 14	67 ± 8
7	66 ± 14	69 ± 10	68 ± 15	62 ± 9
8	63 ± 16	77 ± 10	34 ± 6	70 ± 9
9	55 ± 19	90 ± 11	84 ± 19	132 ± 24
10	56 ± 13	63 ± 6	44 ± 6	54 ± 13

N = 4 - 7 in a group.
Results are given as Mean ± SEM.

Discussion of Experiments 1A and 1B

Experiment 1A demonstrates the ability of R-AI to correct a syndrome of dopaminergic hypofunction associated with Parkinson's Disease to an extent at least comparable, or in some instances better than that of deprenyl. This effect was also evident in the first 2-4 hours of Experiment 1B. This experiment was carried out over a shorter period than Experiment 1A, using a lower dosage of R-AI on a separate population of animals. Both these experiments indicate that 1-aminoindans of formula 1 have a role in the treatment of Parkinson's Disease.

Experiment 1C. The procedure of Experiment 1A was repeated with the following changes:

- (1) Animal: 11-14 month-old rats.

- 84 -

(2) Drug treatment: Test compounds were administered at the dosages indicated, as a single i.p. dose 1 hour prior to α -MPT (150mg/kg).

(3) Animals were placed in an activity cage immediately after drug administration and total movements were measured for the following 10 hours.

The drugs tested with reference to the relevant Chemical Example No were:

(R)-1-aminoindan, (RAI), 0.8mg/kg, n=5
4,5-dimethoxy-1-aminoindan, (31), 0.8mg/kg, n=6
6-fluoro-(R)-1-aminoindan, (FAI), 1.2mg/kg, n=3
(R)-N-acetyl-1-aminoindan, (18), 0.8mg/kg, n=2
(R)-6-hydroxy-1-aminoindan, (35), 1.2mg/kg, n=3

The results are shown in Figure 8 from which it can be seen that all compounds tested antagonized the α -MPT-induced hypokinesia.

EXAMPLE 2: EFFECT OF 1-AMINOINDANS ON AMPHETAMINE-INDUCED STEREOTYPE BEHAVIOR IN HYPOXIC RAT

Procedure

Experiment 2A. Wistar male rats, 15-19 month-old, were exposed to a single hypoxic episode as described above. R-AI or deprenyl were administered to the rats at the same dose and method used in Example 1A. Rats pretreated for 29 days with daily doses of the test drugs (0.5mg/kg), received a sub-cutaneous (s.c.) injection of D-amphetamine sulfate at a dose of 0.5mg/kg.

D-amphetamine is known to cause an enhancement of the effects of CNS dopamine by a mechanism involving dopamine release, and blockage of its uptake and its metabolism by MAO. The behavioral manifestation of amphetamine action is a stereotypic pattern of lateral head movements.

- 85 -

Counts of lateral head movements were taken over two successive intervals of 1 min each, 45-60 min after the injection of amphetamine and then averaged.

5 Experiment 2B. The procedure of the second Experiment 2B was similar to the one used in Experiment 2A with the following changes:

- 1) Animals: 12 month-old rats.
- 2) Drug treatment: R-AI and deprenyl at a daily dose of
10 0.3mg/kg in 0.2 mL. The drugs were given by i.p. injection.
- 3) Duration of the treatment: 14 days.

15 Experiment 2C. The procedure of Experiment 2A was repeated with the following changes:

- 1) None of the rats had previously been exposed to a hypoxic episode.
- 2) Test compounds were administered as a single treatment, at a dose of 1.2mg/kg (base equivalents) 60
20 minutes prior to
D-amphetamine sulphate (0.6mg/kg s.c.).
- 3) Scores of No of head movements were taken 45 minutes after amphetamine injection.

25 The compounds tested were, referring to the relevant Chemical Example No.:

- (R)-N-acetyl-1-aminoindan (18),
- (R)-4,5-dimethoxy-1-aminoindan (29),
- (R)-1-aminoindan (R-AI),
- 30 (R)-6-hydroxy-1-aminoindan (35),
- (R)-6-fluoro-1-aminoindan (R-FAI),
- (S)-4,5-dimethoxy-1-aminoindan (30).

- 86 -

Results

The results of Experiment 2A are shown in Table 5. Table 5 shows the total number of lateral head movements per minute for each of the experimental groups.

TABLE 5

Control untreated	Hypoxia untreated	Hypoxia + R-AI	Hypoxia + deprenyl
63 ± 4	84 ± 2 ^{**}	108 ± 3 ^{**}	76 ± 3 [*]
n = 8	n = 8	n = 7	n = 6

- Mean ± SEM

- * p ≤ 0.05 **p ≤ 0.001

(with respect to corresponding control)

In the hypoxic group, pretreatment with R-AI produced a significant potentiation of the stereotypic behavior induced by amphetamine with respect to their respective control (hypoxia and amphetamine). Under the same conditions, deprenyl pretreatment did not potentiate amphetamine-induced stereotypicity. Drug-untreated hypoxic rats were more active than drug-untreated control rats, owing perhaps to the development of dopamine hypersensitivity in response to presynaptic dopamine deficiency.

The same test was repeated on day 60 of drug treatment in order to check for a possible tolerance to the test compounds that might have developed over time. The results were not different from those found on day 29.

In Experiment 2B pretreatment with R-AI produced a significant potentiation of stereotypic behavior as measured by lateral head movements, but not deprenyl.

This is shown in Table 6.

- 87 -

TABLE 6

Control untreated	Hypoxia untreated	Hypoxia + R-AI	Hypoxia + deprenyl
63 ± 5	79 ± 3*	92 ± 3**	77 ± 3
n = 12	n = 12	n = 6	n = 7

- * p ≤ 0.05 ** p ≤ 0.01

The results of Experiment 2C are shown in Figure 9 from which it can be seen that all compounds tested produced a potentiation of the stereotypic behavior induced by amphetamine.

Discussion of Experiments 2A and 2B

Stereotypic behavior is not caused by amphetamine itself, but by the enhancement of the effect of released dopamine through a combination of effects: release, uptake inhibition and MAO inhibition.

Both Experiments 2A and 2B have demonstrated that R-AI, unlike deprenyl, can greatly enhance the effect of amphetamine.

Since the effect of potentiation of stereotype behavior is assumed to be mediated by CNS dopamine, then pretreatment with R-AI must have been instrumental in the restoration of presynaptic dopamine levels after the hypoxic insult, thus further demonstrating that 1-aminoindans have a role in correcting the symptoms associated with Parkinson's Disease.

EXAMPLE 3: EXPERIMENTAL MODEL FOR COGNITIVE FUNCTION: PASSIVE AVOIDANCE TEST IN HYPOXIC RAT

Procedure

Experiment 3A: Wistar male rats, 15-19 month-old, were

- 88 -

exposed to a single hypoxic episode as described above. R-AI or deprenyl were administered to the rats at the same dose and method used in the α -MPT model. The passive avoidance test was performed on day 13 after initiation the drug treatment. The apparatus consisted of a lit chamber that can be separated from a dark chamber by a sliding door. At training, a rat is placed in the lit chamber for 30 seconds, then the door is opened. The rat moves to the dark chamber after a short delay - the latency, that is recorded. Upon entry into the dark chamber, the door is shut closed and a 0.3-mA footshock is delivered for 3 seconds by a Grass S-88 stimulator. Retention of the experience is determined after 48 hours by repeating the test and recording the latency to an arbitrary maximum of 300 seconds. Longer latencies are ascribed to retention of memory and improved cognition.

Results

The latency, in seconds, is shown in Table 7. Pretreatment of the hypoxic rats with R-AI improved their performance to control level. In contrast, deprenyl-treated hypoxic rats showed no improvement.

TABLE 7

Group	before electroshock	48h after electroshock
Control	75 \pm 21	217 \pm 34
Hypoxia	59 \pm 6	143 \pm 33*
Hypoxia + R-AI	53 \pm 6	245 \pm 33*
Hypoxia + deprenyl	53 \pm 7	153 \pm 37

- (1) Results are latency of response expressed in seconds as Mean \pm SEM.
- (2) n = 11-13 rats in a group.
- (3) * p \leq 0.05 relative to corresponding control

- 89 -

by the student's t-test.

Experiment 3B: WATER MAZE WORKING MEMORY TEST

5 The apparatus used consists of a circular water tank
160cm in diameter filled with water to a depth of 38cm.
The water was made cloudy by the addition of milk powder.
A clear Plexiglass 15cm platform, supported by a movable
stand rest on the bottom of the tank was submerged to a
10 depth of 2cm from the water surface. Normally a swimming
rat cannot perceive the location of the platform but it
may recall it from a previous experience and training,
unless it suffers from some memory impairment. The time
taken to locate the platform is measured in seconds and
referred to as the latency. During the experiment all
15 orientational cues such as ceiling lights etc. remained
unchanged. Longer latencies are observed with rats with
some impairment to their memory.

20 As described above the rats were exposed to a hypoxic
episode and R-AI was administered to rats daily as
described in Experiment 1A.

Each rat was given two trails a day for four days,
entering the pool from the same point of entry each day.
25 The position of the platform was changed daily to one of
four predetermined positions. Each rat was tested twice
each day over the four days, referred to as runs 1 and 2
on sessions I-IV. Initially the rat was placed on the
platform for 60 seconds. It was then removed and placed
30 at the point of entry and allowed a maximum of 120
seconds to locate the platform (run 1). The second run
for that day followed 60 seconds later (run 2). In the
second run the rat is expected to find the platform much
sooner, having benefitted from its earlier experience.
35 Performance is assumed to represent the rate of

- 90 -

acquisition from the more recent experience, hence this is termed working memory. The average latency of run 1 in four sessions on four different days was then related to the corresponding parameter of run 2. The smaller the ratio of run 1/run 2, the better the short range learning score.

Results

The results are given in Table 8 and Figure 7. Performance of the hypoxia group was inferior to that of the control group in sessions I-III, but did not improve in session IV.

Among the R-AI-treated hypoxia group tended towards superior performance to the hypoxia group.

Table 8. Performance of hypoxia-lesioned rats in the water maze-working memory test after pretreatment with 1-R-aminoindan (AI) or deprenyl at the dose of 0.5mg/kg/day for the duration of 60 days. The data are the latencies in seconds \pm SEM that it took a given group to locate a submerged and invisible platform the location of which was shifted from one session to the other. The time interval between sessions was one day, and that between successive runs was 60 seconds. (n=7-8 rats per group)

25

- 91 -

TABLE 8

Group	Session I		Session II		Session III		Session IV	
	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2
Control	43±13	20±8	11±2	9±2	9±2	6±1	11±3	7±1
Hypoxia	47±19	50±17	31±12	20±10	29±6	10±2	8±2	15±8
Hypoxia+ AI	50±16	25±12	25±8	14±3	19±5	14±3	15±5	6±2
Hypoxia+ deprenyl	42±16	40±17	42±18	35±16	32±15	8±2	19±6	12±4

Discussion of Experiments 3A and 3B

In learning and memory tests, normal performance in the passive avoidance response is generally related to unimpaired cholinergic function. For example, treatment with the potent muscarinic antagonist scopolamine results in amnesia in humans and an inferior performance in passive avoidance in rats. Tacrine, a cholinesterase inhibitor, has been reported recently to be of value in the restoration of memory in senile dementia patients of the Alzheimer type and kainic acid-lesioned rats.

In addition, chronic administration of tacrine improved performance in the passive avoidance test of anoxia-lesioned rats (see Fig. 7 in Speiser et al. 1989 Neuropharm. 28(12) 1325-1332).

These findings demonstrated that R-AI can correct a syndrome of cognitive dysfunction and loss of memory which are prevalent in dementia's such as senile dementia, Parkinson-type dementia and dementia of the Alzheimer's type.

- 92 -

EXAMPLE 4: EFFECT OF AMINOINDANS ON NEUROTRAUMAExperiment 4A. The effect of 1-aminoindans following closed head injury in rats

5 Methods

1. Induction of trauma.

Head trauma was induced in male rats under ether anesthesia by a well calibrated drop weight device. The weight falls over the exposed skull, covering the left cerebral hemisphere, 1-2mm lateral to the midline in the midcoronal plane. A detailed description of this method is given in Shohami et al. J. Neurotrauma 1993 10(2) 109.

2. Evaluation of motor function.

One hour after the induction of trauma the rats were tested by a set of criteria to evaluate their neurological status. These criteria are listed in Shohami supra. as is the scoring method thereof which is referred to as the Neurological Severity Status (NSS). Points are given based on the absence of these criteria, thus a high NSS indicates a highly traumatized rat whereas a low NSS indicates a non-traumatized rat. Consequently a high Δ NSS indicates that a good recovery has occurred. The rats were re-evaluated 24 hours after the induction of trauma.

25 3. Evaluation of brain oedema.

After the second evaluation of motor function, the animals were sacrificed and the brains were removed. A piece of tissue was weighed to yield a wet weight (WW), then dried in an oven for 24 hours at 95C and re-weighed to yield a dry weight (DW). Percentage water content in the tissue was calculated as $(WW-DW) \times 100 / WW$.

30 4. Drug treatment.

1-R-aminoindan (RAI) was dissolved in water and injected into the rats by an intra-peritoneal route at a dose of

- 93 -

0.1mg/kg at 0,4,8, and 12 hours post-trauma. The control group received similar volumes of water at the same times.

5 Results.

Table 9 below shows the NSS scores taken 1 hour and 24 hours post-trauma. Δ NSS is the change in NSS over that time.

10

TABLE 9

	NSS 1 hr	24 hr	Δ NSS	% water in the brain
Control (n=6)	16.6	12.3	4.3 ± 0.5	85.4 ± 0.4
RAI (n=6)	16.8	8.3	$8.5 \pm 0.5^*$	$81.5 \pm 0.5^{**}$
SAI (n=6)	16.4	10.8	5.6 ± 0.5	84.0 ± 0.8

15

20

* $p < 0.01$ (Mann-Whitney test)
 ** $p < 0.001$ (t-test)

25

30

From Table 9 it is clear that the 1-aminoindanes have a role in improving post-trauma motor function and in decreasing the trauma induced cerebral oedema. This latter point is more relevant when considering that the normal non-traumatized brain has a water content of 78.5 % (see Shohami et al. page 116, Figure 2). Thus the activity of RAI shown above represents a 50% reduction in trauma-induced oedema.

35

Experiment 4B. The method of Experiment 1A was repeated with RAI and 1-S-aminoindan (SAI) being administered at a 0.1mg/kg dosage once a day for a period of 14 days. NSS assessment was performed at 1 hour, 24 hours, 7 days and 14 days. The results are shown in Table 10 below from which it can be seen that aminoindans have an

- 94 -

improved effect on post trauma motor function when administered over a prolonged period and that RAI can restore almost complete motor function to a traumatized rat.

5

TABLE 10

	NSS at 1hr	Δ NSS at 24hr	Δ NSS at 48hr	Δ NSS at 7d	Δ NSS at 14d
Control (n=5)	15.2 \pm 0.2	4.0 \pm 0.3	4.8 \pm 0.5	5.6 \pm 0.2	6.4 \pm 0.2
RAI 35 (n=6)	17.7 \pm 0.5	7.3 \pm 0.8	9.3 \pm 0.8	11.8 \pm 0.5	14.0 \pm 0.4
SAI (n=6)	16.6 \pm 0.3	5.5 \pm 0.4	6.8 \pm 2.7	8.3 \pm 1.0	9.5 \pm 1.0

10

15

Experiment 4C. The method above was repeated using a range of doses of RAI from 0.03mg/kg to 3mg/kg. The results are shown in the same manner as above in Table 11 from which it is evident that a maximal response was observed at 0.3mg/kg and this level of response was retained thereafter.

25

TABLE 11

RAI mg/kg	NSS 1hr	24hr	Δ NSS	% water in the brain
Control	16.9	12.7	4.2 \pm 0.4	83.6 \pm 0.4
0.03	16.3	10.4	5.9 \pm 0.3	81.0 \pm 0.7
0.1	16.2	10.4	5.8 \pm 0.4	81.8 \pm 0.6
0.3	16.6	8.5	8.1 \pm 0.5	81.8 \pm 0.7
1.0	16.8	8.8	8.0 \pm 0.5	81.5 \pm 0.5
3.0	16.4	7.8	8.6 \pm 0.7	81.9 \pm 0.7

30

35

Experiment 4D: The method of Experiment 4A was repeated using a 1mg/kg dosage of RAI at the time of trauma

- 95 -

induction ($t=0$) and at different times thereafter e.g. 4hr, 8hr and 12hr after trauma induction, i.e. a total of only two treatments. An addition control comparison was performed administering RAI at 0, 4, 8 and 12 hours. The results are shown in Table 12 below from which it can be seen that both regardless of the number and timing of administration, all treated groups showed the same degree of improvement of both NSS and oedema.

TABLE 12

Times of RAI administration	Δ NSS	% water in the brain	n
Control	4.8 ± 0.3	83.3 ± 0.6	6
0	8.8 ± 10.8	81.2 ± 0.6	6
0 + 4h	8.0 ± 1.0	81.2 ± 0.4	6
0 + 8h	8.0 ± 0.1	81.8 ± 0.5	6
0 + 12h	8.7 ± 0.6	80.7 ± 0.5	6
0,4,8,12h	8.2 ± 0.7	81.5 ± 0.5	6

Experiment 4E: In order to obtain an idea as to the effective "therapeutic window" during which RAI can be given and still be effective, Experiment 4A was repeated giving RAI at 1mg/kg 1, 2 or 3 hours post induction of head trauma. As shown in Table 13 below RAI was still effective even if given 3 hours after the induction of head trauma.

TABLE 13

Time of RAI administration (post head trauma)	Δ NSS	% water in the brain	n
Control	4.8 ± 0.3	84.5 ± 0.4	7
+ 1h	8.4 ± 0.6	81.7 ± 0.4	8
+ 2h	7.0 ± 0.5	82.5 ± 0.4	8
+ 3h	7.4 ± 0.5	81.8 ± 0.5	8

- 96 -

Rate of MAO inhibition

The brains of some rats from each experimental group in Exp. 1 (chronic treatment of 80 days) and Exp. 2 (acute treatment of 14 days) were ex vivo analyzed for MAO-A and MAO-B activity. Results are shown in Table 14 below.

TABLE 14

Treatment	% inhibition of MAO A		% inhibition of MAO B	
	chronic treatment	acute treatment	chronic treatment	acute treatment
R-AI	6	13	44	21
deprenyl	23	18	90	89

Chronic or acute treatment of R-AI does not have an effect on MAO-A activity. These findings also indicate that only chronic treatment of RAI can partially inhibit the MAO-B activity. As expected, acute or chronic treatment with deprenyl can strongly and selectively inhibit the activity of MAO-B.

EXAMPLE 5: Anticonvulsive Activity of Aminoindans

Compounds provided herein were screened for their ability to protect against electrical and chemically induced convulsions. The standard electrically induced test model is the Maximal electroshock (MES) model. This model is used to show efficacy for antiepileptic agents against generalized and partial seizures. The standard model for chemically induced seizures is the subcutaneous pentylenetetrazol (s.c.Met) seizure threshold test model. This model is used to show efficacy for agents against absence seizures. In these studies, convulsions were

- 97 -

administration in rats after oral (p.o.) administration, and/or in mice after intraperitoneal (i.p.) administration of the compound. Both the MES and s.c.Met models are described in E.A. Swinyard et al., in
5 "Antiepileptic Drugs" E.R.H. Levy et al., Raven Press, New York (1985). The methods described therein were followed in the present examples.

Results

10 The results of the MES model are shown in Table 15 and where relevant the results of scMet in Table 16. All results in the Tables are in mg/kg. Compounds are deemed to be within the scope of the invention if they displayed an ED50 of less than 200mg/kg in at least one of the
15 models.

In both tables as well as in the text following Table 16 the compounds are referred to with reference to an Example number, with reference to a letter code
20 identified in the key beneath Table 15, or with reference to a number code identified in the text.

- 98 -

TABLE 15

	COMPOUND	RATS			MICE		
		MES 50	PI	TD50	MES ED50	PI	TD50
5	A	36	>4.7	>168	<100	>1	>100
	B	184	2.7	492	80	1.1	71
	C	17	>29.4	>500	18	1.4	25
	18	14	>35.7	>500	31	2.4	75
	19	24	>20.8	>500	40	1.5	61
10	4				<100		
	1	50	>1	>50	77	2.6	198
	2	21	>23	>500	39	3.5	137
	D	105	>1.7	>180	83	>1.5	127
	E	<50	>1	>50	79	>1.9	153
15	F				<300	>1	>300
	G	57	>9	>500	57	>9	>500
	H	50			50	2.8	141
	14	94	>1.5	>142	<100	>1	100
	15	50		>50			<100
20	I	<50	>1	>50	66	1.1	58
	J	<50	>1	>50	65	1.2	78
	K				115		<250
	L	50	>1	>50	74	2.5	188
	5				<100	>3	>300
25	34				<300		>300
	31			>50	<100		<100
	25	50	>1		<100	<1	>100
	M	<50	>1	>50	<100		<100
	39	<50	>1	>50	<100		<100
30	28	<50	>1	>50	<100		<100
	38	50	>1	>50	<100		<100
	40	<50	>1	>50	<100		<100
	21	21		>500	40		137
	8	24		>500			
35	17				33	3	90
	23	25	20	>500	65	2.2	155
	26	40	12.5	>500			
	46				82	6	500
	5*				58	2.6	138
40	3*				83	1.6	127
	16	50	>1	>50	<50		
	11	<50	>1	>50	<300	1	<300
	27	<50	>1	>50	<100	>1	>100
	20	<50	>1	>50	<100	>1	100
45	22	<50	>1	>50	<100	>1	>100
	43	<50	>1	>50	<100	1	<100
	3	<50	>1	>50	<100	>1	>100
	42	<50	>1	>50			

- 99 -

- A. 1-aminoindan
 B. (R)-1-aminoindan
 C. (S)-1-aminoindan
 D. HCl salt of 1
 5 E. (R)-N-propargyl-1-aminoindan HCl salt
 F. (R)-N-propargyl-1-aminoindan mesylate salt
 G. (S)-N-propargyl-1-aminoindan HCl salt
 H. (S)-N-propargyl-1-aminoindan mesylate salt
 10 I. 6-fluoro-1-aminoindan
 J. (R)-6-fluoro-1-aminoindan
 K. (S)-6-fluoro-1-aminoindan
 L. 6-fluoro-N-propargyl-1-aminoindan
 M. aminotetralin
 15 5*. base of compound 5
 3*. base of compound 3

TABLE 16

COMPOUND	RATS			MICE		
	scMet ED50	PI	TD50	scMet ED50	PI	TD50
20 A	>250		>168			>100
B	>250		492	>100		71
C	>250		>500	>60		25
18	>250		>500	66		75
19	>250		>500	86		61
25 4						
1			>50	>200		198
2	>250		>500	>150		137
D			>180	>130		127
E	>154		>50			153
30 F						>300
G	>250		>500	>250		>500
H				>200		141
14	>71		>142			100
15			>50			<100
35 I	>100		>50			58
J	>100		>50			78
K						<250
L	>300		>50			188
21	>250		>500	150		137
40 8	>250		>500			
17				71.5		90
23	>250		>500	155		155
26	>250		>500			
46				>500		>500
45 5*				>200		138
3*				>130		127
3				36		126

- 100 -

The racemic and individual enantiomers of 1-aminoindan showed activity in the MES model, indicating an activity in generalized and partial seizures. Surprisingly, there were significant differences between the activities of the (R) and (S) enantiomers. In the MES test in rats, whereas the racemic compound A had an median effective dose of 36mg/kg, the (R) enantiomer B had an ED50 of 184. The ED50 of the (S) enantiomer C was 17. This difference was also observed in mice. The (R) isomer had an ED50 of 80, whereas the (S) isomer had an ED50 of 18.

An activity against generalized and partial seizures was also observed in with N-acetyl analogs of 1-aminoindan. Compound 18 ((R)-N-acetyl aminoindan) had an ED50 of 14 in the MES test in rats, and 31 in mice. This value in rats is approximately 35 times lower than that observed for valproic acid, 2 times lower than that found for phenytoin and 1.6 times that found for Carbamazepine. As these three agents are considered to be the drugs of choice for generalized an partial epilepsy, efficacy against these seizures are also indicated for this compound and the other compounds specified as active in the application. Compound 19 ((S)-N-acetyl aminoindan) had an ED50 of 24 in MES test in rats, and 40 in mice. These compounds also showed activity in the s.c. Met model in mice, which is representative of absence seizures. Compound 18 had an ED50 of 66, whereas Compound 19 had an ED50 of 86.

The high activity observed with the above compounds was also observed when the 1-amino moiety was substituted with a glycine moiety. As with the 1-aminoindan compounds, the glycine analogs also showed differences between the (R) and (S) enantiomers, and whether the compound was the HCl salt of free base. Compound 2 ((R)-Indanylglycine-

- 101 -

free base) had an ED50 of 21 in rats and 39 in mice. D ((R)-Indanylglycinamide-HCl salt) had an ED50 in rats of 105 and 83 in mice.

5 Compounds were also found to be active when the 1-amino moiety was substituted with propargyl moiety. The compounds were also found to be active whether they were HCl or mesylate salts. E ((R)-Propargylaminoindan-HCl) had an ED50 less than 50 in rats and 79 in mice. G (S)-
10 Propargyl aminoindan had an ED50 of 57 in rats and mice. The mesylate salt of this compound H also had an ED50 of 50 or less in mice and rats in the MES test.

15 Activity was also found with compounds in which the 1-amino moiety was substituted with aliphatic side chains. Compound 14 ((S)-N-methyl aminoindan) showed activity in the MES test in both rats (ED50=94) and mice (ED50<100).

20 Fluorinated analogs of 1-aminoindan also had activity in the MES test. "I" has approximately the same efficacy. J had a better efficacy profile. The ED50 was less than 50 in rats, 3 times more efficacious than that observed for B. K also showed activity in the MES model in mice. Compound 5 also showed activity in mice in the MES model. L also
25 showed activity in mice in this model.

Hydroxylated analogs of 1-aminoindan, also show activity in the MES model. Compound 34 (6-hydroxy analog of 1-aminoindan) showed activity in the MES test in mice.

30

Activity in the MES model was also observed in methoxy analogs of 1-aminoindan. Compound 31 (4,5 dimethoxy 1-aminoindan) showed activity in the mice.

- 102 -

In addition, amino tetralins also showed activity in the MES mode. M (1-amino tetralin) had an ED50 of less than 50 in rats and less than 100 in mice. Substitution on the 1-amino group with glycineamide also showed activity in mice.

5

EXAMPLE 6: Neurotoxicity and Protective Index

Neurotoxicity of the claimed agents was also assessed in mice (i.p. administration) by the rotorod ataxia test and/or in rats (p.o. administration) by positional sense test and gait stance test. See E.A. Swinyard, et al., in Antiepileptic Drugs," ed. by R.H. Levy, et al., Raven Press, New York, at 85-200 (1989). The term quantitating the neurotoxicity is the medial neurological toxic dose (TD50), was determined in the above tests. The results obtained in mg/kg are shown in the relevant positions of Tables 15 and 16. In some of the species, the TD50 was only determined to be above a certain level, indicating a lower neurotoxicity than specified.

20

The Protective Index (PI) is defined as the ratio of TD50 and ED50 ($PI = TD50/ED50$). The PI is used to show a useful separation between neurotoxicity and antiepileptic activity. The larger the PI, the better the separation between the neurotoxic and efficacious doses. The preferred embodiment of this application is therefore those compounds in which we have already demonstrated a $PI > 1$ in the MES model of one of the species tested. Where the TD50 is only listed as greater than a particular value, the PI will represent a minimum value, and therefore a better index.

25

30

The racemic 1-aminoindan analog A and the individual enantiomers B and C had PI values in rats of >4.7, 2.7 and

- 103 -

>29.4, respectively. The PI values of the N-acetyl analogs Compound 17 and Compound 16 was > 20.8, and > 35.7 respectively. The PI values of the N-glycinamide analogs Compound 1 and Compound 2 is > 1, and > 23.

5

EXAMPLE 7: EFFECT OF AMINOINDANS ON MICE HAVING EXPERIENCED A HYPOBARIC HYPOXIC EPISODE

The hypobaric hypoxic model is a well accepted model for assessing the activity of compounds believed to possess neuroprotective activity. The model is based on that described in Nakanishi M et al. Life Sci. (1973) 13, 467, Oshiro et al., J. Med. Chem. (1991) 34, 2004-2013 and US Patent 4,788,130.

5

10

15

20

25

A 12l dessicator (dessicator A) and a 2.5l dessicator (dessicator B) were separately connected to a vacuum pump. Dessicator B was disconnected and allowed to equilibrate with room air whilst dessicator A was evacuated to a pressure of 100mmHg. Four male ICR albino mice (22-28g) were placed in dessicator B. Dessicator B was then closed to room air and connected to dessicator A. The pressure inside dessicator B was monitored using a mercury manometer and at the point where the pressure in dessicator B reached 200mmHg (usually within 14 seconds), the two dessicators were disconnected from the vacuum pump and the pump switched off. The survival time from the moment of induction of hypoxia to the time of cessation of respiration was recorded for each mouse for a maximum of 15 minutes after which time room air was reintroduced to dessicator B. Survivors were monitored for signs of lethargy or vitality.

Effect of drug treatment was assessed as the percent of the survival time of the drug treated group with respect to the

- 104 -

saline injected or vehicle injected control group. Control groups were run twice, before and after each experimental group and consisted of 12-16 mice in groups of 4 mice. Each experimental group always consisted of 4 mice to ensure a constant residual volume of oxygen in all tests. The effect of each dose of test drug was determined in duplicate i.e. two groups of 4 mice. The range of survival times of control mice was from 108-180 seconds.

All drugs were administered intra-peritoneally at the dose indicated one hour prior to exposure to hypoxia. Reference drugs were administered as follows; sodium pentobarbital, 20 or 40 mg/kg given 0.5 hour prior to hypoxia, diazepam, 5 or 10mg/kg given 0.5 hour prior to hypoxia.

The results are shown in Tables 17 and 18 below.

TABLE 17

TREATMENT COMPOUND	DOSE (mg/kg ip)	PROTECTION % OF RESPECTIVE CONTROL	SIGNIFICANCE "t" TEST
Diazepam	10	430±59	p < 0.001
	5	249±166	p < 0.05
Pentobarbitone	40	446±10.5	p < 0.001
	20	325±166	p < 0.002
B	100	395±199	p < 0.001
	50	358±224	p < 0.01
		411±174	p < 0.001
C	100	404±244	p < 0.002
	50	174±39	p < 0.01
		264±66	p < 0.001
18	100	397±244	p < 0.01
	50	271±193	p < 0.05
		383±233	p < 0.01

- 105 -

TABLE 18

TREATMENT COMPOUND DOSE (mg/kg ip)	PROTECTION % OF RESPECTIVE CONTROL	SIGNIFICANCE "t" TEST
(R)-6-fluoro- 100 1-aminoindan 50	241±56 305±185	p < 0.001 p < 0.01
30 100 50	379±202 265±284	p < 0.001 ns
42 100 50	228±119 179±170	p < 0.02 ns
39 100 50	798±249 600±213	p < 0.001 p < 0.001
41 100 50	644±316 187±41	p < 0.001 p < 0.001
28 100 50	941±34 361±106	p < 0.001 p < 0.001
1-Aminotetralin 100 50	345±134 158±54	p < 0.001 p < 0.02
40 100 50	569±173 374±190	p < 0.001 p < 0.001

EXPERIMENT 8: CULTURES OF MECHANICALLY DISSOCIATED
NEONATAL RAT CEREBELLUM

A. Reversal of NMDA induced cell death.

The cerebellum was aseptically dissociated from 6 or 7-day old rat pups and placed in a 15ml sterile plastic conical tube containing 3ml of Dulbecco's modified Eagle's medium (DMEM) with a high glucose concentration (1g/ml) and 2mM (v/v) L-glutamine and an antibiotic antimetabolic mixture. The cerebella were then dissociated after 20-25 passages through a sterile 13 gauge, 10cm long stainless steel needle attached to a 5ml syringe with an inserted 45

- 106 -

micrometer pore nylon sieve. The dissociated cells were centrifuged at 200g for 5 minutes. The supernatant was discarded and the cells resuspended in medium enriched with 15% (v/v) heat inactivated fetal calf serum. Cell viability was determined by the trypan blue exclusion test.

Cells were plated at a density of 200/mm² on poly-L-lysine coated surfaces. Poly-L-lysine coated glass coverslips were prepared at least one hour in advance of plating by immersing sterile coverslips in sterile distilled water solution containing 15 microgram/ml poly-L-lysine, and washing in sterile water just prior to use. The plated cells were covered with enriched medium and incubated at 37°C in an atmosphere of 5% CO₂ in air and 97% humidity. After three days in culture, the media was replaced with media containing the desired test compound. Each test compound was tested in duplicate. Toxic-dose response was determined for each compound.

Four groups were run in each set of experiments;
I. Control, consisting of enriched media alone,
II. N-methyl-D-aspartate (NMDA, 1mM for 3 hours) as the cytotoxic challenge,
III. Test compound plus NMDA, and
IV. Positive control, spermine(0.01 micromoles) plus NMDA.

Nerve cell survival was evaluated by phase contrast microscopy and trypan blue staining after 24 hours.

Results

The results are shown in Table 19 below. Surviving cells in culture are measured relative to control (100%) as described above. Percent protection is the Cell Survival for the test compound minus the NMDA effect. Thus, maximal

- 107 -

protection is 100% minus 30% NMDA effect i.e. 70%. The Effective Protection was calculated as the percent of the Percent Protection (X) divided by the maximal protection value (e.g. $X \times 100/70$).

TABLE 19

COMPOUND	EXPERMNT'L GROUP Dose (μ M)	SURVIVING CELL IN CULTURE	PERCENT PROTECTION	EFFECTIVE PROTECTION
	Control	100		
	NMDA	30		
	Max protection		70	100
	Spermine + NMDA	82	52	74
18	0.005+NMDA	80	50	71
	0.010	80	50	71
	0.100	55	25	36
	1.000	47	17	24
	5.000	32	2	3
(R)-6-fluoro-1-aminoindan	0.005	108	78	111
	0.010	79	49	70
	0.100	62	32	46
	1.000	53	23	33
	5.000	60	30	43
19	0.001	80	50	71
	0.005	30	0	0
	0.010	42	12	17
	1.000	15	-15	-
2	0.005	56	26	37
	0.010	51	21	30
	0.100	33	3	4
35	0.005	60	30	43
	0.010	34	4	6
	0.100	30	0	0
(R)-1-aminoindan	0.005	80	50	71
	0.010	30	0	0
	0.100	28	-2	-

In a separate experiment wherein the Maximum Protection possible was 90%, compound C (1-S-aminoindan) displayed an

- 108 -

Effective Protection value of 43% at 0.01 μ M and 57% at 0.05 μ M.

B. Enhancement of Cell Survival.

5 Cell cultures were grown as described above but in the absence of NMDA and after 3 days a dose of test compound was added. Cell survival was monitored as described above. Naturally (control) the cells die over a period of seven days from plating. Measurements of cell survival taken 24 hours after the addition of test compound (four days after cell plating) showed that the test compounds enhanced the survival of the cells, delaying their natural death. Table 20 below shows the per cent increase in No of cells present on the fourth day expressed as percentage of the number of control cells on that day.

TABLE 20

COMPOUND	DOSE μ M	% ENHANCED SURVIVAL
18	0.01	145
	0.10	130
	1.00	126
19	0.005	120
2	0.005	140
	0.010	125
(R)-1-aminoindan	0.005	121

EXAMPLE 9: GLOBAL BRAIN ISCHEMIA IN GERBILS

25 Male mongolian gerbils, aged 2.5-5 months, housed 4-8 in a cage, were supplied freely with food and water and maintained at 24°C with a 12 hour day/night cycle. For surgery the animals were anesthetized with halothane (1.5% in 100% O₂) and the common carotid arteries exposed bilaterally through a midline ventral neck incision. Each

- 109 -

artery was clamped for 5 minutes with aneurysm clips to produce global brain ischemia. The anesthesia was discontinued upon clamping. After 5 minutes the clamps were removed and the wound closed with skin clips.

5

For treatment, the test compound or vehicle were injected intra-peritoneally (ip) in a volume of 50 microliters of solvent per 10g body weight. The first injection was given two minutes after clamp removal, and thereafter daily for the next 2 post-operative days (total of 3 injections).

10

Seven groups each of 4-8 animals were compared:

15

- I. Control; (sham- or unoperated and saline treated),
- II. Vehicle treated, unoperated (when solvent is other than saline),
- III. Ischemia - untreated or saline treated),
- IV. Ischemia - vehicle treated (when solvent is other than saline),
- V. Ischemia - Test compound treated, one sub-group per concentration tested,
- VI. Ischemia and pentobarbital (40 mg/kg) as positive control).

20

25

Analysis of neuronal damage was performed 14 days post-ischemia by counting pyramidal neurons throughout the CA1 layer of the anterior hippocampus in 4 micromolar thick (paraffin) coronal brain sections stained with hematoxylin and eosin.

30

The Results are shown in the Table 21 below. Percent Protection values represent the fraction of hippocampi protected from ischemia in a group of animals treated with the stated dose of compound.

35

- 110 -

TABLE 21

TEST COMPOUND (n)	DOSE (mg/kg)	% INTACT NEURONS	PERCENT PROTECTION
Control Ischemia Pentobarbital (8)		100 0	87.5
18 (8)	0.1		25.0
(8)	1.0		25.0
(4)	10.0		66.7
(R)-6-fluoro-1-aminoindan (8)	0.1		27.5
(8)	1.0		25.0
(8)	10.0		25.0
19 (4)	0.1		25.0
(2)	1.0		0
(4)	10.0		37.5
(R)-1-aminoindan (4)	0.1		25.0
(4)	1.0		25.0
(4)	10.0		25.0
(S)-1-aminoindan (4)	0.1		0
(4)	1.0		50.0
(4)	10.0		75.0
2 (4)	0.1		0
(2)	1.0		50.0
(4)	10.0		37.5
35 (8)	0.1		25.0
(8)	1.0		37.5
(7)	10.0		37.5

EXAMPLE 10: ELECTRICALLY KINDLED RAT MODEL OF EPILEPSY

The rat electrical kindling model of epilepsy has been

- 111 -


known to show efficacy of antiepileptic agents against complex partial seizures that evolve into generalized motor seizures. In these tests, rats were electrically stimulated via corneal electrodes twice daily for approximately 5 days and then once daily for an additional 10 days. Once the seizure criteria, as described by R.J. Racine, et al., Electroenceph. Clin. Neurophysiol. 32: 281-294 (1972), were met, the test substance was administered p.o. to rats, and the rat electrically stimulated, and observed for the presence or absence of a seizure. The detailed procedure of this test model can be found in, E.A. Swinyard, et al., in "Antiepileptic Drugs," ed. by R.H. Levy, et al., Raven Press, New York, at 85-100 (1989) and Racine, Id.

Further, in the electrically kindled rat model, compound 18 (administered p.o.) prevented seizures with an ED_{50} of 24.6 Mg/kg; compound 17 with an ED_{50} of <75 mg/kg; and compound 19 with an ED_{50} of >50 mg/kg. The results are therefore indicative of these compounds having an efficacy against generalized seizures and complex partial seizures which evolve into generalized motor seizures.

- 112 -

What is claimed is:

1. A method for treating Parkinson's disease, dementia, epilepsy, convulsions, or seizures in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:



- or a pharmaceutically acceptable salt thereof;
 wherein n is 0, 1 or 2;
 R₁ and R₂ are each independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁-C₄ alkoxy, halogen, nitro, NH-R₃, C(O)-R₃, or C(O)-NR₃R₁₀;
 R₃ is hydrogen, substituted or unsubstituted C₁-C₄ alkyl, hydroxy, substituted or unsubstituted C₁-C₄ alkoxy, substituted or unsubstituted C₆-C₁₂ aryl; and
 R₄ and R₅ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, -C(O)-R₆, -Y-C(O)-R₇, or Y-(SO₂)NR₃R₁₀;
 wherein R₆ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or A-NR₃R₁₀,
 wherein A is substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-

- 113 -

C₁₂ aralkyl, and

R₉ and R₁₀ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl;

Y is substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl or substituted or unsubstituted C₇-C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl or NR₉R₁₀,

wherein R₉ and R₁₀ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

- 20 2. The method according to claim 1 wherein the subject is a human subject.
- 25 3. The method according to claim 1 wherein the administering comprises administering orally, rectally, transdermally, or parenterally.
- 30 4. The method according to claim 1, wherein the therapeutically effective amount is from about 1 mg to about 1000 mg.
5. The method according to claim 4, wherein the therapeutically effective amount is from about 10 mg to about 100 mg.

- 114 -

6. The method according to claim 1 wherein the pharmaceutically acceptable salt is a hydrochloride salt, a mesylate salt, an ethylsulphonate salt, or a sulfate salt.
- 5 7. The method according to claim 1 wherein n is 1.
8. The method according to claim 1 wherein n is 2.
- 10 9. The method according to claim 1 wherein R₁ and R₂ are each independently hydrogen, fluoro, hydroxy, methyl or methoxy.
- 15 10. The method according to claim 1 wherein R₄ and R₅ are each independently hydrogen, or substituted or unsubstituted C₁-C₁₂ alkyl.
- 20 11. The method according to claim 1 wherein R₄ is C₁-C₁₂ alkyl substituted with a lipophilic group, C₆-C₁₂ aryl substituted with a lipophilic group, or C₇-C₁₂ aralkyl substituted with a lipophilic group.
- 25 12. The method according to claim 11 wherein the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidyl, and substituted derivatives thereof.
- 30 13. The method according to claim 1 wherein R₅ is C₁-C₁₂ alkyl substituted with a lipophilic group, C₆-C₁₂ aryl substituted with a lipophilic group, or C₇-C₁₂ aralkyl substituted with a lipophilic group.
14. The method according to claim 13 wherein the

- 115 -

lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidyl, and substituted derivatives thereof.

- 5
15. The method of claim 1 wherein A is substituted or unsubstituted C₁-C₁₂ alkyl.
- 10
16. The method of claim 1 wherein Y is substituted or unsubstituted C₁-C₁₂ alkyl.
17. The method of claim 1 wherein R₁ is substituted or unsubstituted C₁-C₁₂ alkyl.
- 15
18. The method according to claim 1 wherein R₄ is -C(0)-R₆, wherein R₆ is alkyl or ANR₉R₁₀, wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, or substituted or unsubstituted C₁-C₁₂ alkyl.
- 20
19. The method according to claim 1 wherein R₅ is -C(0)-R₆, wherein R₆ is alkyl or ANR₉R₁₀, wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, or substituted or
- 25
- unsubstituted C₁-C₁₂ alkyl.
20. The method according to claim 1 wherein R₄ is -Y-C(0)-R₇, wherein Y is substituted or unsubstituted C₁-C₁₂ alkyl and R₇ is NR₉R₁₀.
- 30
21. The method according to claim 1 wherein R₅ is -Y-C(0)-R₇, wherein Y is substituted or unsubstituted C₁-C₁₂ alkyl and R₇ is NR₉R₁₀.

- 116 -

22. The method according to claim 1 wherein R_3 and NR_4R_5 are in a cis spatial configuration.
23. The method according to claim 1 wherein R_3 and NR_4R_5 are in a trans spatial configuration.
24. The method according to claim 1 wherein the compound is an R enantiomer.
25. The method according to claim 1 wherein the compound is selected from the group consisting of 1-aminoindan, (R)-1-aminoindan, 1-aminotetralin, 1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 7-hydroxy-1-aminoindan, 6-fluoro-1-aminoindan, (R)-6-fluoro-1-aminoindan, 5-methoxy-1-aminoindan, 7-methyl-1-aminoindan, 5-methyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, trans-2-methyl-1-aminoindan, cis-2-methyl-1-aminoindan, 3,5,7-trimethyl-1-aminoindan, N-methyl-1-aminoindan, (R)-N-methyl-1-aminoindan, N,N-dimethyl-1-aminoindan, N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan, N-acetyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan, 6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-butyryl-1-aminoindan, N-benzyl-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan, N-(4-butanamido)-1-

- 117 -

- aminoindan, N-(2-acetamido)-1-aminotetralin, N,N-Di-(1-indanyl)amine, N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-Propylpentanoyl)-1-aminoindan, N-acetyl-6-nitro-1-aminoindan, 6-amino-N-acetyl-1-aminoindan, 6-acetamido-N-acetyl-1-aminoindan, cis-3-(methoxycarbonyl)-1-aminoindan, cis-1-aminoindan-3-carboxylic acid, trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, (R)-N-trifluoroacetyl-1-aminoindan, N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan, N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)succinamide, and pharmaceutically acceptable acid addition salts thereof.
26. A method for treating Parkinson's disease in a subject according to the method of claim 1.
27. The method according to claim 26 wherein the compound is an R enantiomer.
28. The method according to claim 26 which further

- 118 -


comprises administering to the subject a therapeutically effective amount of Levodopa.

- 5 29. The method according to claim 28 wherein the therapeutically effective amount of Levodopa is from about 50 mg to about 250 mg.
- 10 30. The method according to claim 28 which further comprises administering to the subject a therapeutically effective amount of decarboxylase inhibitor.
- 15 31. The method according to claim 30 wherein the decarboxylase inhibitor is L-Carbidopa.
32. The method according to claim 31 wherein the therapeutically effective amount of L-Carbidopa is from about 10 mg to about 25 mg.
- 20 33. The method according to claim 30 wherein the decarboxylase inhibitor is benserazide.
34. The method according to claim 33 wherein the therapeutically effective amount of benserazide is from about 12.5 mg to about 50 mg.
- 25 35. A method for treating dementia, epilepsy, convulsions, or seizures in a subject according to the method of claim 1.
- 30 36. The method according to claim 35 wherein the compound is an R enantiomer.
37. The method according to claim 35 wherein the compound

- 119 -

is an S enantiomer.

38. The method according to claim 35 wherein the compound
is selected from the group consisting of (S)-1-
aminoindan, (S)-6-fluoro-1-aminoindan, (S)-6-methoxy-
1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, (S)-N-
methyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, (S)-N-
acetyl-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,
N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-
N-formyl-1-aminoindan, (S)-(1-indanyl)-glycine, and
pharmaceutically acceptable acid addition salts
thereof.
39. A method for treating Parkinson's-type dementia in a
subject according to the method of claim 35.
40. A method for treating senile dementia in a subject
according to the method of claim 35.
41. A method for treating Alzheimer's-type dementia in a
subject according to the method of claim 35.
42. A method for treating epilepsy, convulsions, or
seizures in a subject comprising administering to the
subject a therapeutically effective amount of a
compound of the formula:



or a pharmaceutically acceptable salt thereof;

- 120 -

wherein n is 0, 1 or 2;

R₁ and R₂ are each independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁-C₄ alkoxy, halogen, nitro, NH-R₃, C(O)-R₃, or C(O)-NR₃R₁₀;

R₃ is hydrogen, substituted or unsubstituted C₁-C₄ alkyl, hydroxy, substituted or unsubstituted C₁-C₄ alkoxy, substituted or unsubstituted C₆-C₁₂ aryl; and R₄ and R₅ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, alkynyl, -C(O)-R₆, -Y-C(O)-R₇, or Y-(SO₂)NR₉R₁₀;

wherein R₆ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or A-NR₉R₁₀,

wherein A is substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, and

R₉ and R₁₀ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, or substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl;

Y is substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl or substituted or unsubstituted C₇-C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl or NR₉R₁₀,

wherein R₉ and R₁₀ are each independently

- 121 -

hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, or substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

5

43. The method according to claim 42 wherein n is 1.

44. The method according to claim 42 wherein R₄ is propargyl.

10

45. The method according to claim 42 wherein R₅ is propargyl.

15

46. The method according to claim 42 wherein the compound is an R enantiomer.

47. The method according to claim 42 wherein the compound is an S enantiomer.

20

48. A method for treating epilepsy in a subject according to the method of claim 42.

49. A method for treating convulsions or seizures in a subject according to the method of claim 42.

25

50. A compound selected from the group consisting of 7-methyl-1-aminoindan, 5-methyl-1-aminoindan, (R)-6-hydroxy-1-aminoindan, 3,5,7-trimethyl-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan, (R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan,

30

- 122 -

N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan, (S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan, N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan, N-(2-acetamido)-1-aminotetralin, N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-Propylpentanoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan, (S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis(R)-(1-indanyl)succinamide, trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, and salts thereof.

51. The salt according to claim 50, wherein the salt is a hydrochloride salt, a mesylate salt, an ethylsulfonate salt, or a sulfate salt.

52. A pharmaceutical composition comprising a therapeutically effective amount of the compound of

- 123 -

claim 50 and a pharmaceutically acceptable carrier.

53. The pharmaceutical composition according to claim 52 wherein the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet.
54. The pharmaceutical composition according to claim 53 wherein the therapeutically effective amount is from about 1 mg to about 1000 mg.
55. The pharmaceutical composition according to claim 54 wherein the therapeutically effective amount is from about 10 mg to about 100 mg.
56. The pharmaceutical composition according to claim 52 wherein the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution.
57. The pharmaceutical composition according to claim 56 wherein the therapeutically effective amount is from about 1 mg/ml to about 1000 mg/ml.
58. The pharmaceutical composition according to claim 57 wherein the therapeutically effective amount is from about 10 mg/ml to about 100 mg/ml.
59. The pharmaceutical composition according to claim 52 wherein the carrier is a gel and the pharmaceutical composition is a suppository.
60. The pharmaceutical composition according to claim 52, further comprising a therapeutically effective amount of Levodopa.

- 124 -

61. The pharmaceutical composition according to claim 60, further comprising a therapeutically effective amount of a decarboxylase inhibitor.

5 62. The pharmaceutical composition according to claim 61 wherein the decarboxylase inhibitor is L-Carbidopa.


63. The pharmaceutical composition according to claim 62 wherein the therapeutically effective amount of the
10 compound is from about 1 mg to about 1000 mg, the therapeutically effective amount of Levodopa is from about 50 mg to about 250 mg, and the therapeutically effective amount of L-Carbidopa is from about 10 mg to about 25 mg.

15 64. The pharmaceutical composition according to claim 61 wherein the decarboxylase inhibitor is benserazide.

20 65. The pharmaceutical composition of claim 64 wherein the therapeutically effective amount of the compound is from about 1 mg to about 1000 mg, the therapeutically effective amount of Levodopa is from about 50 mg to about 200 mg, and the therapeutically effective amount of benserazide is from about 12.5 mg to about 50 mg.

25 66. A method for treating acute neurological traumatic disorder or neurotrauma in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula:

30



- 125 -

or a pharmaceutically acceptable salt thereof;

wherein n is 0, 1 or 2;

R₁ and R₂ are each independently hydrogen, hydroxy,
5 substituted or unsubstituted C₁-C₄ alkyl, substituted
or unsubstituted C₁-C₄ alkoxy, halogen, nitro, NH-R₃,
C(O)-R₃, or C(O)-NR₃R₁₀;

R₃ is hydrogen, substituted or unsubstituted C₁-C₄
alkyl, hydroxy, substituted or unsubstituted C₁₋₄
10 alkoxy, substituted or unsubstituted C₆₋₁₂ aryl; and
R₄ and R₅ are each independently hydrogen, substituted
or unsubstituted C₁-C₁₂ alkyl, substituted or
unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted
C₇-C₁₂ aralkyl, -C(O)-R₆,

15 -Y-C(O)-R₇, or Y-(SO₂)NR₉R₁₀;

wherein R₆ is hydrogen, hydroxy, substituted or
unsubstituted C₁-C₁₂ alkyl, substituted or
unsubstituted C₆-C₁₂ aryl, substituted or
unsubstituted C₇-C₁₂ aralkyl, or A-NR₉R₁₀,

20 wherein A is substituted or unsubstituted
C₁-C₁₂ alkyl, substituted or unsubstituted
C₆-C₁₂ aryl, substituted or unsubstituted C₇-
C₁₂ aralkyl, and

R₉ and R₁₀ are each independently hydrogen,
25 substituted or unsubstituted C₁-C₁₂ alkyl,
substituted or unsubstituted C₆-C₁₂ aryl,
substituted or unsubstituted C₇-C₁₂ aralkyl,
or indanyl;

Y is substituted or unsubstituted C₁-C₁₂ alkyl,
30 substituted or unsubstituted C₆-C₁₂ aryl or
substituted or unsubstituted C₇-C₁₂ aralkyl, and
R₇ is hydrogen, hydroxy, substituted or
unsubstituted C₁-C₁₂ alkyl, substituted or
unsubstituted C₆-C₁₂ aryl, substituted or

- 126 -

unsubstituted C₇-C₁₂ aralkyl or NR₉R₁₀,

wherein R₉ and R₁₀ are each independently hydrogen, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆-C₁₂ aryl, substituted or unsubstituted C₇-C₁₂ aralkyl, or indanyl.

- 5
67. The method according to claim 66 wherein the subject is a human subject.
- 10
68. The method according to claim 66 wherein the administering comprises administering orally, rectally, transdermally, or parenterally.
- 15
69. The method according to claim 66, wherein the therapeutically effective amount is from about 1 mg to about 1000 mg.
- 20
70. The method according to claim 69, wherein the therapeutically effective amount is from about 10 mg to about 100 mg.
- 25
71. The method according to claim 66 wherein the pharmaceutically acceptable salt is a hydrochloride salt, a mesylate salt, an ethylsulfonate salt, or a sulfate salt.
72. The method according to claim 66 wherein n is 1.
- 30
73. The method according to claim 66 wherein n is 2.
74. The method according to claim 66 wherein R₁ and R₂ are each independently hydrogen, fluoro, hydroxy, methyl or methoxy.

- 127 -

75. The method according to claim 66 wherein R_4 and R_5 are each independently hydrogen, or substituted or unsubstituted C_1 - C_{12} alkyl.
- 5 76. The method according to claim 66 wherein R_4 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group.
- 10 77. The method according to claim 76 wherein the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidinyl, and substituted derivatives thereof.
- 15 78. The method according to claim 66 wherein R_5 is C_1 - C_{12} alkyl substituted with a lipophilic group, C_6 - C_{12} aryl substituted with a lipophilic group, or C_7 - C_{12} aralkyl substituted with a lipophilic group.
- 20 79. The method according to claim 78 wherein the lipophilic group is selected from the group consisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl, quinuclidinyl, and substituted derivatives thereof.
- 25 80. The method of claim 66 wherein A is substituted or unsubstituted C_1 - C_{12} alkyl.
- 30 81. The method of claim 66 wherein Y is substituted or unsubstituted C_1 - C_{12} alkyl.
82. The method of claim 66 wherein R_7 is substituted or unsubstituted C_1 - C_{12} alkyl.

- 128 -

83. The method according to claim 66 wherein R_4 is $-C(0)-R_6$, wherein R_6 is alkyl or ANR_9R_{10} ,
wherein A is alkyl, and R_9 and R_{10} are each
independently hydrogen, or substituted or
unsubstituted C_1-C_{12} alkyl.
84. The method according to claim 66 wherein R_5 is $-C(0)-R_6$, wherein R_6 is alkyl or ANR_9R_{10} ,
wherein A is alkyl, and R_9 and R_{10} are each
independently hydrogen, or substituted or
unsubstituted C_1-C_{12} alkyl.
85. The method according to claim 66 wherein R_4 is $-Y-C(0)-R_7$, wherein Y is substituted or unsubstituted C_1-C_{12} alkyl and R_7 is NR_9R_{10} .
86. The method according to claim 66 wherein R_5 is $-Y-C(0)-R_7$, wherein Y is substituted or unsubstituted C_1-C_{12} alkyl and R_7 is NR_9R_{10} .
87. The method according to claim 66 wherein R_3 and NR_4R_5 are in a cis spatial configuration.
88. The method according to claim 66 wherein R_3 and NR_4R_5 are in a trans spatial configuration.
89. The method according to claim 66 wherein the compound is an R enantiomer.
90. The method according to claim 66 wherein the compound is an S enantiomer.
91. The method according to claim 66 wherein the compound is selected from the group consisting of 1-aminoindan,

- 129 -


(R)-1-aminoindan, (S)-1-aminoindan, 1-aminotetralin,
1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan, (R)-
6-hydroxy-1-aminoindan, 6-fluoro-1-aminoindan, (R)-6-
fluoro-1-aminoindan, (S)-6-fluoro-1-aminoindan, 5-
5 methoxy-1-aminoindan, (S)-6-methoxy-1-aminoindan, 7-
methyl-1-aminoindan, 5-methyl-1-aminoindan, 4,5-
dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-
aminoindan, (S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-
5-methoxy-1-aminoindan, 6-hydroxy-5-methoxy-1-
10 aminoindan, trans-2-methyl-1-aminoindan, cis-2-methyl-
1-aminoindan, 3,4,7-trimethyl-1-aminoindan, N-methyl-
1-aminoindan, (R)-N-methyl-1-aminoindan, (S)-N-methyl-
1-aminoindan, N,N-dimethyl-1-aminoindan, N-formyl-1-
aminoindan, (R)-N-formyl-1-aminoindan, (S)-N-formyl-1-
15 aminoindan, N-acetyl-1-aminoindan, (R)-N-acetyl-1-
aminoindan, (S)-N-acetyl-1-aminoindan, N-acetyl-7-
methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan,
(R)-N-acetyl-6-fluoro-1-aminoindan, 6-Methoxy-1-
aminoindan, (S)-6-Methoxy-1-aminoindan, N-acetyl-6-
20 methoxy-1-aminoindan, 4,5-dimethoxy-1-aminoindan, (R)-
N-acetyl-4,5-dimethoxy-1-aminoindan, N-butyryl-1-
aminoindan, N-benzyl-1-aminoindan, N-(4-
aminobutanoyl)-1-aminoindan, N-(2-acetamido)-1-
aminoindan, (R)-N-(2-acetamido)-1-aminoindan, N-(2-
25 acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-
aminoindan, N-(4-butanamido)-1-aminoindan, (S)-N-(2-
acetamido)-1-aminoindan, N-(2-acetamido)-1-
aminotetralin, N,N-Di-(1-indanyl)amine, N-(2-N-Boc-
aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-
30 aminoindan, N-Benzoyl-1-aminoindan, N-(2-n-
Propylpentanoyl)-1-aminoindan, N-acetyl-6-nitro-1-
aminiondan, 6-amino-N-acetyl-1-aminoindan, 6-
acetamido-N-acetyl-1-aminoindan, cis-3-
(methoxycarbonyl)-1-aminoindan, cis-1-aminoindan-3-

- 130 -

- carboxylic acid, trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, (R)-N-trifluoroacetyl-1-aminoindan, N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan, (S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan, 6-ethoxycarbonyl-N-acetyl-1-aminoindan, 2-(1-indanamino)-N-isopropylethanesulfonamide, 2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, (R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)succinamide, and pharmaceutically acceptable acid addition salts thereof.
92. A method for treating acute neurological traumatic disorder in a subject according to the method of claim 66.
93. A method for treating neurotrauma in a subject according to the method of claim 66.
94. A method for treating neurotrauma caused by a closed head injury according to the method of claim 93.


1/9

FIGURE 1




2/9

FIGURE 2




3/9

FIGURE 3




4/9

FIGURE 4




5/9

FIGURE 5




6/9

FIGURE 6




7/9

FIGURE 7




8/9

FIGURE 8



9/9

FIGURE 9



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/00245

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CASON SEARCH: STRUCTURAL FORMULA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A, 3,886,168(HIMMELE ET.AL) 27 MAY 1975, COLUMN 1, LINES 5-15.	50-59
X	US,A, 4,096,173(MOLLOY) 20 JUNE 1978, COLUMN 2, LINES 1-60	50-59
Y	US,A, 3,637,740(SARGES) 25 JANUARY 1972, SEE ENTIRE DOCUMENT.	1-11, 13,15-17,22-27 AND 50-59
Y	EP,A, 0,538,134(JEFF ET.AL) 21 APRIL 1993, SEE THE ENTIRE DOCUMENT.	1-11,13,15-17,22-27 AND 50-59
Y	J.MED.CHEM, VOLUME 16, NO. 2, ISSUED 1973, MARTIN ET.AL, "POTENTIAL ANTI-PARKINSON DRUGS DESIGNED BY RECEPTOR MAPPING", PAGES 148-150, ENTIRE	1-11,13,15-17,22-27 AND 50-59

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 MAY 1995

Date of mailing of the international search report

22 MAY 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHALENDRA KUMAR

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/00245

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 31/495, 31/445, 31/535, 31/40, 31/44;
C07D 241/04, 265/28, 295/02, 453/02, 211/06;
C07C 211/38, 233/05.

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

514/255, 329, 231.2, 426, 305, 657, 621, 630;
544/383, 162;
546/133, 205;
564/215, 428, 429

B. FIELDS SEARCHED

Minimum documentation searched
Classification System: U.S.

514/255, 329, 231.2, 426, 305, 657, 621, 630;
544/383, 162;
546/133, 205;
564/215, 428, 429

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

- I. Claims 1-27 and 50-59, drawn to compounds, composition and method of treating Parkinson's disease.
- II. Claims 1-25 and 35-41, drawn to a method of treating Dementia.
- III. Claims 1-25 35 and 42-48, drawn to a method of treating epilepsy.
- IV. Claims 1-25, 35 and 49, when method is drawn to treating convulsions.
- V. Claims 1-25, 35 and 49 when method is drawn to treating seizure.
- VI. Claims 28-29, drawn to method of treating Parkinson's disease comprising further Levodopa.
- VII. Claims 30-34, drawn to a method of treating Parkinson's disease, comprising further decarboxylase inhibitor.
- VIII. Claim 60, drawn to composition further comprising Levodopa.
- IX. Claims 61-65, drawn to composition further comprising decarboxylase inhibitor.
- X. Claims 66-94, drawn to a method of treating neurologic traumatic disorder or neurotrauma, when R4 or R5 are non lipophilic groups.
- XI. Claims 66-94, drawn to a method of treating neurological traumatic disorder or neurotrauma, when R4 or R5 are lipophilic groups.

The inventions listed as Groups I and II through XI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Inventions of Group I belong to a different method of treatment than Group II through VII and X, and a reference anticipating a method of treating Parkinson's disease may not be a reference for treating Dementia or Seizure. Likewise, inventions of Group VIII and IX are distinct compositions (37 CFR 1.475(d)). A reference anticipating

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/00245

composition with Levodopa would not be a reference to a composition containing decarboxylase inhibitors. Finally, Group X and XI are distinct method in the sense that the method of treating neurologic disorder by composition using compounds having lipophilic group is different than having non lipophilic group, because the said lipophilic and non lipophilic groups provide special technical feature to the composition which is not the same for each composition and foreshadows the common special technical features common to both.